US6207430B1 - Nucleic acids encoding polypeptides having laccase activity - Google Patents

Nucleic acids encoding polypeptides having laccase activity Download PDF

Info

Publication number
US6207430B1
US6207430B1 US09/389,528 US38952899A US6207430B1 US 6207430 B1 US6207430 B1 US 6207430B1 US 38952899 A US38952899 A US 38952899A US 6207430 B1 US6207430 B1 US 6207430B1
Authority
US
United States
Prior art keywords
gly
val
pro
ala
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US09/389,528
Inventor
Debbie Sue Yaver
Kimberley M. Brown
Sakari Kauppinen
Torben Halkier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novozymes Inc
Original Assignee
Novo Nordisk Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Biotech Inc filed Critical Novo Nordisk Biotech Inc
Priority to US09/389,528 priority Critical patent/US6207430B1/en
Application granted granted Critical
Publication of US6207430B1 publication Critical patent/US6207430B1/en
Assigned to NOVOZYMES BIOTECH, INC. reassignment NOVOZYMES BIOTECH, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: NOVO NORDISK BIOTECH, INC.
Assigned to NOVOZYMES A/S reassignment NOVOZYMES A/S ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NOVO NORDISK A/S
Assigned to NOVOZYMES, INC. reassignment NOVOZYMES, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: NOVOZYMES, INC.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
    • C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
    • C12N9/0061—Laccase (1.10.3.2)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi

Definitions

  • the present invention relates to polypeptides having laccase activity and isolated nucleic acid sequences encoding the polypeptides.
  • the invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing the polypeptides.
  • Laccases (benzenediol:oxygen oxidoreductases) are multi-copper containing enzymes that catalyze the oxidation of phenolics. Laccase-mediated oxidations result in the production of aryloxy-radical intermediates from suitable phenolic substrate; the ultimate coupling of the intermediates so produced provides a combination of dimeric, oligomeric, and polymeric reaction products. Such reactions are important in nature in biosynthetic pathways which lead to the formation of melanin, alkaloids, toxins, lignins, and humic acids.
  • Laccases are produced by a wide variety of fungi, including ascomycetes such as Aspergillus, Neurospora, and Podospora, the deuteromycete Botrytis, and basidiomycetes such as Collybia, Fomes, Lentinus, Pleurotus, Trametes, and perfect forms of Rhizoctonia. Laccase exhibits a wide range of substrate specificity, and each different fungal laccase usually differs only quantitatively from others in its ability to oxidize phenolic substrates. Because of the substrate diversity, laccases generally have found many potential industrial applications. Among these are lignin modification, paper strengthening, dye transfer inhibition in detergents, phenol polymerization, juice manufacture, phenol resin production, and waste water treatment.
  • the present invention relates to isolated polypeptides having laccase activity, obtained from a Coprinus strain.
  • the present invention further relates to isolated polypeptides having laccase activity which have: (a) a pH optimum in the range of about 5 to about 9 at 20° C. using syringaldazine as a substrate; and (b) an isoelectric point in the range of about 3.7 to about 4.0.
  • the present invention also relates to isolated polypeptides which have an amino acid sequence which has at least 65% identity with the amino acid sequence set forth in SEQ ID NO:27, SEQ ID NO:29, or SEQ ID NO:33.
  • the present invention further relates to isolated nucleic acid sequences encoding the polypeptides and to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing the polypeptides.
  • FIG. 1 illustrates the nucleotide sequence and the deduced amino acid sequence of the Coprinus cinereus lcc 1 gene.
  • FIG. 2 illustrates the nucleotide sequence and the deduced amino acid sequence of the Coprinus cinereus lcc 3 gene.
  • FIG. 3 illustrates the nucleotide sequence and the deduced amino acid sequence of the Coprinus cinereus lcc 2 gene.
  • FIG. 4 illustrates the construction of plasmid pDSY67.
  • FIG. 5 illustrates a map of plasmid pDSY68.
  • FIG. 6 illustrates the pH activity profiles of recombinant and wild-type Coprinus cinereus laccases using (A) syringaldazine and (B) of 2,2′-azinobis-(3-ethybenzthiazoline-6-sulfonic acid (ABTS) as substrates.
  • A syringaldazine
  • B 2,2′-azinobis-(3-ethybenzthiazoline-6-sulfonic acid (ABTS) as substrates.
  • ABTS 2,2′-azinobis-(3-ethybenzthiazoline-6-sulfonic acid
  • the present invention relates to isolated polypeptides having laccase activity (hereinafter “polypeptides”), obtained from a Coprinus strain.
  • polypeptides obtained from a Coprinus strain.
  • the present invention further relates to isolated polypeptides having laccase activity which have:
  • the polypeptides preferably have a molecular weight of about 63 kDa (using SDS-PAGE).
  • the polypeptides are obtained from a strain of the family Coprinaceae, preferably a Coprinus strain, and more preferably a Coprinus cinereus strain, e.g., Coprinus cinereus IFO 8371 or a mutant strain thereof.
  • the polypeptide has the amino acid sequence set forth in SEQ ID NO:27, SEQ ID NO:29, or SEQ ID NO:33.
  • the present invention also relates to polypeptides obtained from microorganisms which are synonyms of Coprinus as defined by, for example, Webster, 1980, In Introduction to the Fungi, Second Edition, Cambridge University Press, New York. Strains of Coprinus are readily accessible to the public in a number of culture collections, such as the American Type Culture Collection (ATCC), Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSM), Centraalbureau Voor Schimmelcultures (CBS), and Agricultural Research Service Patent Culture Collection, Northern Regional Research Center (NRRL), e.g., from the American Type Culture Collection, ATCC 12890, 36519, 38628, 42727, 48566 ( Coprinus cinereus ); 15744 ( Coprinus clastophyllus ); 12640, 22314 ( Coprinus comatus ); 46457, 46972 ( Coprinus congregatus ); 48096 ( Coprinus cothurnatus ); 48098 ( Coprinus curtus
  • the invention also embraces polypeptides having laccase activity of other fungi and other members of the family Coprinaceae, for example, laccases from the genera Podaxis, Montagnea, Macrometrula, Psathyrella, Panaeolina, Panaeolus, Copelandia, Anellaria, Limnoperdon, Panaelopsis, and Polyplocium.
  • the term “obtained from” as used herein in connection with a given source shall mean that the polypeptide is produced by the source or by a cell in which a gene from the source has been inserted.
  • the present invention also relates to polypeptides which are encoded by nucleic acid sequences which are capable of hybridizing under standard conditions with an oligonucleotide probe which hybridizes under the same conditions with the nucleic acid sequence set forth in SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:32 as well as a complementary strand thereof or a subsequence thereof (J. Sambrook, E. F. Fritsch, and T. Maniatus, 1989, Molecular Cloning, A Laboratory Manual, 2nd edition, Cold Spring Harbor, New York).
  • Hybridization indicates that the analogous nucleic acid sequence hybridizes to the oligonucleotide probe corresponding to the polypeptide encoding part of the nucleic acid sequence shown in SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:32, or a subsequence thereof, under medium to high stringency conditions (for example, prehybridization and hybridization at 42° C. in 5X SSPE, 0.3% SDS, 200 ⁇ g/ml sheared and denatured salmon sperm DNA, and either 35 or 50% formamide for medium and high stringencies, respectively), following standard Southern blotting procedures.
  • medium to high stringency conditions for example, prehybridization and hybridization at 42° C. in 5X SSPE, 0.3% SDS, 200 ⁇ g/ml sheared and denatured salmon sperm DNA, and either 35 or 50% formamide for medium and high stringencies, respectively.
  • the nucleic acid sequences set forth in SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:32, or subsequences thereof may be used to identify and clone DNA encoding laccases from other strains of different genera or species according to methods well known in the art.
  • a genomic or cDNA library prepared from such other organisms may be screened for DNA which hybridizes with SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:32, or subsequences thereof.
  • Genomic or other DNA from such other organisms may be separated by agarose or polyacrylamide gel electrophoresis, or other separation techniques. DNA from the libraries or the separated DNA may be transferred to and immobilized on nitrocellulose or other suitable carrier material.
  • the carrier material is used in a Southern blot in which the carrier material is finally washed three times for 30 minutes each using 0.2XSSC, 0.1% SDS at 40° C., more preferably not higher than 45° C., more preferably not higher than 50° C., more preferably not higher than 55° C., even more preferably not higher than 60° C., especially not higher than 65° C. Molecules to which the oligonucleotide probe hybridizes under these conditions are detected using a X-ray film.
  • the present invention also relates to polypeptides which have an amino acid sequence which has a degree of identity to the amino acid sequence set forth in SEQ ID NO:27, SEQ ID NO:29, or SEQ ID NO:33 of at least about 65%, preferably about 70%, preferably about 75%, preferably about 80%, preferably about 85%, more preferably about 90%, even more preferably about 95%, and most preferably about 97%, which qualitatively retain the activity of the polypeptides (hereinafter “homologous polypeptides”).
  • the homologous polypeptides have an amino acid sequence which differs by five amino acids, preferably by four amino acids, more preferably by three amino acids, even more preferably by two amino acids, and most preferably by one amino acid from the amino acid sequence set forth SEQ ID NO:27, SEQ ID NO:29, or SEQ ID NO:33.
  • the degree of identity between two or more amino acid sequences may be determined by means of computer programs known in the art such as GAP provided in the GCG program package (Needleman and Wunsch, 1970, Journal of Molecular Biology 48:443-453).
  • the Clustal method (DNASTAR, Inc., Madison, Wis.) is used with an identity table, a gap penalty of 10, and a gap length of 10.
  • amino acid sequences of the homologous polypeptides differ from the amino acid sequence set forth in SEQ ID NO:27, SEQ ID NO:29, or SEQ ID NO:33 by an insertion or deletion of one or more amino acid residues and/or the substitution of one or more amino acid residues by different amino acid residues.
  • amino acid changes are of a minor nature, that is conservative amino acid substitutions that do not significantly affect the folding and/or activity of the protein; small deletions, typically of one to about 30 amino acids; small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue; a small linker peptide of up to about 20-25 residues; or a small extension that facilitates purification by changing net charge or another function, such as a poly-histidine tract, an antigenic epitope or a binding domain.
  • conservative substitutions are within the group of basic amino acids (such as arginine, lysine and histidine), acidic amino acids (such as glutamic acid and aspartic acid), polar amino acids (such as glutamine and asparagine), hydrophobic amino acids (such as leucine, isoleucine and valine), aromatic amino acids (such as phenylalanine, tryptophan and tyrosine) and small amino acids (such as glycine, alanine, serine, threonine and methionine).
  • Amino acid substitutions which do not generally alter the specific activity are known in the art and are described, e.g., by H. Neurath and R. L.
  • the present invention also relates to polypeptides having immunochemical identity or partial immunochemical identity to the polypeptides having laccase activity which are native to Coprinus cinereus IFO 8371.
  • a polypeptide having immunochemical identity to the polypeptide native to Coprinus cinereus IFO 8371 means that an antiserum containing antibodies against the antigens of the native polypeptide reacts with the antigens of the other polypeptide in an identical fashion such as total fusion of precipitates, identical precipitate morphology, and/or identical electrophoretic mobility using a specific immunochemical technique.
  • a further explanation of immunochemical identity is described by Axelsen, Bock, and Kr ⁇ ll, In N. H. Axelsen, J. Kr ⁇ ll, and B.
  • Partial immunochemical identity means that an antiserum containing antibodies against the antigens of the native polypeptide reacts with the antigens of the other polypeptide in an partially identical fashion such as partial fusion of precipitates, partially identical precipitate morphology, and/or partially identical electrophoretic mobility using a specific immunochemical technique.
  • a further explanation of partial immunochemical identity is described by Bock and Axelsen, In N. H. Axelsen, J. Kr ⁇ ll, and B. Weeks, editors, A Manual of Quantitative Immunoelectrophoresis, Blackwell Scientific Publications, 1973, Chapter 11.
  • the immunochemical properties are determined by immunological cross-reaction identity tests by the well-known Ouchterlony double immunodiffusion procedure. Specifically, an antiserum against the polypeptide of the invention is raised by immunizing rabbits (or other rodents according to the procedure described by Harboe and Ingild, In N. H. Axelsen, J. Kr ⁇ ll, and B. Weeks, editors, A Manual of Quantitative Immunoelectrophoresis, Blackwell Scientific Publications, 1973, Chapter 23, or Johnstone and Thorpe, Immunochemistry in Practice, Blackwell Scientific Publications, 1982 (more specifically pages 27-31). Monoclonal antibodies may be prepared, e.g., according to the methods of E. Harlow and D.
  • Purified immunoglobulins may be obtained from the antiserum, e.g., by ammonium sulfate precipitation, followed by dialysis and ion exchange chromatography (e.g., DEAE-Sephadex).
  • Homologous polypeptides and polypeptides having identical or partially identical immunological properties may be obtained from microorganisms of any genus, preferably from a bacterial or fungal source.
  • Sources for homologous genes are strains of the family Coprinaceae, preferably of the genus Coprinus and species thereof available in public depositories.
  • homologous genes may be identified and obtained from other sources including microorganisms isolated from nature (e.g., soil, composts, water, etc.) using the above-mentioned probes. Techniques for isolating microorganisms from natural habitats are well known in the art. The nucleic acid sequence may then be derived by similarly screening a cDNA library of another microorganism.
  • nucleic acid sequence encoding a polypeptide may be isolated or cloned by utilizing techniques which are known to those of ordinary skill in the art (see, e.g., Sambrook et al., supra).
  • an “isolated” polypeptide is a polypeptide which is essentially free of other non-laccase polypeptides, e.g., at least about 20% pure, preferably at least about 40% pure, more preferably about 60% pure, even more preferably about 80% pure, most preferably about 90% pure, and even most preferably about 95% pure, as determined by SDS-PAGE.
  • the present invention also relates to isolated nucleic acid sequences obtained from a Coprinus strain, which encode a polypeptide of the present invention.
  • the nucleic acid sequence encodes a polypeptide obtained from Coprinus cinereus and in a more preferred embodiment, the nucleic acid sequence is obtained from Coprinus cinereus IFO 8371, e.g. , the nucleic acid sequence set forth in SEQ ID NO:26, SEQ ID NO:28, or SEQ ID NO:32.
  • the present invention also encompasses nucleic acid sequences which encode a polypeptide having the amino acid sequence set forth in SEQ ID NO:27, SEQ ID NO:29, or SEQ ID NO:33, which differ from SEQ ID NO:26, SEQ ID NO:28, or SEQ ID NO:32, respectively, by virtue of the degeneracy of the genetic code.
  • nucleic acid sequences may be obtained from microorganisms which are synonyms of Coprinus as defined by Webster, 1980, supra.
  • the techniques used to isolate or clone a nucleic acid sequence encoding a polypeptide are known in the art and include isolation from genomic DNA, preparation from cDNA, or a combination thereof.
  • the cloning of the nucleic sequences of the present invention from such genomic DNA can be effected, e.g., by using the well known polymerase chain reaction (PCR). See, e.g., Innis et al., 1990, A Guide to Methods and Application, Academic Press, New York.
  • the nucleic acid sequence may be cloned from a strain of the Coprinus producing the polypeptide, or another or related organism and thus, for example, may be an allelic or species variant of the polypeptide encoding region of the nucleic acid sequence.
  • isolated nucleic acid sequence refers to a nucleic acid sequence encoding a polypeptide of the present invention which is isolated by standard cloning procedures used in genetic engineering to relocate the nucleic acid sequence from its natural location to a different site where it will be reproduced.
  • the cloning procedures may involve excision and isolation of a desired nucleic acid fragment comprising the nucleic acid sequence encoding the polypeptide, insertion of the fragment into a vector molecule, and incorporation of the recombinant vector into a host cell where multiple copies or clones of the nucleic acid sequence will be replicated.
  • the nucleic acid sequence may be of genomic, cDNA, RNA, semisynthetic, synthetic origin, or any combinations thereof.
  • the present invention also relates to nucleic acid sequences which have a nucleic acid sequence which has a degree of identity to the nucleic acid sequence set forth in SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:32, or subsequences thereof of at least about 65%, preferably about 70%, preferably about 75%, preferably about 80%, preferably about 85% more preferably about 90%, even more preferably about 95%, and most preferably about 97% which encode an active polypeptide.
  • the degree of identity between two nucleic acid sequences may be determined by means of computer programs known in the art such as GAP provided in the GCG program package (Needleman and Wunsch, 1970, Journal of Molecular Biology 48:443-453). For purposes of determining the degree of identity between two nucleic acid sequences for the present invention, the Clustal method (DNASTAR, Inc., Madison, Wis.) is used with an identity table, a gap penalty of 10, and a gap length of 10.
  • Modification of the nucleic acid sequence encoding the polypeptide may be necessary for the synthesis of polypeptides substantially similar to the polypeptide.
  • the term “substantially similar” to the polypeptide refers to non-naturally occurring forms of the polypeptide.
  • These polypeptides may differ in some engineered way from the polypeptide isolated from its native source. For example, it may be of interest to synthesize variants of the polypeptide where the variants differ in specific activity, thermostability, pH optimum, or the like using, e.g., site-directed mutagenesis.
  • the analogous sequence may be constructed on the basis of the nucleic acid sequence presented as the polypeptide encoding part of SEQ ID NO:26, SEQ ID NO:28, or SEQ ID NO:32, e.g., a sub-sequence thereof, and/or by introduction of nucleotide substitutions which do not give rise to another amino acid sequence of the polypeptide encoded by the nucleic acid sequence, but which corresponds to the codon usage of the host organism intended for production of the enzyme, or by introduction of nucleotide substitutions which may give rise to a different amino acid sequence.
  • nucleotide substitution see, e.g., Ford et al., 1991, Protein Expression and Purification 2:95-107.
  • amino acid residues essential to the activity of the polypeptide encoded by the isolated nucleic acid sequence of the invention may be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (see, e.g., Cunningham and Wells, 1989, Science 244:1081-1085). In the latter technique mutations are introduced at every residue in the molecule, and the resultant mutant molecules are tested for laccase activity to identify amino acid residues that are critical to the activity of the molecule.
  • Sites of substrate-enzyme interaction can also be determined by analysis of crystal structure as determined by such techniques as nuclear magnetic resonance analysis, crystallography or photoaffinity labelling (see, e.g., de Vos et al., 1992, Science 255, 306-312; Smith et al., 1992, Journal of Molecular Biology 224:899-904; Wlodaver et al., 1992, FEBS Letters 309, 59-64).
  • Polypeptides of the present invention also include fused polypeptides in which another polypeptide is fused at the N-terminus or the C-terminus of the polypeptide or fragment thereof.
  • a fused polypeptide is produced by fusing a nucleic acid sequence (or a portion thereof) encoding another polypeptide to a nucleic acid sequence (or a portion thereof) of the present invention.
  • Techniques for producing fusion polypeptides are known in the art, and include, ligating the coding sequences encoding the polypeptides so that they are in frame and that expression of the fused polypeptide is under control of the same promoter(s) and terminator.
  • the present invention also relates nucleic acid sequences which are capable of hybridizing under standard conditions with an oligonucleotide probe which hybridizes under the same conditions with the nucleic acid sequence set forth in SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:32, a subsequence thereof, or its complementary strand (Sambrook et al., supra).
  • Hybridization indicates that the analogous nucleic acid sequence hybridizes to the oligonucleotide probe corresponding to the polypeptide encoding part of the nucleic acid sequence shown in SEQ ID NO:26, SEQ ID NO:28, or SEQ ID NO:32 under standard conditions.
  • amino acid sequence set forth in SEQ ID NO:27, SEQ ID NO:29, or SEQ ID NO:33 or a partial amino acid sequence thereof may be used to design an oligonucleotide probe, or a gene encoding a polypeptide of the present invention or a subsequence thereof can also be used as a probe, to isolate homologous genes of any genus or species.
  • probes can be used for hybridization with the genomic or cDNA of the genus or species of interest, following standard Southern blotting procedures, in order to identify and isolate the corresponding gene therein.
  • Such probes can be considerably shorter than the entire sequence, but should be at least 15, preferably at least 25, and more preferably at least 40 nucleotides in length.
  • Probes Longer probes, preferably no more than 1200 nucleotides in length, can also be used. Both DNA and RNA probes can be used. The probes are typically labeled for detecting the corresponding gene (for example, with 32 P, 1 H, biotin, or avidin).
  • a PCR reaction using the degenerate probes mentioned herein and genomic DNA or first-strand cDNA from a Coprinus cinereus can also yield a Coprinus cinereus laccase-specific product which can then be used as a probe to clone the corresponding genomic or cDNA.
  • the present invention also relates to nucleic acid constructs comprising a nucleic acid sequence of the present invention operably linked to one or more control sequences capable of directing the expression of the coding sequence in a suitable host cell under conditions compatible with the control sequences.
  • Nucleic acid construct is defined herein as a nucleic acid molecule, either single- or double-stranded, which is isolated from a naturally occurring gene or which has been modified to contain segments of nucleic acid which are combined and juxtaposed in a manner which would not otherwise exist in nature.
  • the term nucleic acid construct may be synonymous with the term expression cassette when the nucleic acid construct contains all the control sequences required for expression of a coding sequence of the present invention.
  • coding sequence as defined herein is a sequence which is transcribed into mRNA and translated into a polypeptide of the present invention when placed under the control of the above mentioned control sequences.
  • a coding sequence can include, but is not limited to, DNA, cDNA, and recombinant nucleic acid sequences.
  • An isolated nucleic acid sequence encoding a polypeptide of the present invention may be manipulated in a variety of ways to provide for expression of the polypeptide. Manipulation of the nucleic acid sequence encoding a polypeptide prior to its insertion into a vector may be desirable or necessary depending on the expression vector. The techniques for modifying nucleic acid sequences utilizing cloning methods are well known in the art.
  • control sequences is defined herein to include all components which are necessary or advantageous for expression of the coding sequence of the nucleic acid sequence.
  • Each control sequence may be native or foreign to the nucleic acid sequence encoding the polypeptide.
  • control sequences include, but are not limited to, a leader, a polyadenylation sequence, a propeptide sequence, a promoter, a signal sequence, and a transcription terminator.
  • the control sequences include a promoter, and transcriptional and translational stop signals.
  • the control sequences may be provided with linkers for the purpose of introducing specific restriction sites facilitating ligation of the control sequences with the coding region of the nucleic acid sequence encoding a polypeptide.
  • the control sequence may be an appropriate promoter sequence, a nucleic acid sequence which is recognized by a host cell for expression of the nucleic acid sequence.
  • the promoter sequence contains transcription and translation control sequences which mediate the expression of the polypeptide.
  • the promoter may be any nucleic acid sequence which shows transcriptional activity in the host cell of choice and may be obtained from genes encoding extracellular or intracellular polypeptides either homologous or heterologous to the host cell.
  • Suitable promoters for directing the transcription of the nucleic acid constructs of the present invention are the promoters obtained from the E. coli lac operon, the Streptomyces coelicolor agarase gene (dagA), the Bacillus subtilis levansucrase gene (sacB), the Bacillus licheniformis alpha-amylase gene (amyL), the Bacillus stearothermophilus maltogenic amylase gene (amyM), the Bacillus amyloliquefaciens alpha-amylase gene (amyQ), the Bacillus licheniformis penicillinase gene (penP), the Bacillus subtilis xylA and xylB genes, and the prokaryotic beta-lactamase gene (Villa-Kamaroff et al., 1978 , Proceedings of the National Academy of Sciences USA 75:3727-3731), as well as the tac gene (DeBoer
  • promoters for directing the transcription of the nucleic acid constructs of the present invention in a filamentous fungal host cell are promoters obtained from the genes encoding Aspergillus oryzae TAKA amylase, Rhizomucor miehei aspartic proteinase, Aspergillus niger neutral alpha-amylase, Aspergillus niger acid stable alpha-amylase, Aspergillus niger or Aspergillus awamori glucoamylase (glaA), Rhizomucor miehei lipase, Aspergillus oryzae alkaline protease, Aspergillus oryzae triose phosphate isomerase, Aspergillus nidulans acetamidase, Fusarium oxysporum trypsin-like protease (as described in U.S.
  • promoters for use in filamentous fungal host cells are the TAKA amylase, NA2-tpi (a hybrid of the promoters from the genes encoding Aspergillus niger neutral ⁇ -amylase and Aspergillus oryzae triose phosphate isomerase), and glaA promoters.
  • useful promoters are obtained from the Saccharomyces cerevisiae enolase (ENO-1) gene, the Saccharomyces cerevisiae galactokinase gene (GAL1), the Saccharomyces cerevisiae alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase genes (ADH2/GAP), and the Saccharomyces cerevisiae 3-phosphoglycerate kinase gene.
  • ENO-1 Saccharomyces cerevisiae enolase
  • GAL1 Saccharomyces cerevisiae galactokinase gene
  • ADH2/GAP Saccharomyces cerevisiae alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase genes
  • Saccharomyces cerevisiae 3-phosphoglycerate kinase gene Other useful promoters for yeast host cells are described by Romanos et al.,
  • useful promoters include viral promoters such as those from Simian Virus 40 (SV40), Rous sarcoma virus (RSV), adenovirus, and bovine papilloma virus (BPV).
  • SV40 Simian Virus 40
  • RSV Rous sarcoma virus
  • BPV bovine papilloma virus
  • the control sequence may also be a suitable transcription terminator sequence, a sequence recognized by a host cell to terminate transcription.
  • the terminator sequence is operably linked to the 3′ terminus of the nucleic acid sequence encoding the polypeptide. Any terminator which is functional in the host cell of choice may be used in the present invention.
  • Preferred terminators for filamentous fungal host cells are obtained from the genes encoding Aspergillus oryzae TAKA amylase, Aspergillus niger glucoamylase, Aspergillus nidulans anthranilate synthase, Aspergillus niger alpha-glucosidase, and Fusarium oxysporum trypsin-like protease.
  • Preferred terminators for yeast host cells are obtained from the genes encoding Saccharomyces cerevisiae enolase, Saccharomyces cerevisiae cytochrome C (CYC1), or Saccharomyces cerevisiae glyceraldehyde-3-phosphate dehydrogenase.
  • Other useful terminators for yeast host cells are described by Romanos et al., 1992, supra. Terminator sequences are well known in the art for mammalian host cells.
  • the control sequence may also be a suitable leader sequence, a nontranslated region of a mRNA which is important for translation by the host cell.
  • the leader sequence is operably linked to the 5′ terminus of the nucleic acid sequence encoding the polypeptide. Any leader sequence which is functional in the host cell of choice may be used in the present invention.
  • Preferred leaders for filamentous fungal host cells are obtained from the genes encoding Aspergillus oryzae TAKA amylase and Aspergillus oryzae triose phosphate isomerase.
  • Suitable leaders for yeast host cells are obtained from the Saccharomyces cerevisiae enolase (ENO-1) gene, the Saccharomyces cerevisiae 3-phosphoglycerate kinase gene, the Saccharomyces cerevisiae alpha-factor, and the Saccharomyces cerevisiae alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase genes (ADH2/GAP).
  • ENO-1 Saccharomyces cerevisiae enolase
  • Saccharomyces cerevisiae 3-phosphoglycerate kinase gene the Saccharomyces cerevisiae alpha-factor
  • Saccharomyces cerevisiae alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase genes ADH2/GAP
  • the control sequence may also be a polyadenylation sequence, a sequence which is operably linked to the 3′ terminus of the nucleic acid sequence and which, when transcribed, is recognized by the host cell as a signal to add polyadenosine residues to transcribed mRNA. Any polyadenylation sequence which is functional in the host cell of choice may be used in the present invention.
  • Preferred polyadenylation sequences for filamentous fungal host cells are obtained from the genes encoding Aspergillus oryzae TAKA amylase, Aspergillus niger glucoamylase, Aspergillus nidulans anthranilate synthase, and Aspergillus niger alpha-glucosidase.
  • polyadenylation sequences for yeast host cells are described by Guo and Sherman, 1995 , Molecular Cellular Biology 15:5983-5990. Polyadenylation sequences are well known in the art for mammalian host cells.
  • the control sequence may also be a signal peptide coding region, which codes for an amino acid sequence linked to the amino terminus of the polypeptide which can direct the expressed polypeptide into the cell's secretory pathway.
  • the 5′ end of the coding sequence of the nucleic acid sequence may inherently contain a signal peptide coding region naturally linked in translation reading frame with the segment of the coding region which encodes the secreted polypeptide.
  • the 5′ end of the coding sequence may contain a signal peptide coding region which is foreign to that portion of the coding sequence which encodes the secreted polypeptide.
  • the foreign signal peptide coding region may be required where the coding sequence does not normally contain a signal peptide coding region.
  • the foreign signal peptide coding region may simply replace the natural signal peptide coding region in order to obtain enhanced secretion of the laccase relative to the natural signal peptide coding region normally associated with the coding sequence.
  • the signal peptide coding region may be obtained from a glucoamylase or an amylase gene from an Aspergillus species, a lipase or proteinase gene from a Rhizomucor species, the gene for the ⁇ -factor from Saccharomyces cerevisiae , an amylase or a protease gene from a Bacillus species, or the calf preprochymosin gene.
  • any signal peptide coding region capable of directing the expressed laccase into the secretory pathway of a host cell of choice may be used in the present invention.
  • An effective signal peptide coding region for bacterial host cells is the signal peptide coding region obtained from the maltogenic amylase gene from Bacillus NCIB 11837, the Bacillus stearothermophilus alpha-amylase gene, the Bacillus licheniformis subtilisin gene, the Bacillus licheniformis beta-lactamase gene, the Bacillus stearothermophilus neutral proteases genes (nprT, nprS, nprM), and the Bacillus subtilis PrsA gene. Further signal peptides are described by Simonen and Palva, 1993 , Microbiological Reviews 57:109-137.
  • An effective signal peptide coding region for filamentous fungal host cells is the signal peptide coding region obtained from Aspergillus oryzae TAKA amylase gene, Aspergillus niger neutral amylase gene, the Rhizomucor miehei aspartic proteinase gene, the Humicola lanuginosa cellulase gene, or the Rhizomucor miehei lipase gene.
  • Useful signal peptides for yeast host cells are obtained from the genes for Saccharomyces cerevisiae alpha-factor and Saccharomyces cerevisiae invertase. Other useful signal peptide coding regions are described by Romanos et al., 1992, supra.
  • the control sequence may also be a propeptide coding region, which codes for an amino acid sequence positioned at the amino terminus of a polypeptide.
  • the resultant polypeptide is known as a proenzyme or propolypeptide (or a zymogen in some cases).
  • a propolypeptide is generally inactive and can be converted to a mature active polypeptide by catalytic or autocatalytic cleavage of the propeptide from the propolypeptide.
  • the propeptide coding region may be obtained from the Bacillus subtilis alkaline protease gene (aprE), the Bacillus subtilis neutral protease gene (nprT), the Saccharomyces cerevisiae alpha-factor gene, or the Myceliophthora thermophilum laccase gene (WO 95/33836).
  • the nucleic acid constructs of the present invention may also comprise one or more nucleic acid sequences which encode one or more factors that are advantageous in the expression of the polypeptide, e.g., an activator (e.g., a trans-acting factor), a chaperone, and a processing protease. Any factor that is functional in the host cell of choice may be used in the present invention.
  • an activator e.g., a trans-acting factor
  • a chaperone e.g., a chaperone
  • processing protease e.g., a factor that is functional in the host cell of choice.
  • the nucleic acids encoding one or more of these factors are not necessarily in tandem with the nucleic acid sequence encoding the polypeptide.
  • An activator is a protein which activates transcription of a nucleic acid sequence encoding a polypeptide (Kudla et al., 1990, EMBO Journal 9:1355-1364; Jar:o and Buxton, 1994, Current Genetics 26:2238-244; Verdier, 1990, Yeast 6:271-297).
  • the nucleic acid sequence encoding an activator may be obtained from the genes encoding Bacillus stearothermophilus NprA (nprA), Saccharomyces cerevisiae heme activator protein 1 (hap1), Saccharomyces cerevisiae galactose metabolizing protein 4 (gal4), and Aspergillus nidulans ammonia regulation protein (areA).
  • nprA Bacillus stearothermophilus NprA
  • hap1 Saccharomyces cerevisiae heme activator protein 1
  • gal4 Saccharomyces cerevisiae galacto
  • a chaperone is a protein which assists another polypeptide in folding properly (Hard et al., 1994, TIBS 19:20-25; Bergeron et al., 1994, TIBS 19:124-128; Demolder et al., 1994, Journal of Biotechnology 32:179-189; Craig, 1993, Science 260:1902-1903; Gething and Sambrook, 1992, Nature 355:33-45; Puig and Gilbert, 1994, Journal of Biological Chemistry 269:7764-7771; Wang and Tsou, 1993, The FASEB Journal 7:1515-11157; Robinson et al., 1994, Bio/Technology 1:381-384).
  • the nucleic acid sequence encoding a chaperone may be obtained from the genes encoding Bacillus subtilis GroE proteins, Aspergillus oryzae protein disulphide isomerase, Saccharomyces cerevisiae calnexin, Saccharomyces cerevisiae BiP/GRP78, and Saccharomyces cerevisiae IIsp70. For further examples, see Gething and Sambrook, 1992, supra, and Hard et al., 1994, supra.
  • a processing protease is a protease that cleaves a propeptide to generate a mature biochemically active polypeptide (Enderlin and Ogrydziak, 1994, Yeast 10:67-79; Fuller et al., 1989, Proceedings of the National Academy of Sciences USA 86:1434-1438; Julius et al., 1984, Cell 37:1075-1089; Julius et al., 1983, Cell 32:839-852).
  • the nucleic acid sequence encoding a processing protease may be obtained from the genes encoding Saccharomyces cerevisiae dipeptidylaminopeptidase, Saccharomyces cerevisiae Kex2, and Yarowia lipolytica dibasic processing endoprotease (xpr6).
  • regulatory sequences which allow the regulation of the expression of the polypeptide relative to the growth of the host cell.
  • regulatory systems are those which cause the expression of the gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound.
  • Regulatory systems in prokaryotic systems would include the lac, tac, and trp operator systems.
  • yeast the ADH2 system or GAL1 system may be used.
  • filamentous fungi the TAKA alpha-amylase promoter.
  • Aspergillus niger glucoamylase promoter the Aspergillus oryzae glucoamylase promoter may be used as regulatory sequences.
  • Other examples of regulatory sequences are those which allow for gene amplification.
  • these include the dihydrofolate reductase gene which is amplified in the presence of methotrexate, and the metallothionein genes which are amplified with heavy metals.
  • the nucleic acid sequence encoding the polypeptide would be placed in tandem with the regulatory sequence.
  • the present invention also relates to recombinant expression vectors comprising a nucleic acid sequence of the present invention, a promoter, and transcriptional and translational stop signals.
  • the various nucleic acid and control sequences described above may be joined together to produce a recombinant expression vector which may include one or more convenient restriction sites to allow for insertion or substitution of the nucleic acid sequence encoding the polypeptide at such sites.
  • the nucleic acid sequence of the present invention may be expressed by inserting the nucleic acid sequence or a nucleic acid construct comprising the sequence into an appropriate vector for expression.
  • the coding sequence is located in the vector so that the coding sequence is operably linked with the appropriate control sequences for expression, and possibly secretion.
  • the recombinant expression vector may be any vector which can be conveniently subjected to recombinant DNA procedures and can bring about the expression of the nucleic acid sequence.
  • the choice of the vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced.
  • the vectors may be linear or closed circular plasmids.
  • the vector may be an autonomously replicating vector, i.e., a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome.
  • the vector may contain any means for assuring self-replication.
  • the vector may be one which, when introduced into the host cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated.
  • the vector system may be a single vector or plasmid or two or more vectors or plasmids which together contain the total DNA to be introduced into the genome of the host cell, or a transposon.
  • the vectors of the present invention preferably contain one or more selectable markers which permit easy selection of transformed cells.
  • a selectable marker is a gene the product of which provides for biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs, and the like.
  • Example's of bacterial selectable markers are the dal genes from Bacillus subtilis or Bacillus licheniformis, or markers which confer antibiotic resistance such as ampicillin, kanamycin, chloramphenicol or tetracycline resistance.
  • a frequently used mammalian marker is the dihydrofolate reductase gene. Suitable markers for yeast host cells are ADE2, HIS3, LEU2, LYS2, MET3, TRP1, and URA3.
  • a selectable marker for use in a filamentous fungal host cell may be selected from the group including, but not limited to, amdS (acetamidase), argB (ornithine carbamoyltransferase), bar (phosphinothricin acetyltransferase), hygB (hygromycin phosphotransferase), niaD (nitrate reductase), pyrG (orotidine-5′-phosphate decarboxylase), sC (sulfate adenyltransferase), trpC (anthranilate synthase), and glufosinate resistance markers, as well as equivalents from other species.
  • amdS acetamidase
  • argB ornithine carbamoyltransferase
  • bar phosphinothricin acetyltransferase
  • hygB hygromycin phosphotransferase
  • amdS and pyrG markers of Aspergillus nidulans or Aspergillus oryzae and the bar marker of Streptomyces hygroscopicus .
  • selection may be accomplished by co-transformation, e.g., as described in WO 91/17243, where the selectable marker is on a separate vector.
  • the vectors of the present invention preferably contain an element(s) that permits stable integration of the vector into the host cell genome or autonomous replication of the vector in the cell independent of the genome of the cell.
  • the vectors of the present invention may be integrated into the host cell genome when introduced into a host cell.
  • the vector may rely on the nucleic acid sequence encoding the polypeptide or any other element of the vector for stable integration of the vector into the genome by homologous or nonhomologous recombination.
  • the vector may contain additional nucleic acid sequences for directing integration by homologous recombination into the genome of the host cell. The additional nucleic acid sequences enable the vector to be integrated into the host cell genome at a precise location(s) in the chromosome(s).
  • the integrational elements should preferably contain a sufficient number of nucleic acids, such as 100 to 1,500 base pairs, preferably 400 to 1,500 base pairs, and most preferably 800 to 1,500 base pairs, which are highly homologous with the corresponding target sequence to enhance the probability of homologous recombination.
  • the integrational elements may be any sequence that is homologous with the target sequence in the genome of the host cell.
  • the integrational elements may be non-encoding or encoding nucleic acid sequences.
  • the vector may be integrated into the genome of the host cell by non-homologous recombination.
  • These nucleic acid sequences may be any sequence that is homologous with a target sequence in the genome of the host cell, and, furthermore, may be non-encoding or encoding sequences.
  • the vector may further comprise an origin of replication enabling the vector to replicate autonomously in the host cell in question.
  • origins of replication are the origins of replication of plasmids pBR322, pUC19, pACYC177, pACYC184, pUB110, pE194, pTA1060, and pAM ⁇ 1.
  • origin of replications for use in a yeast host cell are the 2 micron origin of replication, the combination of CEN6 and ARS4, and the combination of CEN3 and ARS1.
  • the origin of replication may be one having a mutation which makes its functioning temperature-sensitive in the host cell (see, e.g., Ehrlich, 1978 , Proceedings of the National Academy of Sciences USA 75:1433).
  • More than one copy of a nucleic acid sequence encoding a polypeptide of the present invention may be inserted into the host cell to amplify expression of the nucleic acid sequence.
  • Stable amplification of the nucleic acid sequence can be obtained by integrating at least one additional copy of the sequence into the host cell genome using methods well known in the art and selecting for transformants.
  • the present invention also relates to recombinant host cells, comprising a nucleic acid sequence of the invention, which are advantageously used in the recombinant production of the polypeptides.
  • the cell is preferably transformed with a vector comprising a nucleic acid sequence of the invention followed by integration of the vector into the host chromosome.
  • Transformation means introducing a vector comprising a nucleic acid sequence of the present invention into a host cell so that the vector is maintained as a chromosomal integrant or as a self-replicating extra-chromosomal vector. Integration is generally considered to be an advantage as the nucleic acid sequence is more likely to be stably maintained in the cell. Integration of the vector into the host chromosome may occur by homologous or non-homologous recombination as described above.
  • the choice of a host cell will to a large extent depend upon the gene encoding the polypeptide and its source.
  • the host cell may be a unicellular microorganism or a non-unicellular microorganism.
  • Useful unicellular cells are bacterial cells such as gram positive bacteria including, but not limited to, a Bacillus cell, e.g., Bacillus subtilis, Bacillus licheniformis, Bacillus lentus, Bacillus brevis, Bacillus stearothermophilus, Bacillus alkalophilus, Bacillus amyloliquefaciens, Bacillus coagulans, Bacillus circulans, Bacillus lautus, Bacillus megaterium, and Bacillus thuringiensis ; or a Streptomyces cell, e.g., Streptomyces lividans or Streptomyces murinus , or gram negative bacteria such as E.
  • the bacterial host cell is a Bacillus lentus , a Bacillus licheniformis, a Bacillus subtilis , or a Bacillus stearothermophilus cell.
  • the transformation of a bacterial host cell may, for instance, be effected by protoplast transformation (see e.g., Chang and Cohen, 1979 , Molecular General Genetics 168:111-115), by using competent cells (see, e.g., Young and Spizizin, 1961 , Journal of Bacteriology 81:823-829, or Dubnar and Davidoff-Abelson, 1971 , Journal of Molecular Biology 56:209-221), by electroporation (see, e.g., Shigekawa and Dower, 1988 , Biotechniques 6:741-751), or by conjugation (see, e.g., Koehler and Thorne, 1987 , Journal of Bacteriology 169:5771-5278).
  • protoplast transformation see e.g., Chang and Cohen, 1979 , Molecular General Genetics 168:111-115
  • competent cells see, e.g., Young and Spizizin, 1961 , Journal of Bacteriology 81:823-829, or Dub
  • the host cell may be a eukaryote, such as a mammalian cell, an insect cell, a plant cell or, preferably, a fungal cell.
  • a mammalian cell such as a mammalian cell, an insect cell, a plant cell or, preferably, a fungal cell.
  • Useful mammalian cells include Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, COS cells, or any number of other immortalized cell lines available, e.g., from the American Type Culture Collection.
  • the fungal host cell may be a yeast cell or a filamentous fungal cell.
  • yeast as used herein includes ascosporogenous yeast (Endomycetales), basidiosporogenous yeast, and yeast belonging to the Fungi Imperfecti (Blastomycetes).
  • the ascosporogenous yeasts are divided into the families Spermophthoraceae and Saccharomycetaceae. The latter is comprised of four subfamilies, Schizosaccharomycoideae (e.g., genus Schizosaccharomyces), Nadsonioideae, Lipomycoideae, and Saccharomycoideae (e.g., genera Pichia, Kluyveromyces and Saccharomyces).
  • Schizosaccharomycoideae e.g., genus Schizosaccharomyces
  • Nadsonioideae e.g., Lipomycoideae
  • Saccharomycoideae e.g., genera Pichia, Kluyveromyces and Saccharomyces
  • the basidiosporogenous yeasts include the genera Leucosporidim, Rhodosporidium, Sporidiobolus, Filobasidium, and Filobasidiella.
  • Yeast belonging to the Fungi Imperfecti are divided into two families, Sporobolomycetaceae (e.g., genera Sorobolomyces and Bullera) and Cryptococcaceae (e.g., genus Candida). Since the classification of yeast may change in the future, for the purposes of this invention, yeast shall be defined as described in Biology and Activities of Yeast (Skinner, F, A., Passmore, S. M., and Davenport, R. R., eds, Soc. App. Bacteriol. Symposium Series No. 9, 1980.
  • yeast and manipulation of yeast genetics are well known in the art (see, e.g., Biochemistry and Genetics of Yeast , Bacil, M., Horecker, B. J., and Stopani, A.O.M., editors, 2nd edition, 1987 ; The Yeasts, Rose, A. H., and Harrison, J. S., editors, 2nd edition, 1987; and The Molecular Biology of the Yeast Saccharomyces , Strathern et al., editors, 1981).
  • “Fungi” as used herein includes the phyla Ascomycota, Basidiomycota, Chytridiomycota, and Zygomycota (as defined by Hawksworth et al., In, Ainsworth and Bisby's Dictionary of the Fungi , 8th edition, 1995, CAB International, University Press, Cambridge, UK) as well as the Oomycota (as cited in Hawksworth et al., 1995, supra, page 171) and all mitosporic fungi (Hawksworth et al., 1995, supra).
  • Basidiomycota include mushrooms, rusts, and smuts.
  • Representative groups of Chytridiomycota include, e.g., Allomyces, Blastocladiella, Coelomomyces, and aquatic fungi.
  • Representative groups of Oomycota include, e.g., Saprolegniomycetous aquatic fungi (water molds) such as Achlya. Examples of mitosporic fungi include Aspergillus, Penicillium, Candida, and Alternaria.
  • Representative groups of Zygomycota include, e.g., Rhizopus and Mucor.
  • “Filamentous fungi” include all filamentous forms of the subdivision Eumycota and Oomycota (as defined by Hawksworth et al., 1995, supra).
  • the filamentous fungi are characterized by a vegetative mycelium composed of chitin, cellulose, glucan, chitosan, mannan, and other complex polysaccharides. Vegetative growth is by hyphal elongation and carbon catabolism is obligately aerobic. In contrast, vegetative growth by yeasts such as Saccharomyces cerevisiae is by budding of a unicellular thallus and carbon catabolism may be fermentative.
  • the fungal host cell is a yeast cell.
  • the yeast host cell is a cell of a species of Candida, Kluyveromyces, Saccharomyces, Schizosaccharomyces, Pichia, or Yarrowia.
  • the yeast host cell is a Saccharomyces cerevisiae , a Saccharomyces calsbergenis , a Saccharomyces diastaricus , a Saccharomyces douglasii , a Saccharomyces kluyveri , a Saccharomyces norbensis , or a Saccharomyces oviformis cell.
  • the yeast host cell is a Kluyveromyces lactis cell.
  • the yeast host cell is a Yarrowia lipolytica cell.
  • the fungal host cell is a filamentous fungal cell.
  • the filamentous fungal host cell is a cell of a species of, but not limited to, Acremonium, Aspergillus, Fusarium, Humicola, Myceliophthora, Mucor, Neurospora, Penicillium, Thielavia, Tolypocladium, and Trichoderma.
  • the filamentous fungal host cell is an Aspergillus cell.
  • the filamentous fungal host cell is a Fusartum cell.
  • the filamentous fungal host cell is an Aspergillus oryzae , an Aspergillus niger , an Aspergillus foeridus , or an Aspergillus japonicus cell. In another most preferred embodiment, the filamentous fungal host cell is a Fusarium orysporum or a Fusarium graminearum cell.
  • Fungal cells may be transformed by a process involving protoplast formation, transformation of the protoplasts, and regeneration of the cell wall in a matter known per se. Suitable procedures for transformation of Aspergillus host cells are described in EP 238 023 and Yelton et al., 1984 , Proceedings of the National Academy of Science:USA 81:1470-1474. A suitable method of transforming Fusarium species is described by Malardier et al., 1989 , Gene 78:147-156 or in copending U.S. Ser. No. 08/269,449. Yeast may be transformed using the procedures described by Becker and Guarente, In Alelson, J. N. and Simon, M.
  • Mammalian cells may be transformed by direct uptake using the calcium phosphate precipitation method of Graham and Van der Hb (1978 , Virology 52:546).
  • the present invention also relates to methods for producing a polypeptide of the present invention comprising (a) cultivating a Coprinus strain to produce a supernatant comprising the polypeptide; and (b) recovering the polypeptide.
  • the present invention also relates to methods for producing a polypeptide of the present invention comprising (a) cultivating a host cell under conditions conducive to expression of the polypeptide; and (b) recovering the polypeptide.
  • the cells are cultivated in a nutrient medium suitable for production of the polypeptide using methods known in the art.
  • the cell may be cultivated by shake flask cultivation, small-scale or large-scale fermentation (including continuous, batch, fed-batch, or solid state fermentations) in laboratory or industrial fermentors performed in a suitable medium and under conditions allowing the polypeptide to be expressed and/or isolated.
  • the cultivation takes place in a suitable nutrient medium comprising carbon and nitrogen sources and inorganic salts, using procedures known in the art (see, e.g., references for bacteria and yeast; Bennett, J. W. and LaSure, L., editors, More Gene Manipulations in Fungi , Academic Press, California, 1991).
  • Suitable media are available from commercial suppliers or may be prepared according to published compositions (e.g., in catalogues of the American Type Culture Collection). If the polypeptide is secreted into the nutrient medium, the polypeptide can be recovered directly from the medium. If the polypeptide is not secreted, it is recovered from cell lysates.
  • the polypeptides may be detected using methods known in the art that are specific for the polypeptides. These detection methods may include use of specific antibodies, formation of an enzyme product or disappearance of an enzyme substrate. For example, an enzyme assay may be used to determine the activity of the polypeptide. Procedures for determining laccase activity are known in the art and include, e.g., the oxidation of 2,2′-azinobis-(3-ethybenzthiazoline-6-sulfonic acid (ABTS) (Childs et al., 1975 , Biochemical Journal 145:93-103) or syringaldazine (Bauer et al., 1971 , Analytical Chemistry 43: 421-425) as substrate.
  • ABTS 2,2′-azinobis-(3-ethybenzthiazoline-6-sulfonic acid
  • the resulting polypeptide may be recovered by methods known in the art.
  • the polypeptide may be recovered from the nutrient medium by conventional procedures including, but not limited to, centrifugation, filtration, extraction, spray-drying, evaporation, or precipitation.
  • the recovered polypeptide may then be further purified by a variety of chromatographic procedures, e.g., ion exchange chromatography, gel filtration chromatography, affinity chromatography, or the like.
  • polypeptides of the present invention may be purified by a variety of procedures known in the art including, but not limited to, chromatography (e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (e.g., preparative isoelectric focusing (IEF), differential solubility (e.g., ammonium sulfate precipitation), or extraction (see, e.g., Protein Purification , J.-C. Janson and Lars Ryden, editors, VCH Publishers, New York, 1989).
  • chromatography e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion
  • electrophoretic procedures e.g., preparative isoelectric focusing (IEF), differential solubility (e.g., ammonium sulfate precipitation), or extraction (see, e.g., Protein Purification , J.-C. Janson and Lars Ryden, editors, VCH Publishers, New York,
  • the polypeptides of the present invention may be used in a number of different industrial processes. These processes include polymerization of lignin, both Kraft and lignosulfates, in solution, in order to produce a lignin with a higher molecular weight.
  • a neutral/alkaline laccase is a particular advantage in that Kraft lignin is more soluble at higher pHs. Such methods are described in, for example, Jin et al., 1991 , Holzaba 45: 467-468; U.S. Pat. No. 4,432,921; EP 0 275 544; PCT/DK93/00217, 1993. Laccase is also useful in the copolymerization of lignin with low molecular weight compounds, such as is described by Milstein et al., 1994 , Appl. Microbiol, Biotechnol. 40: 760-767.
  • the laccase of the present invention can also be used for in-situ depolymerization of lignin in Kraft pulp, thereby producing a pulp with lower lignin content.
  • This use of laccase is an improvement over the current use of chloride for depolymerization of lignin, which leads to the production of chlorinated aromatic compounds, which are an environmentally undesirable by-product of paper mills.
  • Such uses are described in, for example, Current Opinion in Biotechnology 3: 261-266, 1992; Journal of Biotechnology 25: 333-339, 1992; Hiroi et al., 1976 , Svensk Papperstidning 5:162-166, 1976. Since the environment in a paper mill is typically alkaline, the present laccase is more useful for this purpose than other known laccases, which function best under acidic conditions.
  • Laccase can be used for this purpose, which can be particularly advantageous in a situation in which a dye transfer between fabrics is undesirable, e.g., in the textile industry and in the detergent industry.
  • Methods for dye transfer inhibition and dye oxidation can be found in WO 92/01406; WO 92/18683; WO 92/18687; WO 91/05839; EP 0495836; Calvo, 1991 , Mededelingen van de Faculteit Landbouwwetenschappen/Rijiksuniversitet Gent. 56: 1565-1567; Tsujino et al., 1991 , J. Soc.
  • Laccases of the present invention are particularly useful in oxidation at high pH, i.e., over pH 7, as disclosed in DK0982/94, the contents of which are incorporated herein by reference.
  • Use of laccase in oxidation of dye precursors for hair dyeing is disclosed in U.S. Pat. No. 3,251,742, the contents of which are incorporated herein by reference.
  • the present laccase can also be used for the polymerization or oxidation of phenolic compounds present in liquids.
  • An example of such utility is the treatment of juices, such as apple juice, so that the laccase will accelerate a precipitation of the phenolic compounds present in the juice, thereby producing a more stable juice.
  • juices such as apple juice
  • Such applications have been described by Stutz, Fruit processing 7/93, 248-252, 1993; Maier et al., 1990 , Dt. Strukturrindschau 86: 137-142; Dietrich et al., 1990 , Fluss. Obst. 57: 67-73.
  • Laccases of the present invention are also useful in soil detoxification (Nannipieri et al., 1991 , J. Environ. Qual. 20: 510-517; Dec and Bollag, 1990 , Arch. Environ. Contam. Toxicol. 19: 543-550).
  • Chemicals used as buffers and substrates are commercial products of at least reagent grade.
  • the laccase is initially isolated from Coprinus cinereus strain A3387 culture broth by filtration (Propex 23+HSC) and concentration (Filtron 2 ⁇ 10K).
  • the cationic flocculent Magnifloc® 521C (American Cyanamid, Wallingford, Conn.) is added to the resulting preparation, mixed for 30 minutes, and then centrifuged. This step removes colored substances from the preparation.
  • the supernate is then precipitated with ammonium sulfate (55% saturation) and resuspended twice in ammonium sulfate (40% saturation), which also results in color removal.
  • the resuspension is further concentrated to reduce the volume, and filtered, but not washed out.
  • the concentrate in ammonium sulfate (40% saturation) is then subjected to Butyl ToyoPearl hydrophobic chromatography (Tosoh Corp., Tokyo, Japan) and eluted with an ammonium sulfate gradient from 40% to 0% saturation.
  • Buffer exchange to 20 mM MES pH 6.0 and concentration with an Amicon cell equipped with a membrane of 20,000 molecular weight cut-off is then conducted.
  • the resulting solution is then subjected to Q-Sepharose (Pharmacia, Uppsala, Sweden) anion exchange chromatography (150 ml) in 20 mM MES pH 6.0 with a linear gradient from 0 to 0.4 M NaCl.
  • the sample is finally rechromatographed by HPQ-Sepharose (Pharmacia, Upsala, Sweden) chromatography (50 ml) in 20 mM MES pH 6.0 with a linear gradient from 0 to 0.4 M NaCl.
  • the laccase elutes at 0.25-0.30 M NaCl.
  • the N-terminal amino acid residue of the purified laccase is blocked.
  • the laccase is therefore reduced, S-carboxymethylated, and digested with Endoproteinase Lys-C (Boehringer Mannheim, Indianapolis, Ind.) and with chymotrypsin.
  • the resulting peptides are purified by reversed phase HPLC using a Vydac C18 column (Vydac, Inc., Hesperia, Calif.) eluted with a linear gradient of either acetonitrile of 2-propanol in 0.1% aqueous trifluoroacetic acid.
  • the purified peptides are sequenced on an Applied Biosystems 473A Protein Sequencer according to the manufacture's instructions.
  • Xaa represents an indeterminable residue.
  • Peptide 3 apparently encompasses peptide 2.
  • residues designated Xaa/Yaa indicate both residues are found at that position. Residues in parentheses are uncertain.
  • Peptide 9 is included in peptide 13.
  • Peptide 2 (SEQ ID NO:2):
  • Peptide 3 (SEQ ID NO:3):
  • Peptide 6 (SEQ ID NO:7):
  • Peptide 7 (SEQ ID NO:8):
  • Peptide 8 (SEQ ID NO:9):
  • Peptide 12 (SEQ ID NO:13):
  • Coprinus cinereus strain A3387 is cultivated at 26° C. in FG4 medium comprised of 30 g of soybean meal, 15 g of maltodextrin, 5 g of Bacto peptone, and 0.2 g of pluronic acid per liter.
  • the mycelia are harvested after six days of growth, frozen in liquid N 2 , and stored at ⁇ 80° C.
  • Total RNA is prepared from the frozen, powdered mycelium of Coprinus cinereus A3387 by extraction with guanidinium thiocyanate followed by ultracentrifugation through a 5.7 M cesium chloride cushion (Chirgwin et al., 1979 , Biochemistry 18: 5294-5299).
  • Poly(A)+RNA is isolated by oligo(dT)-cellulose affinity chromatography according to Aviv and Leder (1972 , Proceedings of the National Academy of Sciences USA 69: 1408-1412).
  • Double-stranded cDNA is synthesized from 5 ⁇ g of Coprinus cinereus poly(A)+RNA of Example 2 as described by Gubler and Hoffman (1983 , Gene 25: 263-269) and Sambrook et al. (1989 , Molecular Cloning: A Laboratory Manual , Cold Spring Harbor Press, Cold Spring Harbor, N.Y.), except that an oligo(dT)-NotI anchor primer, instead of an oligo(dT)12-18 primer, is used in the first strand reaction.
  • the cDNA is treated with Mung bean nuclease (Life Technologies, Gaithersburg, Md.), blunt-ended with T4 DNA polymerase (Boehringer Mannheim, Indianapolis, Ind.), and ligated to non-palindromic BstXI adaptors (Invitrogen, San Diego, Calif.), using about 50-fold molar excess of the adaptors.
  • the adapted cDNA is digested with NotI, size-fractionated for 1.2-3.0 kb cDNAs by agarose gel electrophoresis, and ligated into BstXI/NotI cleaved pYES2.0 vector (Invitrogen, San Diego, Calif.).
  • the ligation mixture is transformed into electrocompetent E. coli DH10B cells (Life Technologies, Gaithersburg, Md.) according to the manufacturer's instructions.
  • the library consisting of 1 ⁇ 10 6 independent clones i stored as individual pools (25,000-30,000 colony forming units/pool) in 20% glycerol at ⁇ 80° C., and as double stranded cDNA and ligation mixture at ⁇ 20° C.
  • oligonucleotides with low codon degeneracy are designed based on two conserved motifs in laccases from Rhizoctonia, Phlebia, Polyporus, and Coriolus.
  • the oligos have the following sequences.
  • plasmid DNA from the Coprinus cinereus library pool described in Example 3 is PCR amplified in a thermal cycler according to Frohman et al., 1988 , Proceedings of the National Academy of Sciences USA 85: 8998-9002 using 500 pmol of each laccase sense primer in two combinations (s1 and as1, s2 and as1) with 500 pmol of the laccase antisense primer, and 2.5 units of Taq polymerase (Perkin Elmer Cetus, Branchburg, N.J.). Thirty cycles of PCR are performed using a cycle profile of denaturation at 94° C. for 1 minute, annealing at 55° C. for two minutes, and extension at 72° C. for 3 minutes.
  • PCR fragment of interest is subcloned into a pUC18 vector and sequenced according to Siggaard-Andersen et al., 1991 , Proceedings of the National Academy of Sciences USA 88: 4114-4118. Sequencing of the ends of two PCR subclones in pUC18 reveals a cDNA sequence coding for a laccase polypeptide.
  • the deduced amino acid sequence aligns with two peptide sequences obtained from the purified wild-type laccase, indicating that PCR has specifically amplified the desired region of a Coprinus cinereus laccase cDNA.
  • the PCR product described in Example 4 is ligated into pCRII using a TA Cloning Kit (Invitrogen, San Diego, Calif.) according to the manufacturer's instructions. Seven subclones are prepared and sequenced using both the M13 universal ⁇ 21 mer oligonucleotide and the M13 ⁇ 48 reverse oligonucleotide. Nucleotide sequences are determined on both strands by primer walking using Taq polymerase cycle-sequencing with fluorescent-labeled nucleotides, and reactions are electrophoresed on an Applied Biosystems Automatic DNA Sequencer (Model 373A, version 2.0.1).
  • Clones CCLACC4, 8 and 7 are designated as partial cDNAs of Coprinus cinereus lcc1 (SEQ ID NOS:18 and 19).
  • Clones CCLACC 1, 3 and 11 are designated as partial cDNAs of Coprinus cinereus lcc2 (SEQ ID NOS:20 and 21).
  • Clone CCLACC 15 (pDSY72) is designated as a partial cDNA of Coprinus cinereus lcc3 (SEQ ID NOS:22 and 23).
  • the deduced amino acid sequences of the partial cDNAs of lcc1, lcc2, and lcc3 are compared to the peptide sequences determined above, and the closest match is found between lcc1 and the peptide sequences.
  • a genomic library of Coprinus cinereus A3387 is constructed in ⁇ ZipLox.
  • a culture of Coprinus cinereus A3387 is grown at room temperature for 4 days with shaking at 200 rpm in YEG medium comprised of 0.5% yeast extract and 2% dextrose.
  • Mycelia are harvested through Miracloth (Calbiochem, La Jolla, Calif.), washed twice with 10 mM Tris-0.1 mM EDTA pH 7.4 buffer (TE) and frozen quickly in liquid nitrogen.
  • DNA is isolated as described by Timberlake and Barnard, 1981 , Cell 26: 29-37.
  • a genomic library of Coprinus cinereus A3387 is constructed using a ⁇ ZipLox Kit (Life Technologies, Gaithersburg, Md.) according to the manufacturer's instructions.
  • Genomic DNA ( ⁇ 30 ⁇ g) is digested with Tsp509I (New England Biolabs, Beverly, Mass.) at 65° C. in a total volume of 150 ⁇ l in the buffer provided by the supplier.
  • Samples of 30 ⁇ l are taken at 3, 5, 7, 8, and 9 minutes and electrophoresed on a 1% agarose preparative gel. Bands of 3 to 8 kb in size are excised from the gel.
  • the DNA is then isolated from the gel slices using a Qiaex Kit (Qiagen, San Diego, Calif.).
  • the size-fractionated DNA is ligated overnight at room temperature to ⁇ ZipLox EcoRI arms following the protocols provided with the kit.
  • the ligations are packaged into phage using a Giga Pak Gold Packaging Kit (Stratagene, La Jolla, Calif.), and the packaging reactions are titered using E. coli Y1090 cells. A total of 6 ⁇ 10 5 pfu are obtained.
  • the packaging extract is plated to amplify the library, and the titer of the library is determined to be 1 ⁇ 10 11 pfu/ml. Twenty individual plaques are picked, and the plasmids are excised from the plaques by passage through E. coli DH10B. Plasmid DNA is isolated from the cultures and is digested with PstI/NotI to determine the percent of molecules in the library which have inserts. Eight of the twenty, or 40% of those tested, have inserts which range in size from 3 to 6 kb.
  • a DIG-labeled probe for nonradioactive screening of the library is prepared by PCR using the Coprinus cinereus partial lcc1 cDNA described in Example 5 as a template.
  • the primers used in the reaction are shown below:
  • the PCR conditions are 1 cycle at 95° C. for 5 minutes, 50° C. for 1 minute, and 72° C. for 1.5 minutes; 29 cycles each at 95° C. for 1 minute, 50° C. for 1 minute, and 72° C. for 1.5 minutes; and 1 cycle at 95° C. for 30 seconds, 50° C. for 1 minute, and 72° C. for 3 minutes.
  • the reaction contains 0.1 ⁇ g of the Coprinus cinereus partial lcc1 cDNA, 10 ⁇ l 10X PCR Buffer (Perkin Elmer, Branchburg, N.J.), 5 ⁇ l 10X DIG labeling mix (Boehringer Mannheim, Indianapolis, Ind.), 75 pmol of each primer, and 0.5 unit of Taq DNA polymerase (Perkin-Elmer Corp., Branchburg, N.J.).
  • a probe concentration of 250 ng/ ⁇ l is determined after PCR following protocols provided with the Genius Kit (Boehringer Mannheim, Indianapolis, Ind.).
  • Appropriate dilutions of the ⁇ XipLox Coprinus cinereus genomic library are plated with E. coli Y1090 cells on NZY plates comprised of 0.5% NaCl, 0.2% MgSO 4 , 0.5% yeast extract, and 1% NZ amine pH 7.5 per liter with 0.7% top agarose.
  • the plaques are lifted to Hybond N+ filters (Amersham Co., Amersham, UK) using standard procedures (Sambrook et al. 1989, supra).
  • the filters are hybridized in Engler Blue hybridization buffer at 65° C. for 1 hour.
  • the DIG labeled probe of Example 8 is added at a final concentration of 3 ng/ml and allowed to hybridize overnight at 65° C.
  • the filters are washed at 65° C. twice for 5 minutes in 2XSSC, 0.1% SDS, twice for 15 minutes in 0.5XSSC, 0.1% SDS, and then are processed to detect the hybridized DIG-label using the Genius Kit and Lumi-Phos 530 substrate according to the manufacturer's instructions. Following the detection protocol, film is placed on top of the filters for 2 hours.
  • filter lifts are prepared as described above, and prehybridized at 65° C. in 2XSSPE, 1% SDS, 0.5% nonfat dry milk and 200 ⁇ g denatured salmon sperm DNA. After 1 hour prehybridization, the 32 -P-labeled probes are added to a final concentration of 10 6 cpm/ml and hybridizations are continued overnight at 65° C. The filters are washed twice at 65° C. for 15 minutes in 0.2XSSC, 1% SDS, and 0.1% sodium pyrophosphate.
  • the genomic library is probed with the DIG-labeled fragment of lcc1. Approximately 200,000 plaques are screened using the conditions described above, and 9 positive clones are obtained. The plasmids are excised from the clones by passage through E. coli DH10B(ZL), and then are characterized by digestion with PstI/NotI. All 9 clones contain inserts. Based on the nucleotide sequence of the partial lcc1 cDNA, the genomic clones which may be lcc1 genomic clones are determined.
  • the nucleotide sequence of clone 4-19 (pDSY73) is determined completely on both strands and shown to contain the full length lcc1 gene (FIG. 1, SEQ ID NO:26).
  • the deduced amino acid sequence (FIG. 1, SEQ ID NO:27) of the genomic lcc1 matches 100% with the determined N-terminal sequence (see Example 14) although the predicted signal peptide cleavage site is between A18 and Q19 while the peptide sequence begins 4 residues downstream at S23.
  • the lcc1 gene contains 7 introns ranging in size from 54 to 77 bp.
  • the deduced protein contains 3 potential N-glycosylation sites (AsnXaaThr/Ser), and the predicted mature protein after removal of the signal peptide is 521 amino acids in length.
  • the percent identities of the Lcc1 protein to other fungal laccases is shown in Table 2. The highest percent identity, 57.8%, is found when compared to the laccase from the unidentified basidiomycete PM1 (Coll et al., 1993, supra). When alignments of Lcc1 and other basidiomycete laccases are performed, it appears that Lcc1 may have either a C-terminal extension or a C-terminal peptide that is removed by processing.
  • the genomic library is also screened with the 32 P-labeled probes for the Coprinus cinereus lcc2 and lcc3 partial cDNAs.
  • For screening with the lcc2 probe approximately 50,000 plaques are hybridized with the probe, and 4 positive clones are obtained.
  • For screening of the library with the lcc3 probe approximately 35,000 plaques are probed, and 2 positive clones are obtained.
  • the nucleotide sequence of one of the lcc3 clones (DSY100) is determined by primer walking as described in Example 5 (FIG. 2, SEQ ID NO:28).
  • the lcc3 gene contains 13 introns (as indicated by lowercase in FIG.
  • introns 4 through 10 are confirmed from the partial cDNA while the positions of the other 6 introns are deduced based on the consensus sequences found at the 5′ and 3′ splice sites of fungal introns and by homology of the deduced amino acid sequence (FIG. 2, SEQ ID NO:29) to other laccases.
  • the lcc3 gene encodes for a precursor protein of 517 amino acids. There is one potential N-glycosylation site, and the mature protein after the predicted signal peptide cleavage (indicated by an arrow) is 501 amino acids in length.
  • a DIG-labeled probe for nonradioactive screening of the library is prepared by PCR using the Coprinus cinereus lcc2 partial genomic clone as template in order to obtain a full-length clone of lcc2.
  • the primers used in the reaction are shown below:
  • AGCTCGATGACTTTGTTACGG (1868R CCLCC2) (SEQ ID NO:30)
  • CAGCGCTACTCGTTCGTTCTC (1460 CCLCC2) (SEQ ID NO:31)
  • the PCR conditions are 1 cycle at 95° C. for 1 minute; and 30 cycles each at 94° C. for 1 minute, 55° C. for 1 minute, and 72° C. for 2 minutes.
  • the reaction contains 0.1 ⁇ g of Coprinus cinereus lcc2 partial genomic clone (CCLACC1-4), 10 ⁇ l of 10X PCR Buffer (Perkin Elmer, Branchburg, N.J.), 5 ⁇ l of 10X DIG labeling mix (Boehringer Mannheim, Indianapolis, Inc.), 75 pmol of each primer, and 0.5 Unit of Taq DNA polymerase.
  • the concentration of the DIG-labeled probe is determined using the Genius Kit according to the manufacturer's instructions.
  • Appropriate dilutions of the ⁇ ZipLox Coprinus cinereus genomic library prepared as described in Example 7 are plated with E. coli Y1090 cells on NZY plates (0.5% NaCl, 0.2% MgSO 4 , 0.5% yeast extract, and 1% NZ amine pH 7.5) with 0.7% top agarose.
  • the plaques are lifted to Hybond N+ filters using standard procedures (Sambrook et al., 1989, supra). Filters are prehybridized in Easy Hyb hybridization buffer (Boehringer Mannheim, Indianapolis, Ind.) at 42° C. for 1 hour, and after prehybridization the DIG labeled probe mentioned above is added at a final concentration of 1 ng/ml.
  • the filters and probe are allowed to hybridize overnight at 42° C.
  • the filters are then washed twice at room temperature for 5 minutes in 2XSSC-0.1% SDS and twice at 68° C. for 15 minutes in 0.1XSSC-0.1% SDS.
  • the filters are next processed to detect the hybridized DIG-label using the Genius Kit and CSPD Ready-To-Use (Boehringer Mannheim, Indianapolis, Ind.) as substrate according to the manufacturer's instructions. Following the detection protocol, film is placed on the filters for 20 minutes to 2 hours.
  • the genomic library is screened ( ⁇ 42,000 plaques) using a DIG-labeled fragment containing the 3′ most 400 bp of the CCLACC1-4 insert.
  • Five positive clones are isolated and purified. Plasmid DNA is excised from all five clones by passage through E. coli DH10B.
  • LCC2-5B-1 does not contain the whole gene but is missing part of the 5′ end. Overlapping the sequences of CCLACC1-4 and CCLACC2-5B-1 yields the sequence of the entire gene (FIG. 3, SEQ ID NO:32).
  • a plasmid pDSY105 containing the full-length lcc2 genomic clone is constructed by ligating together fragments from the LCC2-5B-1 and CCLACC1-4 clones.
  • Clone LCC2-5B-1 is digested with EagI and Bg/II and electrophoresed on a 1% agarose gel.
  • the gel slice containing the 1.3 kb EagI/Bg/II fragment is excised, and the DNA is isolated using a Spin Bind column (FMC).
  • FMC Spin Bind column
  • a PCR reaction is performed to obtain an EcoRI/Bg/II fragment containing the N-terminal half of lcc2.
  • the PCR reaction mixture contains 0.1 mg of CCLACC1-4 DNA, 50 pmol each of oligonucleotides 96-0545 and 96-0546, 0.01mM each of dATP, dCTP, dGTP, and dTTP, and 0.5 U Taq DNA polymerase.
  • PCR conditions are 1 cycle at 95° C. for 5 minutes, 55° C. for 1 minute, and 72° C. for 1 minute; and 30 cycles each at 95° C. for 30 seconds, 55° C. for 1 minute, and 72° C. for 1 minute.
  • the primers used in the reaction are:
  • the desired product of 1.6 kb is subcloned into pCRII using the TA Cloning Kit (Invitrogen, San Diego, Calif.). Partial nucleotide sequences of the subclones are determined using M13-20 universal and M13 ⁇ 48 reverse universal primers.
  • the final plasmid is constructed by digesting pBluescript SK- with EcoRI/EagI and ligating with the EagI/Bg/II fragment from LCC2-5B-1 and the Bg/II/EcoRI fragment from the pCRII subclone. The resulting subclones are screened by restriction digests, and the desired product is designated pDSY105.
  • the lcc2 gene contains 13 introns (indicated by lowercase in FIG. 3 ). The positions of introns 4 through 10 are confirmed from the partial cDNA while the positions of the other 6 introns are deduced based on the consensus sequences found at the 5′ and 3′ splice sites of fungal introns and by homology of the deduced amino acid sequence (FIG. 3, SEQ ID NO:33) to other laccases.
  • the lcc2 gene encodes for a precursor protein of 517 amino acids in length. This is one potential N-glycosylation site, and the mature protein after the predicted signal peptide cleavage is 499 amino acids in length.
  • Lcc1 shares 59.3% and 57.5% identity with Lcc2 and Lcc3, respectively (Table 2).
  • Lcc2 and Lcc3 have the highest identity (79.6%) with one another.
  • the percent identities shared with other fungal laccases range from a high of 62.8% for Lcc2 and the basidiomycete PM1 laccase to a low of 21.9% for Neospora Crassa laccase.
  • pDSY67 (FIG. 4) and pDSY68 (FIG. 5) are constructed for expression of Coprinus cinereus lcc1 gene.
  • the Coprinus cinereus lcc1 gene is cloned into the expression vector pKS4 which contains the TAKA promoter, AMG terminator and the Aspergillus nidulans pyrG for selection.
  • the lcc1 gene is inserted as 3 fragments into pKS4 digested with SwaI/NotI to obtain pDSY67 (FIG. 4 ). Sequencing of pDSY67 reveals the presence of 32 extra base pairs between the stop codon and the AMG terminator.
  • pDSY68 is generated by removing the extra thirty-two base pairs.
  • pDSY67 is digested with PacI/NotI and the ends are blunted using T4 DNA polymerase.
  • the blunt-end vector is ligated to itself, and the resulting plasmid pDSY68 is sequenced to confirm the extra base pairs are removed.
  • Aspergillus oryzae strains HowB712, JeRS316, and JeRS317 are grown for 18 hours in YEG medium at 34° C., and protoplasts are generated and transformed as described by Christensen et al. (1988 , Biotechnology 6: 1419-1422).
  • the protoplasts are transformed with 10 ⁇ g of either pDSY67 or pDSY68.
  • Transformants are selected on Minimal medium plates containing 1.0 M sucrose.
  • Minimal medium plates are comprised of 6.0 g of NaNO 3 , 0.52 g of KCl, 1.52 g of KH 2 PO 4 , 1.0 ml of trace metals solution, 20 g of Nobel Agar (Difco), 20 ml of 50 % glucose, 20 ml of methionine (50 g/l), 20 ml of biotin (200 mg/l), 2.5 ml of 20% MgSO 4 -7H 2 O, and 1.0 ml of mg/ml streptomycin per liter.
  • the agar medium is adjusted to pH 6.5 prior to autoclaving and then glucose, methionine, biotin, MgSO 4 - 7H 2 O, and streptomycin are added as sterile solutions to the cooled autoclaved medium and poured into plates.
  • the trace metals solution is comprised of 22 g of ZnSO 4 -7H 2 O, 11 g of H 3 BO 3 , 5 g of MnCl 2 -4H 2 O, 5 g of FeSO 4 -7H 2 O, 1.6 g of CoCl 2 -5H 2 O, 1.6 g of (NH 4 ) 6 Mo 7 O 24 , and 50 g of Na 4 EDTA per liter.
  • ABTS 2,2′-azinobis-(3-ethybenzthiazoline-6-sulfonic acid)
  • MY51 medium comprised of 30 g of maltose, 2 g of MgSO 4 , 10 g of KH 2 PO 4 , 2 g of K 2 SO 4 , 2 g of citric acid, 10 g of yeast extract, 0.5 ml of trace metals solution, 1 g of urea, 2 g of (NH 4 ) 2 SO 4 pH 6.0 per liter.
  • the trace metals solution is comprised of 14.3 g of ZnSO 4 -7H 2 O, 2.5 g of CuSO 4 ⁇ 5H 2 O, 11 g of NiCl 2 -6H 2 O, 13.8 g of FeSO 4 -7H 2 O, 8.5 g of MnSO 4 -H 2 O, and 3.0 g of citric acid per liter. Samples are taken at various intervals and centrifuged. The supernatants are diluted and assayed using ABTS as a substrate.
  • Laccase activity is determined by syringaldazine oxidation. Specifically, 60 ⁇ l of syringaldazine stock solution (0.28 mM in 50% ethanol) and 20 ⁇ l of laccase sample are mixed with 0.8 ml of preheated Britton-Robinson buffer solution and incubated at 20° C. The oxidation is monitored at 530 nm over 5 minutes and activity is expressed as “SOU” ⁇ mole syringaldazine oxidized per minute (“SOU”).
  • Britton-Robinson buffers with various pHs are used. ABTS oxidation assays are performed at 20° C. using 1 mM ABTS, Britton-Robinson buffers (diluted 1.1-fold) by monitoring ⁇ A405 in 96-well plates.
  • Aspergillus oryzae JeRS317 (pDSY68, lcc1) is inoculated into a 10 liter lab fermentor containing medium comprised of Nutriose, yeast extract, (NH 4 ) 2 HPO 4 , MgSO 4 -7H 2 O, critic acid, K 2 SO 4 , CaCl 2 -H 2 O, and trace metals solution and supplemented with CuSO 4 and fermented at 31° C., pH 7, 600-700 rpm for 7 days. The broth is then recovered and filtered through cheesecloth.
  • Buffer A After loading and washing with Buffer A, a linear gradient with Buffer B (Buffer A plus 2 M NaCl) is applied and the active fractions are eluted around 7% Buffer B.
  • the active fractions are dialyzed in Buffer A and then loaded onto a 40 ml Mono-Q 16/10 (Pharmacia, Uppsala, Sweden) column, pre-equilibrated with Buffer A. The active fractions pass through the column.
  • a molecular weight of 66 kDa for the recombinant laccase is observed by SDS-PAGE analysis, similar to that of wild type laccase. The difference between the observed molecular weight and that derived from the DNA sequence (56 kDa) suggests the laccase is 18% glycosylated.
  • the chromatographic elution pattern of recombinant laccase is very close to that of the recombinant Myceliophthora thermophila laccase under the same conditions, where the recombinant Coprinus cinereus laccase has a similar pI to the pI of 4.2 for recombinant Myceliophthora thermophila laccase, which is also close to the pI of wild type Coprinus cinereus laccase (3.7-4.0).
  • Copper (Cu) titration of the purified recombinant laccase with 2,2′-biquinoline is carried out as described by Felsenfeld, 1960 , Archives of Biochemistry and Biophysics 87: 247-251.
  • Photometric titration with 2,2′-biquinoline gives a Cu to protein (subunit) stoichiometry of 3.4 ⁇ 0.2, indicating the four-Cu oxidase nature of recombinant Coprinus cinereus laccase.
  • the purified recombinant Coprinus cinereus laccase shows a UV-visible spectrum with two maxima at 278 and 614 nm.
  • the ratio of absorbance at 280 mm to that at 600 nm is found as 22.
  • the extinction coefficient for the enzyme is determined by amino acid analysis and the molecular weight derived from the DNA sequence. Amino acid analysis suggests an extinction coefficient of 1.6 l/(g*cm), similar to the predicted value of 1.2.
  • the redox potential is measured by monitoring the recombinant Coprinus cinereus laccase's absorbance change at 600 nm with K 3 Fe(CN) 6 -K 4 Fe(CH) 6 couple (0.433 V) and with I 2 -NaI couple (0.536 V) in 9 mM MES-NaOH pH 5.3 buffer. At pH 5.3, a redox potential of 0.55 ⁇ 0.06 V is observed for the recombinant Coprinus cinereus laccase.
  • recombinant Coprinus cinereus laccase shows a LACU/A 250 of 2.7 or a LACU/mg near 4.
  • syringaldazine shows a K m of 26 ⁇ 6 ⁇ M and a k cat of 180 ⁇ 20 min ⁇ 1 .
  • the recombinant laccase shows a pH activity profile in the pH range from about 2.7 to about 7 with optimal activity at pH 4 similar to wild type Coprinus cinereus laccase (FIG. 6 B).
  • a K m of 23 ⁇ 3 ⁇ M and a k cat of 1090 ⁇ 30 min ⁇ 1 are observed for ABTS oxidation.
  • Wild type Coprinus cinereus laccase is treated with a number of deblocking agents in order to remove the blocked N-terminus. Buffer exchange of samples is carried out in BioRad's BioSpin (P-6) device. Samples are treated with pyroglutamate aminopeptidase (Boehringer Mannheim, Indianapolis, Ind. and Sigma, St. Louis Mo.) with deblocking protocols adapted from manufacturer's recommendations as follows.
  • a laccase sample is exchanged into 5% glycerol-10 mM EDTA-0.1 M sodium phosphate pH 8, then mixed with dithiothreitol (DTT) to 0.7 mM and horse liver peptidase (Sigma, St Louis, Mo.) to 1/216 w/w laccase.
  • DTT dithiothreitol
  • horse liver peptidase Sigma, St Louis, Mo.
  • the mixture ( ⁇ 6.2 mg/ml in laccase) is divided into three aliquots, of which one is adjusted 1 M urea and another is adjusted 0.5 M guanidine-HCl. Each sample is incubated at 4° C. for 16 hours.
  • acylamino acid peptidase For acylamino acid peptidase, a laccase sample is exchanged into 0.2 M NH 4 HCO 3 pH 7.8, then mixed with EDTA to 1 mM, 2-mercaptoethanol to 1 mM, and peptidase to 1/5 w/w laccase. The mixture ( ⁇ 14 mg/ml in laccase) is divided into three aliquots, of which one is adjusted 0.01% in SDS, one is adjusted 0.08 M in guanidine-HCl, and another is adjusted 0.7 M is urea. Each sample is incubated at 37° C. for 20 hours.
  • a laccase sample is exchanged into 0.1 M sodium phosphate pH 7 then mixed with the acylase to 1 ⁇ 3 w/w of laccase.
  • the mixture ( ⁇ 15 mg/ml in laccase) is incubated at 37° C. for 22 hours.
  • the enzyme-treated laccase samples are concentrated using Amicon Microcon 10 devices.
  • the concentrated samples are run on SDS-PAGE and electroblotted onto a PVDF membrane of sequencing grade (Novex, San Diego, Calif.).
  • the PVDF membrane is stained with Coommassie blue R-250 to visualize the treated laccase bands.
  • the PVDF membrane is cut to isolate the pieces containing the individual bands.
  • Several lanes are combined and subjected directly to N-terminal sequencing on an ABI 476 Sequencer using a blot cartridge and liquid TFA delivery.
  • the purified wild-type Coprinus cinereus laccase has a blocked N-terminus.
  • treatment with both acylamino acid peptidase and acylase I leads to an identical sequenceable N-terminus.
  • the resulting N-terminal sequence is shown below where it is uncertain whether S represents the actual N-terminus in the mature laccase, as, if this is the case, it would require an unexpected deacylase function by acylamino peptidase.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Paper (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

The present invention relates to polypeptides having laccase activity and isolated nucleic acid sequences encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing the polypeptides.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation of U.S. application Ser. No. 08/689,421 filed on Aug. 9, 1996, now U.S. Pat. No. 6,008,029, which claims priority from U.S. provisional application Ser. No. 60/002,800 filed on Aug. 25, 1995, which applications are fully incorporated herein by reference.
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to polypeptides having laccase activity and isolated nucleic acid sequences encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing the polypeptides.
2. Description of the Related Art
Laccases (benzenediol:oxygen oxidoreductases) are multi-copper containing enzymes that catalyze the oxidation of phenolics. Laccase-mediated oxidations result in the production of aryloxy-radical intermediates from suitable phenolic substrate; the ultimate coupling of the intermediates so produced provides a combination of dimeric, oligomeric, and polymeric reaction products. Such reactions are important in nature in biosynthetic pathways which lead to the formation of melanin, alkaloids, toxins, lignins, and humic acids. Laccases are produced by a wide variety of fungi, including ascomycetes such as Aspergillus, Neurospora, and Podospora, the deuteromycete Botrytis, and basidiomycetes such as Collybia, Fomes, Lentinus, Pleurotus, Trametes, and perfect forms of Rhizoctonia. Laccase exhibits a wide range of substrate specificity, and each different fungal laccase usually differs only quantitatively from others in its ability to oxidize phenolic substrates. Because of the substrate diversity, laccases generally have found many potential industrial applications. Among these are lignin modification, paper strengthening, dye transfer inhibition in detergents, phenol polymerization, juice manufacture, phenol resin production, and waste water treatment.
Although the catalytic capabilities are similar, laccases made by different fungal species do have different temperature and pH optima. A number of these fungal laccases have been isolated, and the genes for several of these have been cloned. For example, Choi et al. (1992, Mol. Plant-Microbe Interactions 5: 119-128) describe the molecular characterization and cloning of the gene encoding the laccase of the chestnut blight fungus Cryphonectria parasitica. Kojima et al. (1990, Journal of Biological Chemistry 265: 15224-15230; JP 2-238885) provide a description of two allelic forms of the laccase of the white-rot basidiomycete Coriolus hirsutus. Germann and Lerch (1985, Experientia 41: 801; 1986, Proceedings of the National Academy of Sciences USA 83: 8854-8858) have reported the cloning and partial sequencing of the Neurospora crassa laccase gene. Saloheimo et al. (1985, Journal of General Microbiology 137:1537-1544; WO 92/01046) have disclosed a structural analysis of the laccase gene from the fungus Phlebia radiata.
It is an object of the present invention to provide polypeptides having laccase activity and nucleic acid constructs encoding these polypeptides.
SUMMARY OF THE INVENTION
The present invention relates to isolated polypeptides having laccase activity, obtained from a Coprinus strain. The present invention further relates to isolated polypeptides having laccase activity which have: (a) a pH optimum in the range of about 5 to about 9 at 20° C. using syringaldazine as a substrate; and (b) an isoelectric point in the range of about 3.7 to about 4.0. The present invention also relates to isolated polypeptides which have an amino acid sequence which has at least 65% identity with the amino acid sequence set forth in SEQ ID NO:27, SEQ ID NO:29, or SEQ ID NO:33.
The present invention further relates to isolated nucleic acid sequences encoding the polypeptides and to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing the polypeptides.
BRIEF DESCRIPTION OF THE FIGURES
FIG. 1 illustrates the nucleotide sequence and the deduced amino acid sequence of the Coprinus cinereus lcc1 gene.
FIG. 2 illustrates the nucleotide sequence and the deduced amino acid sequence of the Coprinus cinereus lcc3 gene.
FIG. 3 illustrates the nucleotide sequence and the deduced amino acid sequence of the Coprinus cinereus lcc2 gene.
FIG. 4 illustrates the construction of plasmid pDSY67.
FIG. 5 illustrates a map of plasmid pDSY68.
FIG. 6 illustrates the pH activity profiles of recombinant and wild-type Coprinus cinereus laccases using (A) syringaldazine and (B) of 2,2′-azinobis-(3-ethybenzthiazoline-6-sulfonic acid (ABTS) as substrates.
DETAILED DESCRIPTION OF THE INVENTION Polypeptides Having Laccase Activity
The present invention relates to isolated polypeptides having laccase activity (hereinafter “polypeptides”), obtained from a Coprinus strain. The present invention further relates to isolated polypeptides having laccase activity which have:
(a) a pH optimum in the range of about 5 to about 9 at 20° C. using syringaldazine as a substrate; and
(b) an isoelectric point in the range of about 3.7 to about 4.0.
The polypeptides preferably have a molecular weight of about 63 kDa (using SDS-PAGE).
In another embodiment, the polypeptides are obtained from a strain of the family Coprinaceae, preferably a Coprinus strain, and more preferably a Coprinus cinereus strain, e.g., Coprinus cinereus IFO 8371 or a mutant strain thereof. In a most preferred embodiment, the polypeptide has the amino acid sequence set forth in SEQ ID NO:27, SEQ ID NO:29, or SEQ ID NO:33.
The present invention also relates to polypeptides obtained from microorganisms which are synonyms of Coprinus as defined by, for example, Webster, 1980, In Introduction to the Fungi, Second Edition, Cambridge University Press, New York. Strains of Coprinus are readily accessible to the public in a number of culture collections, such as the American Type Culture Collection (ATCC), Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSM), Centraalbureau Voor Schimmelcultures (CBS), and Agricultural Research Service Patent Culture Collection, Northern Regional Research Center (NRRL), e.g., from the American Type Culture Collection, ATCC 12890, 36519, 38628, 42727, 48566 (Coprinus cinereus); 15744 (Coprinus clastophyllus); 12640, 22314 (Coprinus comatus); 46457, 46972 (Coprinus congregatus); 48096 (Coprinus cothurnatus); 48098 (Coprinus curtus); 46973 (Coprinus disseminatus); 26829 (Coprinus domesticus); 48100 (Coprinus ephemeroides); 36567 (Coprinus fimentarius); 48097 (Coprinus gonophyllus); 20122 (Coprinus micaceus); from the Institute for Fermentation (IFO, Osaka, Japan), IFO 8371, 30116 (Coprinus cinereus); from Centraalbureau voor Schimmelcultures (CBS; Netherlands) CBS 147.39, 148.39, 175.51 (Coprinus angulatus), 147.29 (Coprinus astramentarius); 143,39 (Coprinus auricomus); 185.52 (Coprinus callinus); 159.39, 338.69 (Coprinus cinereus); 631.95 (Coprinus comatus); 629.95 (Coprinus friesii); 627.95 (Coprinus plicatilis) 628.95 (Psathyrella condolleana); 630.95 (Panaeolus papilionaceus) from Deutsche Sammlung von Mikroorganismenn und Zellkulturen (DSM; Germany) DSM 888 (Coprinus radians); 4916 (Csprinus xanthothrix); 3341 (Coprinus sterquilinius). The invention also embraces polypeptides having laccase activity of other fungi and other members of the family Coprinaceae, for example, laccases from the genera Podaxis, Montagnea, Macrometrula, Psathyrella, Panaeolina, Panaeolus, Copelandia, Anellaria, Limnoperdon, Panaelopsis, and Polyplocium.
For purposes of the present invention, the term “obtained from” as used herein in connection with a given source shall mean that the polypeptide is produced by the source or by a cell in which a gene from the source has been inserted.
The present invention also relates to polypeptides which are encoded by nucleic acid sequences which are capable of hybridizing under standard conditions with an oligonucleotide probe which hybridizes under the same conditions with the nucleic acid sequence set forth in SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:32 as well as a complementary strand thereof or a subsequence thereof (J. Sambrook, E. F. Fritsch, and T. Maniatus, 1989, Molecular Cloning, A Laboratory Manual, 2nd edition, Cold Spring Harbor, New York). Hybridization indicates that the analogous nucleic acid sequence hybridizes to the oligonucleotide probe corresponding to the polypeptide encoding part of the nucleic acid sequence shown in SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:32, or a subsequence thereof, under medium to high stringency conditions (for example, prehybridization and hybridization at 42° C. in 5X SSPE, 0.3% SDS, 200 μg/ml sheared and denatured salmon sperm DNA, and either 35 or 50% formamide for medium and high stringencies, respectively), following standard Southern blotting procedures.
The nucleic acid sequences set forth in SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:32, or subsequences thereof may be used to identify and clone DNA encoding laccases from other strains of different genera or species according to methods well known in the art. Thus, a genomic or cDNA library prepared from such other organisms may be screened for DNA which hybridizes with SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:32, or subsequences thereof. Genomic or other DNA from such other organisms may be separated by agarose or polyacrylamide gel electrophoresis, or other separation techniques. DNA from the libraries or the separated DNA may be transferred to and immobilized on nitrocellulose or other suitable carrier material. In order to identify clones or DNA which are homologous with SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:32, or subsequences thereof, the carrier material is used in a Southern blot in which the carrier material is finally washed three times for 30 minutes each using 0.2XSSC, 0.1% SDS at 40° C., more preferably not higher than 45° C., more preferably not higher than 50° C., more preferably not higher than 55° C., even more preferably not higher than 60° C., especially not higher than 65° C. Molecules to which the oligonucleotide probe hybridizes under these conditions are detected using a X-ray film.
The present invention also relates to polypeptides which have an amino acid sequence which has a degree of identity to the amino acid sequence set forth in SEQ ID NO:27, SEQ ID NO:29, or SEQ ID NO:33 of at least about 65%, preferably about 70%, preferably about 75%, preferably about 80%, preferably about 85%, more preferably about 90%, even more preferably about 95%, and most preferably about 97%, which qualitatively retain the activity of the polypeptides (hereinafter “homologous polypeptides”). In a preferred embodiment, the homologous polypeptides have an amino acid sequence which differs by five amino acids, preferably by four amino acids, more preferably by three amino acids, even more preferably by two amino acids, and most preferably by one amino acid from the amino acid sequence set forth SEQ ID NO:27, SEQ ID NO:29, or SEQ ID NO:33. The degree of identity between two or more amino acid sequences may be determined by means of computer programs known in the art such as GAP provided in the GCG program package (Needleman and Wunsch, 1970, Journal of Molecular Biology 48:443-453). For purposes of determining the degree of identity between two amino acid sequences for the present invention, the Clustal method (DNASTAR, Inc., Madison, Wis.) is used with an identity table, a gap penalty of 10, and a gap length of 10.
The amino acid sequences of the homologous polypeptides differ from the amino acid sequence set forth in SEQ ID NO:27, SEQ ID NO:29, or SEQ ID NO:33 by an insertion or deletion of one or more amino acid residues and/or the substitution of one or more amino acid residues by different amino acid residues. Preferably, amino acid changes are of a minor nature, that is conservative amino acid substitutions that do not significantly affect the folding and/or activity of the protein; small deletions, typically of one to about 30 amino acids; small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue; a small linker peptide of up to about 20-25 residues; or a small extension that facilitates purification by changing net charge or another function, such as a poly-histidine tract, an antigenic epitope or a binding domain.
Examples of conservative substitutions are within the group of basic amino acids (such as arginine, lysine and histidine), acidic amino acids (such as glutamic acid and aspartic acid), polar amino acids (such as glutamine and asparagine), hydrophobic amino acids (such as leucine, isoleucine and valine), aromatic amino acids (such as phenylalanine, tryptophan and tyrosine) and small amino acids (such as glycine, alanine, serine, threonine and methionine). Amino acid substitutions which do not generally alter the specific activity are known in the art and are described, e.g., by H. Neurath and R. L. Hill, 1979, In, The Proteins, Academic Press, New York. The most commonly occurring exchanges are Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Tyr/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, and Asp/Gly as well as these in reverse.
The present invention also relates to polypeptides having immunochemical identity or partial immunochemical identity to the polypeptides having laccase activity which are native to Coprinus cinereus IFO 8371. A polypeptide having immunochemical identity to the polypeptide native to Coprinus cinereus IFO 8371 means that an antiserum containing antibodies against the antigens of the native polypeptide reacts with the antigens of the other polypeptide in an identical fashion such as total fusion of precipitates, identical precipitate morphology, and/or identical electrophoretic mobility using a specific immunochemical technique. A further explanation of immunochemical identity is described by Axelsen, Bock, and Krøll, In N. H. Axelsen, J. Krøll, and B. Weeks, editors, A Manual of Quantitative Immunoelectrophoresis, Blackwell Scientific Publications, 1973, Chapter 10. Partial immunochemical identity means that an antiserum containing antibodies against the antigens of the native polypeptide reacts with the antigens of the other polypeptide in an partially identical fashion such as partial fusion of precipitates, partially identical precipitate morphology, and/or partially identical electrophoretic mobility using a specific immunochemical technique. A further explanation of partial immunochemical identity is described by Bock and Axelsen, In N. H. Axelsen, J. Krøll, and B. Weeks, editors, A Manual of Quantitative Immunoelectrophoresis, Blackwell Scientific Publications, 1973, Chapter 11. The immunochemical properties are determined by immunological cross-reaction identity tests by the well-known Ouchterlony double immunodiffusion procedure. Specifically, an antiserum against the polypeptide of the invention is raised by immunizing rabbits (or other rodents according to the procedure described by Harboe and Ingild, In N. H. Axelsen, J. Krøll, and B. Weeks, editors, A Manual of Quantitative Immunoelectrophoresis, Blackwell Scientific Publications, 1973, Chapter 23, or Johnstone and Thorpe, Immunochemistry in Practice, Blackwell Scientific Publications, 1982 (more specifically pages 27-31). Monoclonal antibodies may be prepared, e.g., according to the methods of E. Harlow and D. Lane, editors, 1988, Antibodies, A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, New York. Purified immunoglobulins may be obtained from the antiserum, e.g., by ammonium sulfate precipitation, followed by dialysis and ion exchange chromatography (e.g., DEAE-Sephadex).
Homologous polypeptides and polypeptides having identical or partially identical immunological properties may be obtained from microorganisms of any genus, preferably from a bacterial or fungal source. Sources for homologous genes are strains of the family Coprinaceae, preferably of the genus Coprinus and species thereof available in public depositories. Furthermore, homologous genes may be identified and obtained from other sources including microorganisms isolated from nature (e.g., soil, composts, water, etc.) using the above-mentioned probes. Techniques for isolating microorganisms from natural habitats are well known in the art. The nucleic acid sequence may then be derived by similarly screening a cDNA library of another microorganism. Once a nucleic acid sequence encoding a polypeptide has been detected with the probe(s), the sequence may be isolated or cloned by utilizing techniques which are known to those of ordinary skill in the art (see, e.g., Sambrook et al., supra).
As defined herein, an “isolated” polypeptide is a polypeptide which is essentially free of other non-laccase polypeptides, e.g., at least about 20% pure, preferably at least about 40% pure, more preferably about 60% pure, even more preferably about 80% pure, most preferably about 90% pure, and even most preferably about 95% pure, as determined by SDS-PAGE.
Nucleic Acid Sequences
The present invention also relates to isolated nucleic acid sequences obtained from a Coprinus strain, which encode a polypeptide of the present invention. In a preferred embodiment, the nucleic acid sequence encodes a polypeptide obtained from Coprinus cinereus and in a more preferred embodiment, the nucleic acid sequence is obtained from Coprinus cinereus IFO 8371, e.g. , the nucleic acid sequence set forth in SEQ ID NO:26, SEQ ID NO:28, or SEQ ID NO:32. The present invention also encompasses nucleic acid sequences which encode a polypeptide having the amino acid sequence set forth in SEQ ID NO:27, SEQ ID NO:29, or SEQ ID NO:33, which differ from SEQ ID NO:26, SEQ ID NO:28, or SEQ ID NO:32, respectively, by virtue of the degeneracy of the genetic code.
As described above, the nucleic acid sequences may be obtained from microorganisms which are synonyms of Coprinus as defined by Webster, 1980, supra.
The techniques used to isolate or clone a nucleic acid sequence encoding a polypeptide are known in the art and include isolation from genomic DNA, preparation from cDNA, or a combination thereof. The cloning of the nucleic sequences of the present invention from such genomic DNA can be effected, e.g., by using the well known polymerase chain reaction (PCR). See, e.g., Innis et al., 1990, A Guide to Methods and Application, Academic Press, New York. The nucleic acid sequence may be cloned from a strain of the Coprinus producing the polypeptide, or another or related organism and thus, for example, may be an allelic or species variant of the polypeptide encoding region of the nucleic acid sequence.
The term “isolated nucleic acid sequence” as used herein refers to a nucleic acid sequence encoding a polypeptide of the present invention which is isolated by standard cloning procedures used in genetic engineering to relocate the nucleic acid sequence from its natural location to a different site where it will be reproduced. The cloning procedures may involve excision and isolation of a desired nucleic acid fragment comprising the nucleic acid sequence encoding the polypeptide, insertion of the fragment into a vector molecule, and incorporation of the recombinant vector into a host cell where multiple copies or clones of the nucleic acid sequence will be replicated. The nucleic acid sequence may be of genomic, cDNA, RNA, semisynthetic, synthetic origin, or any combinations thereof.
The present invention also relates to nucleic acid sequences which have a nucleic acid sequence which has a degree of identity to the nucleic acid sequence set forth in SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:32, or subsequences thereof of at least about 65%, preferably about 70%, preferably about 75%, preferably about 80%, preferably about 85% more preferably about 90%, even more preferably about 95%, and most preferably about 97% which encode an active polypeptide. The degree of identity between two nucleic acid sequences may be determined by means of computer programs known in the art such as GAP provided in the GCG program package (Needleman and Wunsch, 1970, Journal of Molecular Biology 48:443-453). For purposes of determining the degree of identity between two nucleic acid sequences for the present invention, the Clustal method (DNASTAR, Inc., Madison, Wis.) is used with an identity table, a gap penalty of 10, and a gap length of 10.
Modification of the nucleic acid sequence encoding the polypeptide may be necessary for the synthesis of polypeptides substantially similar to the polypeptide. The term “substantially similar” to the polypeptide refers to non-naturally occurring forms of the polypeptide. These polypeptides may differ in some engineered way from the polypeptide isolated from its native source. For example, it may be of interest to synthesize variants of the polypeptide where the variants differ in specific activity, thermostability, pH optimum, or the like using, e.g., site-directed mutagenesis. The analogous sequence may be constructed on the basis of the nucleic acid sequence presented as the polypeptide encoding part of SEQ ID NO:26, SEQ ID NO:28, or SEQ ID NO:32, e.g., a sub-sequence thereof, and/or by introduction of nucleotide substitutions which do not give rise to another amino acid sequence of the polypeptide encoded by the nucleic acid sequence, but which corresponds to the codon usage of the host organism intended for production of the enzyme, or by introduction of nucleotide substitutions which may give rise to a different amino acid sequence. For a general description of nucleotide substitution, see, e.g., Ford et al., 1991, Protein Expression and Purification 2:95-107.
It will be apparent to those skilled in the art that such substitutions can be made outside the regions critical to the function of the molecule and still result in an active polypeptide. Amino acid residues essential to the activity of the polypeptide encoded by the isolated nucleic acid sequence of the invention, and therefore preferably not subject to substitution, may be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis (see, e.g., Cunningham and Wells, 1989, Science 244:1081-1085). In the latter technique mutations are introduced at every residue in the molecule, and the resultant mutant molecules are tested for laccase activity to identify amino acid residues that are critical to the activity of the molecule. Sites of substrate-enzyme interaction can also be determined by analysis of crystal structure as determined by such techniques as nuclear magnetic resonance analysis, crystallography or photoaffinity labelling (see, e.g., de Vos et al., 1992, Science 255, 306-312; Smith et al., 1992, Journal of Molecular Biology 224:899-904; Wlodaver et al., 1992, FEBS Letters 309, 59-64).
Polypeptides of the present invention also include fused polypeptides in which another polypeptide is fused at the N-terminus or the C-terminus of the polypeptide or fragment thereof. A fused polypeptide is produced by fusing a nucleic acid sequence (or a portion thereof) encoding another polypeptide to a nucleic acid sequence (or a portion thereof) of the present invention. Techniques for producing fusion polypeptides are known in the art, and include, ligating the coding sequences encoding the polypeptides so that they are in frame and that expression of the fused polypeptide is under control of the same promoter(s) and terminator.
The present invention also relates nucleic acid sequences which are capable of hybridizing under standard conditions with an oligonucleotide probe which hybridizes under the same conditions with the nucleic acid sequence set forth in SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:32, a subsequence thereof, or its complementary strand (Sambrook et al., supra). Hybridization indicates that the analogous nucleic acid sequence hybridizes to the oligonucleotide probe corresponding to the polypeptide encoding part of the nucleic acid sequence shown in SEQ ID NO:26, SEQ ID NO:28, or SEQ ID NO:32 under standard conditions.
The amino acid sequence set forth in SEQ ID NO:27, SEQ ID NO:29, or SEQ ID NO:33 or a partial amino acid sequence thereof may be used to design an oligonucleotide probe, or a gene encoding a polypeptide of the present invention or a subsequence thereof can also be used as a probe, to isolate homologous genes of any genus or species. In particular, such probes can be used for hybridization with the genomic or cDNA of the genus or species of interest, following standard Southern blotting procedures, in order to identify and isolate the corresponding gene therein. Such probes can be considerably shorter than the entire sequence, but should be at least 15, preferably at least 25, and more preferably at least 40 nucleotides in length. Longer probes, preferably no more than 1200 nucleotides in length, can also be used. Both DNA and RNA probes can be used. The probes are typically labeled for detecting the corresponding gene (for example, with 32P, 1H, biotin, or avidin). A PCR reaction using the degenerate probes mentioned herein and genomic DNA or first-strand cDNA from a Coprinus cinereus can also yield a Coprinus cinereus laccase-specific product which can then be used as a probe to clone the corresponding genomic or cDNA.
Nucleic Acid Constructs
The present invention also relates to nucleic acid constructs comprising a nucleic acid sequence of the present invention operably linked to one or more control sequences capable of directing the expression of the coding sequence in a suitable host cell under conditions compatible with the control sequences.
“Nucleic acid construct” is defined herein as a nucleic acid molecule, either single- or double-stranded, which is isolated from a naturally occurring gene or which has been modified to contain segments of nucleic acid which are combined and juxtaposed in a manner which would not otherwise exist in nature. The term nucleic acid construct may be synonymous with the term expression cassette when the nucleic acid construct contains all the control sequences required for expression of a coding sequence of the present invention. The term “coding sequence” as defined herein is a sequence which is transcribed into mRNA and translated into a polypeptide of the present invention when placed under the control of the above mentioned control sequences. The boundaries of the coding sequence are generally determined by a translation start codon ATG at the 5′-terminus and a translation stop codon at the 3′-terminus. A coding sequence can include, but is not limited to, DNA, cDNA, and recombinant nucleic acid sequences.
An isolated nucleic acid sequence encoding a polypeptide of the present invention may be manipulated in a variety of ways to provide for expression of the polypeptide. Manipulation of the nucleic acid sequence encoding a polypeptide prior to its insertion into a vector may be desirable or necessary depending on the expression vector. The techniques for modifying nucleic acid sequences utilizing cloning methods are well known in the art.
The term “control sequences” is defined herein to include all components which are necessary or advantageous for expression of the coding sequence of the nucleic acid sequence. Each control sequence may be native or foreign to the nucleic acid sequence encoding the polypeptide. Such control sequences include, but are not limited to, a leader, a polyadenylation sequence, a propeptide sequence, a promoter, a signal sequence, and a transcription terminator. At a minimum, the control sequences include a promoter, and transcriptional and translational stop signals. The control sequences may be provided with linkers for the purpose of introducing specific restriction sites facilitating ligation of the control sequences with the coding region of the nucleic acid sequence encoding a polypeptide.
The control sequence may be an appropriate promoter sequence, a nucleic acid sequence which is recognized by a host cell for expression of the nucleic acid sequence. The promoter sequence contains transcription and translation control sequences which mediate the expression of the polypeptide. The promoter may be any nucleic acid sequence which shows transcriptional activity in the host cell of choice and may be obtained from genes encoding extracellular or intracellular polypeptides either homologous or heterologous to the host cell.
Examples of suitable promoters for directing the transcription of the nucleic acid constructs of the present invention, especially in a bacterial host cell, are the promoters obtained from the E. coli lac operon, the Streptomyces coelicolor agarase gene (dagA), the Bacillus subtilis levansucrase gene (sacB), the Bacillus licheniformis alpha-amylase gene (amyL), the Bacillus stearothermophilus maltogenic amylase gene (amyM), the Bacillus amyloliquefaciens alpha-amylase gene (amyQ), the Bacillus licheniformis penicillinase gene (penP), the Bacillus subtilis xylA and xylB genes, and the prokaryotic beta-lactamase gene (Villa-Kamaroff et al., 1978, Proceedings of the National Academy of Sciences USA 75:3727-3731), as well as the tac gene (DeBoer et al., 1983, Proceedings of the National Academy of Sciences USA 80:21-25). Further promoters are described in “Useful proteins from recombinant bacteria” in Scientific American, 1980, 242:74-94; and in Sambrook et al., 1989, supra.
Examples of suitable promoters for directing the transcription of the nucleic acid constructs of the present invention in a filamentous fungal host cell are promoters obtained from the genes encoding Aspergillus oryzae TAKA amylase, Rhizomucor miehei aspartic proteinase, Aspergillus niger neutral alpha-amylase, Aspergillus niger acid stable alpha-amylase, Aspergillus niger or Aspergillus awamori glucoamylase (glaA), Rhizomucor miehei lipase, Aspergillus oryzae alkaline protease, Aspergillus oryzae triose phosphate isomerase, Aspergillus nidulans acetamidase, Fusarium oxysporum trypsin-like protease (as described in U.S. Pat. No. 4,288,627, which is incorporated herein by reference), and hybrids thereof. Particularly preferred promoters for use in filamentous fungal host cells are the TAKA amylase, NA2-tpi (a hybrid of the promoters from the genes encoding Aspergillus niger neutral α-amylase and Aspergillus oryzae triose phosphate isomerase), and glaA promoters.
In a yeast host, useful promoters are obtained from the Saccharomyces cerevisiae enolase (ENO-1) gene, the Saccharomyces cerevisiae galactokinase gene (GAL1), the Saccharomyces cerevisiae alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase genes (ADH2/GAP), and the Saccharomyces cerevisiae 3-phosphoglycerate kinase gene. Other useful promoters for yeast host cells are described by Romanos et al., 1992, Yeast 8:423-488. In a mammalian host cell, useful promoters include viral promoters such as those from Simian Virus 40 (SV40), Rous sarcoma virus (RSV), adenovirus, and bovine papilloma virus (BPV).
The control sequence may also be a suitable transcription terminator sequence, a sequence recognized by a host cell to terminate transcription. The terminator sequence is operably linked to the 3′ terminus of the nucleic acid sequence encoding the polypeptide. Any terminator which is functional in the host cell of choice may be used in the present invention.
Preferred terminators for filamentous fungal host cells are obtained from the genes encoding Aspergillus oryzae TAKA amylase, Aspergillus niger glucoamylase, Aspergillus nidulans anthranilate synthase, Aspergillus niger alpha-glucosidase, and Fusarium oxysporum trypsin-like protease.
Preferred terminators for yeast host cells are obtained from the genes encoding Saccharomyces cerevisiae enolase, Saccharomyces cerevisiae cytochrome C (CYC1), or Saccharomyces cerevisiae glyceraldehyde-3-phosphate dehydrogenase. Other useful terminators for yeast host cells are described by Romanos et al., 1992, supra. Terminator sequences are well known in the art for mammalian host cells.
The control sequence may also be a suitable leader sequence, a nontranslated region of a mRNA which is important for translation by the host cell. The leader sequence is operably linked to the 5′ terminus of the nucleic acid sequence encoding the polypeptide. Any leader sequence which is functional in the host cell of choice may be used in the present invention.
Preferred leaders for filamentous fungal host cells are obtained from the genes encoding Aspergillus oryzae TAKA amylase and Aspergillus oryzae triose phosphate isomerase.
Suitable leaders for yeast host cells are obtained from the Saccharomyces cerevisiae enolase (ENO-1) gene, the Saccharomyces cerevisiae 3-phosphoglycerate kinase gene, the Saccharomyces cerevisiae alpha-factor, and the Saccharomyces cerevisiae alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase genes (ADH2/GAP).
The control sequence may also be a polyadenylation sequence, a sequence which is operably linked to the 3′ terminus of the nucleic acid sequence and which, when transcribed, is recognized by the host cell as a signal to add polyadenosine residues to transcribed mRNA. Any polyadenylation sequence which is functional in the host cell of choice may be used in the present invention.
Preferred polyadenylation sequences for filamentous fungal host cells are obtained from the genes encoding Aspergillus oryzae TAKA amylase, Aspergillus niger glucoamylase, Aspergillus nidulans anthranilate synthase, and Aspergillus niger alpha-glucosidase.
Useful polyadenylation sequences for yeast host cells are described by Guo and Sherman, 1995, Molecular Cellular Biology 15:5983-5990. Polyadenylation sequences are well known in the art for mammalian host cells.
The control sequence may also be a signal peptide coding region, which codes for an amino acid sequence linked to the amino terminus of the polypeptide which can direct the expressed polypeptide into the cell's secretory pathway. The 5′ end of the coding sequence of the nucleic acid sequence may inherently contain a signal peptide coding region naturally linked in translation reading frame with the segment of the coding region which encodes the secreted polypeptide. Alternatively, the 5′ end of the coding sequence may contain a signal peptide coding region which is foreign to that portion of the coding sequence which encodes the secreted polypeptide. The foreign signal peptide coding region may be required where the coding sequence does not normally contain a signal peptide coding region. Alternatively, the foreign signal peptide coding region may simply replace the natural signal peptide coding region in order to obtain enhanced secretion of the laccase relative to the natural signal peptide coding region normally associated with the coding sequence. The signal peptide coding region may be obtained from a glucoamylase or an amylase gene from an Aspergillus species, a lipase or proteinase gene from a Rhizomucor species, the gene for the α-factor from Saccharomyces cerevisiae, an amylase or a protease gene from a Bacillus species, or the calf preprochymosin gene. However, any signal peptide coding region capable of directing the expressed laccase into the secretory pathway of a host cell of choice may be used in the present invention.
An effective signal peptide coding region for bacterial host cells is the signal peptide coding region obtained from the maltogenic amylase gene from Bacillus NCIB 11837, the Bacillus stearothermophilus alpha-amylase gene, the Bacillus licheniformis subtilisin gene, the Bacillus licheniformis beta-lactamase gene, the Bacillus stearothermophilus neutral proteases genes (nprT, nprS, nprM), and the Bacillus subtilis PrsA gene. Further signal peptides are described by Simonen and Palva, 1993, Microbiological Reviews 57:109-137.
An effective signal peptide coding region for filamentous fungal host cells is the signal peptide coding region obtained from Aspergillus oryzae TAKA amylase gene, Aspergillus niger neutral amylase gene, the Rhizomucor miehei aspartic proteinase gene, the Humicola lanuginosa cellulase gene, or the Rhizomucor miehei lipase gene.
Useful signal peptides for yeast host cells are obtained from the genes for Saccharomyces cerevisiae alpha-factor and Saccharomyces cerevisiae invertase. Other useful signal peptide coding regions are described by Romanos et al., 1992, supra.
The control sequence may also be a propeptide coding region, which codes for an amino acid sequence positioned at the amino terminus of a polypeptide. The resultant polypeptide is known as a proenzyme or propolypeptide (or a zymogen in some cases). A propolypeptide is generally inactive and can be converted to a mature active polypeptide by catalytic or autocatalytic cleavage of the propeptide from the propolypeptide. The propeptide coding region may be obtained from the Bacillus subtilis alkaline protease gene (aprE), the Bacillus subtilis neutral protease gene (nprT), the Saccharomyces cerevisiae alpha-factor gene, or the Myceliophthora thermophilum laccase gene (WO 95/33836).
The nucleic acid constructs of the present invention may also comprise one or more nucleic acid sequences which encode one or more factors that are advantageous in the expression of the polypeptide, e.g., an activator (e.g., a trans-acting factor), a chaperone, and a processing protease. Any factor that is functional in the host cell of choice may be used in the present invention. The nucleic acids encoding one or more of these factors are not necessarily in tandem with the nucleic acid sequence encoding the polypeptide.
An activator is a protein which activates transcription of a nucleic acid sequence encoding a polypeptide (Kudla et al., 1990, EMBO Journal 9:1355-1364; Jar:o and Buxton, 1994, Current Genetics 26:2238-244; Verdier, 1990, Yeast 6:271-297). The nucleic acid sequence encoding an activator may be obtained from the genes encoding Bacillus stearothermophilus NprA (nprA), Saccharomyces cerevisiae heme activator protein 1 (hap1), Saccharomyces cerevisiae galactose metabolizing protein 4 (gal4), and Aspergillus nidulans ammonia regulation protein (areA). For further examples, see Verdier, 1990, supra and MacKenzie et al., 1993, Journal of General Microbiology 139:2295-2307.
A chaperone is a protein which assists another polypeptide in folding properly (Hard et al., 1994, TIBS 19:20-25; Bergeron et al., 1994, TIBS 19:124-128; Demolder et al., 1994, Journal of Biotechnology 32:179-189; Craig, 1993, Science 260:1902-1903; Gething and Sambrook, 1992, Nature 355:33-45; Puig and Gilbert, 1994, Journal of Biological Chemistry 269:7764-7771; Wang and Tsou, 1993, The FASEB Journal 7:1515-11157; Robinson et al., 1994, Bio/Technology 1:381-384). The nucleic acid sequence encoding a chaperone may be obtained from the genes encoding Bacillus subtilis GroE proteins, Aspergillus oryzae protein disulphide isomerase, Saccharomyces cerevisiae calnexin, Saccharomyces cerevisiae BiP/GRP78, and Saccharomyces cerevisiae IIsp70. For further examples, see Gething and Sambrook, 1992, supra, and Hard et al., 1994, supra.
A processing protease is a protease that cleaves a propeptide to generate a mature biochemically active polypeptide (Enderlin and Ogrydziak, 1994, Yeast 10:67-79; Fuller et al., 1989, Proceedings of the National Academy of Sciences USA 86:1434-1438; Julius et al., 1984, Cell 37:1075-1089; Julius et al., 1983, Cell 32:839-852). The nucleic acid sequence encoding a processing protease may be obtained from the genes encoding Saccharomyces cerevisiae dipeptidylaminopeptidase, Saccharomyces cerevisiae Kex2, and Yarowia lipolytica dibasic processing endoprotease (xpr6).
It may also be desirable to add regulatory sequences which allow the regulation of the expression of the polypeptide relative to the growth of the host cell. Examples of regulatory systems are those which cause the expression of the gene to be turned on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound. Regulatory systems in prokaryotic systems would include the lac, tac, and trp operator systems. In yeast, the ADH2 system or GAL1 system may be used. In filamentous fungi the TAKA alpha-amylase promoter. Aspergillus niger glucoamylase promoter, the Aspergillus oryzae glucoamylase promoter may be used as regulatory sequences. Other examples of regulatory sequences are those which allow for gene amplification. In eukaryotic systems, these include the dihydrofolate reductase gene which is amplified in the presence of methotrexate, and the metallothionein genes which are amplified with heavy metals. In these cases, the nucleic acid sequence encoding the polypeptide would be placed in tandem with the regulatory sequence.
Expression Vectors
The present invention also relates to recombinant expression vectors comprising a nucleic acid sequence of the present invention, a promoter, and transcriptional and translational stop signals. The various nucleic acid and control sequences described above may be joined together to produce a recombinant expression vector which may include one or more convenient restriction sites to allow for insertion or substitution of the nucleic acid sequence encoding the polypeptide at such sites. Alternatively, the nucleic acid sequence of the present invention may be expressed by inserting the nucleic acid sequence or a nucleic acid construct comprising the sequence into an appropriate vector for expression. In creating the expression vector, the coding sequence is located in the vector so that the coding sequence is operably linked with the appropriate control sequences for expression, and possibly secretion.
The recombinant expression vector may be any vector which can be conveniently subjected to recombinant DNA procedures and can bring about the expression of the nucleic acid sequence. The choice of the vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced. The vectors may be linear or closed circular plasmids. The vector may be an autonomously replicating vector, i.e., a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome. The vector may contain any means for assuring self-replication. Alternatively, the vector may be one which, when introduced into the host cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated. The vector system may be a single vector or plasmid or two or more vectors or plasmids which together contain the total DNA to be introduced into the genome of the host cell, or a transposon.
The vectors of the present invention preferably contain one or more selectable markers which permit easy selection of transformed cells. A selectable marker is a gene the product of which provides for biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs, and the like. Example's of bacterial selectable markers are the dal genes from Bacillus subtilis or Bacillus licheniformis, or markers which confer antibiotic resistance such as ampicillin, kanamycin, chloramphenicol or tetracycline resistance. A frequently used mammalian marker is the dihydrofolate reductase gene. Suitable markers for yeast host cells are ADE2, HIS3, LEU2, LYS2, MET3, TRP1, and URA3. A selectable marker for use in a filamentous fungal host cell may be selected from the group including, but not limited to, amdS (acetamidase), argB (ornithine carbamoyltransferase), bar (phosphinothricin acetyltransferase), hygB (hygromycin phosphotransferase), niaD (nitrate reductase), pyrG (orotidine-5′-phosphate decarboxylase), sC (sulfate adenyltransferase), trpC (anthranilate synthase), and glufosinate resistance markers, as well as equivalents from other species. Preferred for use in an Aspergillus cell are the amdS and pyrG markers of Aspergillus nidulans or Aspergillus oryzae and the bar marker of Streptomyces hygroscopicus. Furthermore, selection may be accomplished by co-transformation, e.g., as described in WO 91/17243, where the selectable marker is on a separate vector.
The vectors of the present invention preferably contain an element(s) that permits stable integration of the vector into the host cell genome or autonomous replication of the vector in the cell independent of the genome of the cell.
The vectors of the present invention may be integrated into the host cell genome when introduced into a host cell. For integration, the vector may rely on the nucleic acid sequence encoding the polypeptide or any other element of the vector for stable integration of the vector into the genome by homologous or nonhomologous recombination. Alternatively, the vector may contain additional nucleic acid sequences for directing integration by homologous recombination into the genome of the host cell. The additional nucleic acid sequences enable the vector to be integrated into the host cell genome at a precise location(s) in the chromosome(s). To increase the likelihood of integration at a precise location, the integrational elements should preferably contain a sufficient number of nucleic acids, such as 100 to 1,500 base pairs, preferably 400 to 1,500 base pairs, and most preferably 800 to 1,500 base pairs, which are highly homologous with the corresponding target sequence to enhance the probability of homologous recombination. The integrational elements may be any sequence that is homologous with the target sequence in the genome of the host cell. Furthermore, the integrational elements may be non-encoding or encoding nucleic acid sequences. On the other hand, the vector may be integrated into the genome of the host cell by non-homologous recombination. These nucleic acid sequences may be any sequence that is homologous with a target sequence in the genome of the host cell, and, furthermore, may be non-encoding or encoding sequences.
For autonomous replication, the vector may further comprise an origin of replication enabling the vector to replicate autonomously in the host cell in question. Examples of bacterial origins of replication are the origins of replication of plasmids pBR322, pUC19, pACYC177, pACYC184, pUB110, pE194, pTA1060, and pAMβ1. Examples of origin of replications for use in a yeast host cell are the 2 micron origin of replication, the combination of CEN6 and ARS4, and the combination of CEN3 and ARS1. The origin of replication may be one having a mutation which makes its functioning temperature-sensitive in the host cell (see, e.g., Ehrlich, 1978, Proceedings of the National Academy of Sciences USA 75:1433).
More than one copy of a nucleic acid sequence encoding a polypeptide of the present invention may be inserted into the host cell to amplify expression of the nucleic acid sequence. Stable amplification of the nucleic acid sequence can be obtained by integrating at least one additional copy of the sequence into the host cell genome using methods well known in the art and selecting for transformants.
The procedures used to ligate the elements described above to construct the recombinant expression vectors of the present invention are well known to one skilled in the art (see, e.g., Sambrook et al., 1989, supra).
Host Cells
The present invention also relates to recombinant host cells, comprising a nucleic acid sequence of the invention, which are advantageously used in the recombinant production of the polypeptides. The cell is preferably transformed with a vector comprising a nucleic acid sequence of the invention followed by integration of the vector into the host chromosome. “Transformation” means introducing a vector comprising a nucleic acid sequence of the present invention into a host cell so that the vector is maintained as a chromosomal integrant or as a self-replicating extra-chromosomal vector. Integration is generally considered to be an advantage as the nucleic acid sequence is more likely to be stably maintained in the cell. Integration of the vector into the host chromosome may occur by homologous or non-homologous recombination as described above.
The choice of a host cell will to a large extent depend upon the gene encoding the polypeptide and its source. The host cell may be a unicellular microorganism or a non-unicellular microorganism. Useful unicellular cells are bacterial cells such as gram positive bacteria including, but not limited to, a Bacillus cell, e.g., Bacillus subtilis, Bacillus licheniformis, Bacillus lentus, Bacillus brevis, Bacillus stearothermophilus, Bacillus alkalophilus, Bacillus amyloliquefaciens, Bacillus coagulans, Bacillus circulans, Bacillus lautus, Bacillus megaterium, and Bacillus thuringiensis; or a Streptomyces cell, e.g., Streptomyces lividans or Streptomyces murinus, or gram negative bacteria such as E. coli and Pseudomonas sp. In a preferred embodiment, the bacterial host cell is a Bacillus lentus, a Bacillus licheniformis, a Bacillus subtilis, or a Bacillus stearothermophilus cell. The transformation of a bacterial host cell may, for instance, be effected by protoplast transformation (see e.g., Chang and Cohen, 1979, Molecular General Genetics 168:111-115), by using competent cells (see, e.g., Young and Spizizin, 1961, Journal of Bacteriology 81:823-829, or Dubnar and Davidoff-Abelson, 1971, Journal of Molecular Biology 56:209-221), by electroporation (see, e.g., Shigekawa and Dower, 1988, Biotechniques 6:741-751), or by conjugation (see, e.g., Koehler and Thorne, 1987, Journal of Bacteriology 169:5771-5278).
The host cell may be a eukaryote, such as a mammalian cell, an insect cell, a plant cell or, preferably, a fungal cell. Useful mammalian cells include Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, COS cells, or any number of other immortalized cell lines available, e.g., from the American Type Culture Collection. The fungal host cell may be a yeast cell or a filamentous fungal cell.
“Yeast” as used herein includes ascosporogenous yeast (Endomycetales), basidiosporogenous yeast, and yeast belonging to the Fungi Imperfecti (Blastomycetes). The ascosporogenous yeasts are divided into the families Spermophthoraceae and Saccharomycetaceae. The latter is comprised of four subfamilies, Schizosaccharomycoideae (e.g., genus Schizosaccharomyces), Nadsonioideae, Lipomycoideae, and Saccharomycoideae (e.g., genera Pichia, Kluyveromyces and Saccharomyces). The basidiosporogenous yeasts include the genera Leucosporidim, Rhodosporidium, Sporidiobolus, Filobasidium, and Filobasidiella. Yeast belonging to the Fungi Imperfecti are divided into two families, Sporobolomycetaceae (e.g., genera Sorobolomyces and Bullera) and Cryptococcaceae (e.g., genus Candida). Since the classification of yeast may change in the future, for the purposes of this invention, yeast shall be defined as described in Biology and Activities of Yeast (Skinner, F, A., Passmore, S. M., and Davenport, R. R., eds, Soc. App. Bacteriol. Symposium Series No. 9, 1980. The biology of yeast and manipulation of yeast genetics are well known in the art (see, e.g., Biochemistry and Genetics of Yeast, Bacil, M., Horecker, B. J., and Stopani, A.O.M., editors, 2nd edition, 1987; The Yeasts, Rose, A. H., and Harrison, J. S., editors, 2nd edition, 1987; and The Molecular Biology of the Yeast Saccharomyces, Strathern et al., editors, 1981).
“Fungi” as used herein includes the phyla Ascomycota, Basidiomycota, Chytridiomycota, and Zygomycota (as defined by Hawksworth et al., In, Ainsworth and Bisby's Dictionary of the Fungi, 8th edition, 1995, CAB International, University Press, Cambridge, UK) as well as the Oomycota (as cited in Hawksworth et al., 1995, supra, page 171) and all mitosporic fungi (Hawksworth et al., 1995, supra). Representative groups of Ascomycota include, e.g., Neurospora, Eupenicillium (=Penicillum), Emericella (=Aspergillus), Eurotium (=Aspergillus), and the true yeasts listed above. Examples of Basidiomycota include mushrooms, rusts, and smuts. Representative groups of Chytridiomycota include, e.g., Allomyces, Blastocladiella, Coelomomyces, and aquatic fungi. Representative groups of Oomycota include, e.g., Saprolegniomycetous aquatic fungi (water molds) such as Achlya. Examples of mitosporic fungi include Aspergillus, Penicillium, Candida, and Alternaria. Representative groups of Zygomycota include, e.g., Rhizopus and Mucor.
“Filamentous fungi” include all filamentous forms of the subdivision Eumycota and Oomycota (as defined by Hawksworth et al., 1995, supra). The filamentous fungi are characterized by a vegetative mycelium composed of chitin, cellulose, glucan, chitosan, mannan, and other complex polysaccharides. Vegetative growth is by hyphal elongation and carbon catabolism is obligately aerobic. In contrast, vegetative growth by yeasts such as Saccharomyces cerevisiae is by budding of a unicellular thallus and carbon catabolism may be fermentative.
In a preferred embodiment, the fungal host cell is a yeast cell. In a more preferred embodiment, the yeast host cell is a cell of a species of Candida, Kluyveromyces, Saccharomyces, Schizosaccharomyces, Pichia, or Yarrowia. In a most preferred embodiment, the yeast host cell is a Saccharomyces cerevisiae, a Saccharomyces calsbergenis, a Saccharomyces diastaricus, a Saccharomyces douglasii, a Saccharomyces kluyveri, a Saccharomyces norbensis, or a Saccharomyces oviformis cell. In another most preferred embodiment, the yeast host cell is a Kluyveromyces lactis cell. In another most preferred embodiment, the yeast host cell is a Yarrowia lipolytica cell.
In another preferred embodiment, the fungal host cell is a filamentous fungal cell. In a more preferred embodiment, the filamentous fungal host cell is a cell of a species of, but not limited to, Acremonium, Aspergillus, Fusarium, Humicola, Myceliophthora, Mucor, Neurospora, Penicillium, Thielavia, Tolypocladium, and Trichoderma. In an even more preferred embodiment, the filamentous fungal host cell is an Aspergillus cell. In another even more preferred embodiment, the filamentous fungal host cell is a Fusartum cell. In a most preferred embodiment, the filamentous fungal host cell is an Aspergillus oryzae, an Aspergillus niger, an Aspergillus foeridus, or an Aspergillus japonicus cell. In another most preferred embodiment, the filamentous fungal host cell is a Fusarium orysporum or a Fusarium graminearum cell.
Fungal cells may be transformed by a process involving protoplast formation, transformation of the protoplasts, and regeneration of the cell wall in a matter known per se. Suitable procedures for transformation of Aspergillus host cells are described in EP 238 023 and Yelton et al., 1984, Proceedings of the National Academy of Science:USA 81:1470-1474. A suitable method of transforming Fusarium species is described by Malardier et al., 1989, Gene 78:147-156 or in copending U.S. Ser. No. 08/269,449. Yeast may be transformed using the procedures described by Becker and Guarente, In Alelson, J. N. and Simon, M. I., editors, Guide to Yeast Genetics and Molecular Biology, Methods in Enzymology, Volume, 194, pp 182-187, Academic Press, Inc., New York; to et al., 1983, Journal of Bacteriology 153:163; and Himen et al., 1978, Proceedings of the National Academy of Sciences USA 75:1920. Mammalian cells may be transformed by direct uptake using the calcium phosphate precipitation method of Graham and Van der Hb (1978, Virology 52:546).
Methods of Production
The present invention also relates to methods for producing a polypeptide of the present invention comprising (a) cultivating a Coprinus strain to produce a supernatant comprising the polypeptide; and (b) recovering the polypeptide.
The present invention also relates to methods for producing a polypeptide of the present invention comprising (a) cultivating a host cell under conditions conducive to expression of the polypeptide; and (b) recovering the polypeptide.
In both methods, the cells are cultivated in a nutrient medium suitable for production of the polypeptide using methods known in the art. For example, the cell may be cultivated by shake flask cultivation, small-scale or large-scale fermentation (including continuous, batch, fed-batch, or solid state fermentations) in laboratory or industrial fermentors performed in a suitable medium and under conditions allowing the polypeptide to be expressed and/or isolated. The cultivation takes place in a suitable nutrient medium comprising carbon and nitrogen sources and inorganic salts, using procedures known in the art (see, e.g., references for bacteria and yeast; Bennett, J. W. and LaSure, L., editors, More Gene Manipulations in Fungi, Academic Press, California, 1991). Suitable media are available from commercial suppliers or may be prepared according to published compositions (e.g., in catalogues of the American Type Culture Collection). If the polypeptide is secreted into the nutrient medium, the polypeptide can be recovered directly from the medium. If the polypeptide is not secreted, it is recovered from cell lysates.
The polypeptides may be detected using methods known in the art that are specific for the polypeptides. These detection methods may include use of specific antibodies, formation of an enzyme product or disappearance of an enzyme substrate. For example, an enzyme assay may be used to determine the activity of the polypeptide. Procedures for determining laccase activity are known in the art and include, e.g., the oxidation of 2,2′-azinobis-(3-ethybenzthiazoline-6-sulfonic acid (ABTS) (Childs et al., 1975, Biochemical Journal 145:93-103) or syringaldazine (Bauer et al., 1971, Analytical Chemistry 43: 421-425) as substrate.
The resulting polypeptide may be recovered by methods known in the art. For example, the polypeptide may be recovered from the nutrient medium by conventional procedures including, but not limited to, centrifugation, filtration, extraction, spray-drying, evaporation, or precipitation. The recovered polypeptide may then be further purified by a variety of chromatographic procedures, e.g., ion exchange chromatography, gel filtration chromatography, affinity chromatography, or the like.
The polypeptides of the present invention may be purified by a variety of procedures known in the art including, but not limited to, chromatography (e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic procedures (e.g., preparative isoelectric focusing (IEF), differential solubility (e.g., ammonium sulfate precipitation), or extraction (see, e.g., Protein Purification, J.-C. Janson and Lars Ryden, editors, VCH Publishers, New York, 1989).
Uses
The polypeptides of the present invention may be used in a number of different industrial processes. These processes include polymerization of lignin, both Kraft and lignosulfates, in solution, in order to produce a lignin with a higher molecular weight. A neutral/alkaline laccase is a particular advantage in that Kraft lignin is more soluble at higher pHs. Such methods are described in, for example, Jin et al., 1991, Holzforschung 45: 467-468; U.S. Pat. No. 4,432,921; EP 0 275 544; PCT/DK93/00217, 1993. Laccase is also useful in the copolymerization of lignin with low molecular weight compounds, such as is described by Milstein et al., 1994, Appl. Microbiol, Biotechnol. 40: 760-767.
The laccase of the present invention can also be used for in-situ depolymerization of lignin in Kraft pulp, thereby producing a pulp with lower lignin content. This use of laccase is an improvement over the current use of chloride for depolymerization of lignin, which leads to the production of chlorinated aromatic compounds, which are an environmentally undesirable by-product of paper mills. Such uses are described in, for example, Current Opinion in Biotechnology 3: 261-266, 1992; Journal of Biotechnology 25: 333-339, 1992; Hiroi et al., 1976, Svensk Papperstidning 5:162-166, 1976. Since the environment in a paper mill is typically alkaline, the present laccase is more useful for this purpose than other known laccases, which function best under acidic conditions.
Oxidation of dyes or dye precursors and other chromophoric compounds leads to decolorization of the compounds. Laccase can be used for this purpose, which can be particularly advantageous in a situation in which a dye transfer between fabrics is undesirable, e.g., in the textile industry and in the detergent industry. Methods for dye transfer inhibition and dye oxidation can be found in WO 92/01406; WO 92/18683; WO 92/18687; WO 91/05839; EP 0495836; Calvo, 1991, Mededelingen van de Faculteit Landbouwwetenschappen/Rijiksuniversitet Gent. 56: 1565-1567; Tsujino et al., 1991, J. Soc. Chem. 42: 273-282. Laccases of the present invention are particularly useful in oxidation at high pH, i.e., over pH 7, as disclosed in DK0982/94, the contents of which are incorporated herein by reference. Use of laccase in oxidation of dye precursors for hair dyeing is disclosed in U.S. Pat. No. 3,251,742, the contents of which are incorporated herein by reference.
The present laccase can also be used for the polymerization or oxidation of phenolic compounds present in liquids. An example of such utility is the treatment of juices, such as apple juice, so that the laccase will accelerate a precipitation of the phenolic compounds present in the juice, thereby producing a more stable juice. Such applications have been described by Stutz, Fruit processing 7/93, 248-252, 1993; Maier et al., 1990, Dt. Lebensmittelrindschau 86: 137-142; Dietrich et al., 1990, Fluss. Obst. 57: 67-73.
Laccases of the present invention are also useful in soil detoxification (Nannipieri et al., 1991, J. Environ. Qual. 20: 510-517; Dec and Bollag, 1990, Arch. Environ. Contam. Toxicol. 19: 543-550).
The present invention is further described by the following examples which should not be construed as limiting the scope of the invention.
EXAMPLES Materials and Strains
Chemicals used as buffers and substrates are commercial products of at least reagent grade. Strains used as Coprinus cinereus A3387 (IFO 8371), E. coli Y1090(ZL) (GIBCO BRL, Gaithersburg, Md.), E. coli DH10B(ZL) (GIBCO BRL), E. coli DH5α (Stratagene, La Jolla, Calif.), Aspergillus oryzae HowB712, Aspergillus oryzae JeRS317, and Aspergillus oryzae JeRS316.
Example 1 Purification and Characterization of Coprinus cinereus Laccase
The laccase is initially isolated from Coprinus cinereus strain A3387 culture broth by filtration (Propex 23+HSC) and concentration (Filtron 2×10K). The cationic flocculent Magnifloc® 521C (American Cyanamid, Wallingford, Conn.) is added to the resulting preparation, mixed for 30 minutes, and then centrifuged. This step removes colored substances from the preparation. The supernate is then precipitated with ammonium sulfate (55% saturation) and resuspended twice in ammonium sulfate (40% saturation), which also results in color removal. The resuspension is further concentrated to reduce the volume, and filtered, but not washed out. The concentrate in ammonium sulfate (40% saturation) is then subjected to Butyl ToyoPearl hydrophobic chromatography (Tosoh Corp., Tokyo, Japan) and eluted with an ammonium sulfate gradient from 40% to 0% saturation. Buffer exchange to 20 mM MES pH 6.0 and concentration with an Amicon cell equipped with a membrane of 20,000 molecular weight cut-off is then conducted. The resulting solution is then subjected to Q-Sepharose (Pharmacia, Uppsala, Sweden) anion exchange chromatography (150 ml) in 20 mM MES pH 6.0 with a linear gradient from 0 to 0.4 M NaCl. The sample is finally rechromatographed by HPQ-Sepharose (Pharmacia, Upsala, Sweden) chromatography (50 ml) in 20 mM MES pH 6.0 with a linear gradient from 0 to 0.4 M NaCl. The laccase elutes at 0.25-0.30 M NaCl.
The purified laccase is about 95% pure as determined by SDS-PAGE which shows the laccase as a band of Mw=63,000. Isoelectric focusing shows two dominating bands with pIs of 3.7 and 4.0.
The N-terminal amino acid residue of the purified laccase is blocked. The laccase is therefore reduced, S-carboxymethylated, and digested with Endoproteinase Lys-C (Boehringer Mannheim, Indianapolis, Ind.) and with chymotrypsin. The resulting peptides are purified by reversed phase HPLC using a Vydac C18 column (Vydac, Inc., Hesperia, Calif.) eluted with a linear gradient of either acetonitrile of 2-propanol in 0.1% aqueous trifluoroacetic acid. The purified peptides are sequenced on an Applied Biosystems 473A Protein Sequencer according to the manufacture's instructions.
Several distinct peptides which result from the protease digestion are listed below. In the following sequences, Xaa represents an indeterminable residue. Peptide 3 apparently encompasses peptide 2. In peptides 4 and 9, residues designated Xaa/Yaa indicate both residues are found at that position. Residues in parentheses are uncertain. Peptide 9 is included in peptide 13.
Peptide 1(SEQ ID NO:1):
Glu-Val-Asp-Gly-Gln-Leu-Thr-Glu-Pro-His-Thr-Val-Asp-Arg-Leu-Gln-Ile-Phe-Thr-Gly-Gln-Agr-Tyr-Ser-Phe-Val-Leu-Asp-Ala-Asn-Gln-Pro-Val-Asp-Asn-Tyr-Trp-Ile-Arg-Ala
Peptide 2 (SEQ ID NO:2):
Xaa-Xaa-Asp-Asn-Pro-Gly-Pro
Peptide 3 (SEQ ID NO:3):
Phe-Val-Thr-Asp-Asn-Pro-Gly-Pro
Peptides 2 and 3 combined (SEQ ID NO:4):
Phe-Val-Thr-Asp-Asn-Pro-Gly-Pro-Trp
Peptide 4 (SEQ ID NO:5):
Ile/Leu-Asp-Pro-Ala-Xaa-Pro-Gly-Ile-Pro-Thr-Pro-Gly-Ala-(Ala)-Asp-Val
Peptide 5 (SEQ ID NO:6):
Gly-Val-Leu-Gly-Asn-Pro-Gly-Ile
Peptide 6 (SEQ ID NO:7):
Xaa-Phe-Asp-Asn-Leu-Thr-Asn
Peptide 7 (SEQ ID NO:8):
Tyr-Arg-Xaa-Arg-Leu-Ile-Ser-Leu-Ser-Cys-Asn-Pro-Asp-(Trp)-Gln-Phe
Peptide 8 (SEQ ID NO:9):
Ala-Asp-Trp-Tyr
Peptide 9 (SEQ ID NO:10):
Ile-Pro-Ala/Asp-Pro-Ser-Ile-Gln
Peptide 10 (SEQ ID NO:11):
Glu-Ser-Pro-Ser-Val-Pro-Thr-Leu-Ile-Arg-Phe
Peptide 11 (SEQ ID NO:12):
Ala-Gly-Thr-Phe
Peptide 12 (SEQ ID NO:13):
Ser-Gly-Ala-Gln-Ser-Ala-Asn-Asp-Leu-Leu-Pro-Ala-Gly
Peptide 13 (SEQ ID NO:14):
Ile-Pro-Ala-Pro-Ser-Ile-Gln-Gly-Ala-Ala-Gln-Pro-Asx-Ala-Thr
Most of the peptides show considerable homology with portions of the amino acid sequence of a Polyporus pinsitus laccase (Yaver et al., 1995, Applied and Environmental Microbiology 62: 834-841).
Example 2 RNA Isolation
Coprinus cinereus strain A3387 is cultivated at 26° C. in FG4 medium comprised of 30 g of soybean meal, 15 g of maltodextrin, 5 g of Bacto peptone, and 0.2 g of pluronic acid per liter. The mycelia are harvested after six days of growth, frozen in liquid N2, and stored at −80° C. Total RNA is prepared from the frozen, powdered mycelium of Coprinus cinereus A3387 by extraction with guanidinium thiocyanate followed by ultracentrifugation through a 5.7 M cesium chloride cushion (Chirgwin et al., 1979, Biochemistry 18: 5294-5299). Poly(A)+RNA is isolated by oligo(dT)-cellulose affinity chromatography according to Aviv and Leder (1972, Proceedings of the National Academy of Sciences USA 69: 1408-1412).
Example 3 Construction of a cDNA Library
Double-stranded cDNA is synthesized from 5 μg of Coprinus cinereus poly(A)+RNA of Example 2 as described by Gubler and Hoffman (1983, Gene 25: 263-269) and Sambrook et al. (1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, N.Y.), except that an oligo(dT)-NotI anchor primer, instead of an oligo(dT)12-18 primer, is used in the first strand reaction. After synthesis, the cDNA is treated with Mung bean nuclease (Life Technologies, Gaithersburg, Md.), blunt-ended with T4 DNA polymerase (Boehringer Mannheim, Indianapolis, Ind.), and ligated to non-palindromic BstXI adaptors (Invitrogen, San Diego, Calif.), using about 50-fold molar excess of the adaptors. The adapted cDNA is digested with NotI, size-fractionated for 1.2-3.0 kb cDNAs by agarose gel electrophoresis, and ligated into BstXI/NotI cleaved pYES2.0 vector (Invitrogen, San Diego, Calif.). The ligation mixture is transformed into electrocompetent E. coli DH10B cells (Life Technologies, Gaithersburg, Md.) according to the manufacturer's instructions. The library consisting of 1×106 independent clones i stored as individual pools (25,000-30,000 colony forming units/pool) in 20% glycerol at −80° C., and as double stranded cDNA and ligation mixture at −20° C.
Example 4 Generation of a cDNA Probe from a Coprinus cinereus cDNA Using PCR
Three oligonucleotides (sense s1 and s2 and antisense as1) with low codon degeneracy are designed based on two conserved motifs in laccases from Rhizoctonia, Phlebia, Polyporus, and Coriolus. The oligos have the following sequences.
s1: 5′-ATI CAc/t TGG CAc/t GGI c/tTI c/tTT-3′ (SEQ ID NO:15)
s2: 5′-ATI CAc/t TGG CAc/t GGI TTc/t Ttc/t-3′ (SEQ ID NO:16)
as1: 3′-GGI ACC AAa/g a/gAI GTa/g Aca/g GTa/g TAI CT-5′ (SEQ ID NO:17)
One μg of plasmid DNA from the Coprinus cinereus library pool described in Example 3 is PCR amplified in a thermal cycler according to Frohman et al., 1988, Proceedings of the National Academy of Sciences USA 85: 8998-9002 using 500 pmol of each laccase sense primer in two combinations (s1 and as1, s2 and as1) with 500 pmol of the laccase antisense primer, and 2.5 units of Taq polymerase (Perkin Elmer Cetus, Branchburg, N.J.). Thirty cycles of PCR are performed using a cycle profile of denaturation at 94° C. for 1 minute, annealing at 55° C. for two minutes, and extension at 72° C. for 3 minutes. Analysis of the PCR products reveals a 1.2 kb major PCR product with one primer pair, s1 and as1, whereas the other pair does not amplify any major products. The PCR fragment of interest is subcloned into a pUC18 vector and sequenced according to Siggaard-Andersen et al., 1991, Proceedings of the National Academy of Sciences USA 88: 4114-4118. Sequencing of the ends of two PCR subclones in pUC18 reveals a cDNA sequence coding for a laccase polypeptide. In addition to the primer encoding residues, the deduced amino acid sequence aligns with two peptide sequences obtained from the purified wild-type laccase, indicating that PCR has specifically amplified the desired region of a Coprinus cinereus laccase cDNA.
Example 5 Subcloning and Sequencing of Partial cDNAs
The PCR product described in Example 4 is ligated into pCRII using a TA Cloning Kit (Invitrogen, San Diego, Calif.) according to the manufacturer's instructions. Seven subclones are prepared and sequenced using both the M13 universal −21 mer oligonucleotide and the M13 −48 reverse oligonucleotide. Nucleotide sequences are determined on both strands by primer walking using Taq polymerase cycle-sequencing with fluorescent-labeled nucleotides, and reactions are electrophoresed on an Applied Biosystems Automatic DNA Sequencer (Model 373A, version 2.0.1).
The seven clones based on deduced amino acid sequence and percent identities between them appear to encode for 3 laccases (Table 1). Clones CCLACC4, 8 and 7 are designated as partial cDNAs of Coprinus cinereus lcc1 (SEQ ID NOS:18 and 19). Clones CCLACC 1, 3 and 11 (pDSY71) are designated as partial cDNAs of Coprinus cinereus lcc2 (SEQ ID NOS:20 and 21). Clone CCLACC 15 (pDSY72) is designated as a partial cDNA of Coprinus cinereus lcc3 (SEQ ID NOS:22 and 23). The deduced amino acid sequences of the partial cDNAs of lcc1, lcc2, and lcc3 (SEQ ID NOS:19, 21, and 23) are compared to the peptide sequences determined above, and the closest match is found between lcc1 and the peptide sequences. In order to obtain a full-length clone for heterologous expression of lcc1 in Aspergillus oryzae, a genomic library of Coprinus cinereus A3387 is constructed in λZipLox.
TABLE 1
Percent identities between Coprinus cinereus cDNAs
1 2 3 4 5 6 7
1 CCLACC4 98 100 65 65 65 62
2 CCLACC7 98 65 64 65 63
3 CCLACC8 65 65 65 62
4 CCLACC1 100 99 81
5 CCLACC3 99 81
6 CCLACC11 81
7 CCLACC15
Example 6 Genomic DNA Isolation
A culture of Coprinus cinereus A3387 is grown at room temperature for 4 days with shaking at 200 rpm in YEG medium comprised of 0.5% yeast extract and 2% dextrose. Mycelia are harvested through Miracloth (Calbiochem, La Jolla, Calif.), washed twice with 10 mM Tris-0.1 mM EDTA pH 7.4 buffer (TE) and frozen quickly in liquid nitrogen. DNA is isolated as described by Timberlake and Barnard, 1981, Cell 26: 29-37.
Example 7 Preparation of Coprinus cinereus Genomic Library
A genomic library of Coprinus cinereus A3387 is constructed using a λZipLox Kit (Life Technologies, Gaithersburg, Md.) according to the manufacturer's instructions. Genomic DNA (˜30 μg) is digested with Tsp509I (New England Biolabs, Beverly, Mass.) at 65° C. in a total volume of 150 μl in the buffer provided by the supplier. Samples of 30 μl are taken at 3, 5, 7, 8, and 9 minutes and electrophoresed on a 1% agarose preparative gel. Bands of 3 to 8 kb in size are excised from the gel. The DNA is then isolated from the gel slices using a Qiaex Kit (Qiagen, San Diego, Calif.). The size-fractionated DNA is ligated overnight at room temperature to λZipLox EcoRI arms following the protocols provided with the kit. The ligations are packaged into phage using a Giga Pak Gold Packaging Kit (Stratagene, La Jolla, Calif.), and the packaging reactions are titered using E. coli Y1090 cells. A total of 6×105 pfu are obtained. The packaging extract is plated to amplify the library, and the titer of the library is determined to be 1×1011 pfu/ml. Twenty individual plaques are picked, and the plasmids are excised from the plaques by passage through E. coli DH10B. Plasmid DNA is isolated from the cultures and is digested with PstI/NotI to determine the percent of molecules in the library which have inserts. Eight of the twenty, or 40% of those tested, have inserts which range in size from 3 to 6 kb.
Example 8 Probe Preparation for Library Screening
A DIG-labeled probe for nonradioactive screening of the library is prepared by PCR using the Coprinus cinereus partial lcc1 cDNA described in Example 5 as a template. The primers used in the reaction are shown below:
5′ ACTGCGATGGTCTCCGTGGTC 3′ (SEQ ID NO:24)
5′ GGGGCCTGGGTTATCGGTGAC 3′ (SEQ ID NO:25)
The PCR conditions are 1 cycle at 95° C. for 5 minutes, 50° C. for 1 minute, and 72° C. for 1.5 minutes; 29 cycles each at 95° C. for 1 minute, 50° C. for 1 minute, and 72° C. for 1.5 minutes; and 1 cycle at 95° C. for 30 seconds, 50° C. for 1 minute, and 72° C. for 3 minutes. The reaction contains 0.1 μg of the Coprinus cinereus partial lcc1 cDNA, 10 μl 10X PCR Buffer (Perkin Elmer, Branchburg, N.J.), 5 μl 10X DIG labeling mix (Boehringer Mannheim, Indianapolis, Ind.), 75 pmol of each primer, and 0.5 unit of Taq DNA polymerase (Perkin-Elmer Corp., Branchburg, N.J.). A probe concentration of 250 ng/μl is determined after PCR following protocols provided with the Genius Kit (Boehringer Mannheim, Indianapolis, Ind.).
32P-labeled probes of Coprinus cinereus lcc2 and lcc3 partial cDNAs are prepared using a RadPrime Kit (Life Technologies, Gaithersburg, Md.) according to the manufacturer's instructions.
Example 9 Genomic Library Screening
Appropriate dilutions of the λXipLox Coprinus cinereus genomic library are plated with E. coli Y1090 cells on NZY plates comprised of 0.5% NaCl, 0.2% MgSO4, 0.5% yeast extract, and 1% NZ amine pH 7.5 per liter with 0.7% top agarose. The plaques are lifted to Hybond N+ filters (Amersham Co., Amersham, UK) using standard procedures (Sambrook et al. 1989, supra). The filters are hybridized in Engler Blue hybridization buffer at 65° C. for 1 hour. After prehybridization, the DIG labeled probe of Example 8 is added at a final concentration of 3 ng/ml and allowed to hybridize overnight at 65° C. The filters are washed at 65° C. twice for 5 minutes in 2XSSC, 0.1% SDS, twice for 15 minutes in 0.5XSSC, 0.1% SDS, and then are processed to detect the hybridized DIG-label using the Genius Kit and Lumi-Phos 530 substrate according to the manufacturer's instructions. Following the detection protocol, film is placed on top of the filters for 2 hours.
For screening of the library using the 32P-labeled probes described in Example 8, filter lifts are prepared as described above, and prehybridized at 65° C. in 2XSSPE, 1% SDS, 0.5% nonfat dry milk and 200 μg denatured salmon sperm DNA. After 1 hour prehybridization, the 32-P-labeled probes are added to a final concentration of 106 cpm/ml and hybridizations are continued overnight at 65° C. The filters are washed twice at 65° C. for 15 minutes in 0.2XSSC, 1% SDS, and 0.1% sodium pyrophosphate.
The genomic library is probed with the DIG-labeled fragment of lcc1. Approximately 200,000 plaques are screened using the conditions described above, and 9 positive clones are obtained. The plasmids are excised from the clones by passage through E. coli DH10B(ZL), and then are characterized by digestion with PstI/NotI. All 9 clones contain inserts. Based on the nucleotide sequence of the partial lcc1 cDNA, the genomic clones which may be lcc1 genomic clones are determined. All 8 unique clones are digested with BamHI/PstI and PstI/BsmI for which fragments of 205 bp and 382 bp, respectively, are expected (neither lcc2 nor lcc3 partial cDNAs contain these fragments). Four of the 8 unique clones contain both predicted fragments. DNA sequencing reactions on all four clones using universal sequencing primers are performed as described in Example 5 to determine which clones are full-length
The nucleotide sequence of clone 4-19 (pDSY73) is determined completely on both strands and shown to contain the full length lcc1 gene (FIG. 1, SEQ ID NO:26). The deduced amino acid sequence (FIG. 1, SEQ ID NO:27) of the genomic lcc1 matches 100% with the determined N-terminal sequence (see Example 14) although the predicted signal peptide cleavage site is between A18 and Q19 while the peptide sequence begins 4 residues downstream at S23. The lcc1 gene contains 7 introns ranging in size from 54 to 77 bp. The deduced protein contains 3 potential N-glycosylation sites (AsnXaaThr/Ser), and the predicted mature protein after removal of the signal peptide is 521 amino acids in length. The percent identities of the Lcc1 protein to other fungal laccases is shown in Table 2. The highest percent identity, 57.8%, is found when compared to the laccase from the unidentified basidiomycete PM1 (Coll et al., 1993, supra). When alignments of Lcc1 and other basidiomycete laccases are performed, it appears that Lcc1 may have either a C-terminal extension or a C-terminal peptide that is removed by processing.
The genomic library is also screened with the 32P-labeled probes for the Coprinus cinereus lcc2 and lcc3 partial cDNAs. For screening with the lcc2 probe, approximately 50,000 plaques are hybridized with the probe, and 4 positive clones are obtained. For screening of the library with the lcc3 probe, approximately 35,000 plaques are probed, and 2 positive clones are obtained. After passage through E. coli and isolation of the plasmid DNA, the nucleotide sequence of one of the lcc3 clones (DSY100) is determined by primer walking as described in Example 5 (FIG. 2, SEQ ID NO:28). The lcc3 gene contains 13 introns (as indicated by lowercase in FIG. 2). The positions of introns 4 through 10 are confirmed from the partial cDNA while the positions of the other 6 introns are deduced based on the consensus sequences found at the 5′ and 3′ splice sites of fungal introns and by homology of the deduced amino acid sequence (FIG. 2, SEQ ID NO:29) to other laccases. The lcc3 gene encodes for a precursor protein of 517 amino acids. There is one potential N-glycosylation site, and the mature protein after the predicted signal peptide cleavage (indicated by an arrow) is 501 amino acids in length.
From the nucleotide sequences of the 4 positive lcc2 clones, it is observed that none of the clones are full-length. The clone with the largest insert (CCLACC1-4) is missing the sequence coding for the last approximately 100 amino acids based on homology to other fungal laccases.
TABLE 2
Percent identities of the Coprinus cinereus lcc1 to other fungal* laccases
Cc Cc Cc Tv Tv Tv Tv Tv
lcc1 lcc2 lcc3 lcc1 lcc2 lcc3 lcc4 lcc5 Ch Pr PMI Ab Nc
Cclcc1
Cclcc2 59.3
Cclcc3 57.5 79.6
Tvlcc1 55.5 61.3 59.5
Tvlcc2 55.7 60.9 59.5 79.6
Tvlcc3 57.0 61.0 58.2 62.8 84.6
Tvlcc4 55.5 59.2 58.8 70.3 67.1 61.4
Tvlcc5 54.4 59.3 57.9 71.1 69.1 64.6 76.5
Ch 55.5 61.5 59.3 91.4 81.4 63.0 70.1 71.3
Pr 50.3 59.1 57.5 63.3 61.5 62.2 63.9 63.9 64.1
PMI 57.8 62.8 59.4 79.6 73.7 62.2 69.1 70.1 80.2 65.7
Ab 40.3 41.7 41.9 43.7 43.1 43.6 44.6 43.1 44.1 42.5 44.4
Nc 25.3 25.3 24.0 25.1 23.8 24.8 21.9 24.2 25.1 23.0 24.4 25.5
*Cc = Coprinus cinereus; Tv = Trametes villosa; Ch = Coriolus hirsutus; PM1 = unidentified basidiomycete; Pr = Phlebia radiata; Mc = Neurospora crassa; Ab = Agaricus bisporus; lcc = laccase gene.
Example 10 Probe Preparation for Library Screening to Obtain the Full Length lcc2 Gene
A DIG-labeled probe for nonradioactive screening of the library is prepared by PCR using the Coprinus cinereus lcc2 partial genomic clone as template in order to obtain a full-length clone of lcc2. The primers used in the reaction are shown below:
AGCTCGATGACTTTGTTACGG (1868R CCLCC2) (SEQ ID NO:30)
CAGCGCTACTCGTTCGTTCTC (1460 CCLCC2) (SEQ ID NO:31)
The PCR conditions are 1 cycle at 95° C. for 1 minute; and 30 cycles each at 94° C. for 1 minute, 55° C. for 1 minute, and 72° C. for 2 minutes. The reaction contains 0.1 μg of Coprinus cinereus lcc2 partial genomic clone (CCLACC1-4), 10 μl of 10X PCR Buffer (Perkin Elmer, Branchburg, N.J.), 5 μl of 10X DIG labeling mix (Boehringer Mannheim, Indianapolis, Inc.), 75 pmol of each primer, and 0.5 Unit of Taq DNA polymerase. The concentration of the DIG-labeled probe is determined using the Genius Kit according to the manufacturer's instructions.
Example 11 Genomic Library Screening to Obtain the Full Length lcc2 Gene
Appropriate dilutions of the λZipLox Coprinus cinereus genomic library prepared as described in Example 7 are plated with E. coli Y1090 cells on NZY plates (0.5% NaCl, 0.2% MgSO4, 0.5% yeast extract, and 1% NZ amine pH 7.5) with 0.7% top agarose. The plaques are lifted to Hybond N+ filters using standard procedures (Sambrook et al., 1989, supra). Filters are prehybridized in Easy Hyb hybridization buffer (Boehringer Mannheim, Indianapolis, Ind.) at 42° C. for 1 hour, and after prehybridization the DIG labeled probe mentioned above is added at a final concentration of 1 ng/ml. The filters and probe are allowed to hybridize overnight at 42° C. The filters are then washed twice at room temperature for 5 minutes in 2XSSC-0.1% SDS and twice at 68° C. for 15 minutes in 0.1XSSC-0.1% SDS. The filters are next processed to detect the hybridized DIG-label using the Genius Kit and CSPD Ready-To-Use (Boehringer Mannheim, Indianapolis, Ind.) as substrate according to the manufacturer's instructions. Following the detection protocol, film is placed on the filters for 20 minutes to 2 hours.
In order to obtain a full-length clone, the genomic library is screened (˜42,000 plaques) using a DIG-labeled fragment containing the 3′ most 400 bp of the CCLACC1-4 insert. Five positive clones are isolated and purified. Plasmid DNA is excised from all five clones by passage through E. coli DH10B. Using a specific primer to the 3′ end of the CCLACC1-4 insert in sequencing reactions as described in Example 5, it is determined that only one of the clones (LCC2-5B-1) contains the 3′ missing portion of lcc2 gene. However, further sequencing demonstrates that (LCC2-5B-1) does not contain the whole gene but is missing part of the 5′ end. Overlapping the sequences of CCLACC1-4 and CCLACC2-5B-1 yields the sequence of the entire gene (FIG. 3, SEQ ID NO:32).
A plasmid pDSY105 containing the full-length lcc2 genomic clone is constructed by ligating together fragments from the LCC2-5B-1 and CCLACC1-4 clones. Clone LCC2-5B-1 is digested with EagI and Bg/II and electrophoresed on a 1% agarose gel. The gel slice containing the 1.3 kb EagI/Bg/II fragment is excised, and the DNA is isolated using a Spin Bind column (FMC). A PCR reaction is performed to obtain an EcoRI/Bg/II fragment containing the N-terminal half of lcc2. The PCR reaction mixture contains 0.1 mg of CCLACC1-4 DNA, 50 pmol each of oligonucleotides 96-0545 and 96-0546, 0.01mM each of dATP, dCTP, dGTP, and dTTP, and 0.5 U Taq DNA polymerase. PCR conditions are 1 cycle at 95° C. for 5 minutes, 55° C. for 1 minute, and 72° C. for 1 minute; and 30 cycles each at 95° C. for 30 seconds, 55° C. for 1 minute, and 72° C. for 1 minute. The primers used in the reaction are:
96-0545: AGAATTGACTCCACCGACGAA (SEQ ID NO:34)
96-0546: GAATTCTGGCATTCCTGACCTTTGTTC (SEQ ID NO:35)
The desired product of 1.6 kb is subcloned into pCRII using the TA Cloning Kit (Invitrogen, San Diego, Calif.). Partial nucleotide sequences of the subclones are determined using M13-20 universal and M13 −48 reverse universal primers. The final plasmid is constructed by digesting pBluescript SK- with EcoRI/EagI and ligating with the EagI/Bg/II fragment from LCC2-5B-1 and the Bg/II/EcoRI fragment from the pCRII subclone. The resulting subclones are screened by restriction digests, and the desired product is designated pDSY105.
The lcc2 gene contains 13 introns (indicated by lowercase in FIG. 3). The positions of introns 4 through 10 are confirmed from the partial cDNA while the positions of the other 6 introns are deduced based on the consensus sequences found at the 5′ and 3′ splice sites of fungal introns and by homology of the deduced amino acid sequence (FIG. 3, SEQ ID NO:33) to other laccases. The lcc2 gene encodes for a precursor protein of 517 amino acids in length. This is one potential N-glycosylation site, and the mature protein after the predicted signal peptide cleavage is 499 amino acids in length.
From the alignment of the Lcc1, Lcc2 and Lcc3 predicted mature proteins, it appears that unlike Lcc1 neither Lcc2 nor Lcc3contains the 23 amino acid extension present on Lcc1. Lcc1 shares 59.3% and 57.5% identity with Lcc2 and Lcc3, respectively (Table 2). When compared to other fungal laccases, Lcc2 and Lcc3 have the highest identity (79.6%) with one another. The percent identities shared with other fungal laccases range from a high of 62.8% for Lcc2 and the basidiomycete PM1 laccase to a low of 21.9% for Neospora Crassa laccase.
Example 12 Construction of pDSY67 and pDSY68 for Heterologous Expression of lcc1 in Aspergillus oryzae
pDSY67 (FIG. 4) and pDSY68 (FIG. 5) are constructed for expression of Coprinus cinereus lcc1 gene. The Coprinus cinereus lcc1 gene is cloned into the expression vector pKS4 which contains the TAKA promoter, AMG terminator and the Aspergillus nidulans pyrG for selection. The lcc1 gene is inserted as 3 fragments into pKS4 digested with SwaI/NotI to obtain pDSY67 (FIG. 4). Sequencing of pDSY67 reveals the presence of 32 extra base pairs between the stop codon and the AMG terminator. pDSY68 is generated by removing the extra thirty-two base pairs. In order to remove the extra base pairs, pDSY67 is digested with PacI/NotI and the ends are blunted using T4 DNA polymerase. The blunt-end vector is ligated to itself, and the resulting plasmid pDSY68 is sequenced to confirm the extra base pairs are removed.
Example 13 Transformation of Aspergillus oryzae
Aspergillus oryzae strains HowB712, JeRS316, and JeRS317 are grown for 18 hours in YEG medium at 34° C., and protoplasts are generated and transformed as described by Christensen et al. (1988, Biotechnology 6: 1419-1422). The protoplasts are transformed with 10 μg of either pDSY67 or pDSY68. Transformants are selected on Minimal medium plates containing 1.0 M sucrose. Minimal medium plates are comprised of 6.0 g of NaNO3, 0.52 g of KCl, 1.52 g of KH2PO4, 1.0 ml of trace metals solution, 20 g of Nobel Agar (Difco), 20 ml of 50 % glucose, 20 ml of methionine (50 g/l), 20 ml of biotin (200 mg/l), 2.5 ml of 20% MgSO4-7H2O, and 1.0 ml of mg/ml streptomycin per liter. The agar medium is adjusted to pH 6.5 prior to autoclaving and then glucose, methionine, biotin, MgSO4- 7H2O, and streptomycin are added as sterile solutions to the cooled autoclaved medium and poured into plates. The trace metals solution is comprised of 22 g of ZnSO4-7H2O, 11 g of H3BO3, 5 g of MnCl2-4H2O, 5 g of FeSO4-7H2O, 1.6 g of CoCl2-5H2O, 1.6 g of (NH4)6Mo7O24, and 50 g of Na4EDTA per liter.
Example 14 Screening of Laccase Transformants
Primary transformants are screened first on Minimal medium plates containing 1% glucose as the carbon source and 1 mM 2,2′-azinobis-(3-ethybenzthiazoline-6-sulfonic acid) (ABTS) to test for production of laccase. Transformants producing green zones on the ABTS plates are picked and spore purified before shake flask analysis. For shake flask analysis, the purified transformants are cultivated at 37° C. in MY51 medium comprised of 30 g of maltose, 2 g of MgSO4, 10 g of KH2PO4, 2 g of K2SO4, 2 g of citric acid, 10 g of yeast extract, 0.5 ml of trace metals solution, 1 g of urea, 2 g of (NH4)2SO4 pH 6.0 per liter. The trace metals solution is comprised of 14.3 g of ZnSO4-7H2O, 2.5 g of CuSO4−5H2O, 11 g of NiCl2-6H2O, 13.8 g of FeSO4-7H2O, 8.5 g of MnSO4-H2O, and 3.0 g of citric acid per liter. Samples are taken at various intervals and centrifuged. The supernatants are diluted and assayed using ABTS as a substrate.
Laccase activity is determined by syringaldazine oxidation. Specifically, 60 μl of syringaldazine stock solution (0.28 mM in 50% ethanol) and 20 μl of laccase sample are mixed with 0.8 ml of preheated Britton-Robinson buffer solution and incubated at 20° C. The oxidation is monitored at 530 nm over 5 minutes and activity is expressed as “SOU” μmole syringaldazine oxidized per minute (“SOU”). Britton-Robinson buffers with various pHs are used. ABTS oxidation assays are performed at 20° C. using 1 mM ABTS, Britton-Robinson buffers (diluted 1.1-fold) by monitoring ΔA405 in 96-well plates.
For pDSY67, 3, 8, and 64 transformants, which are positive on ABTS, are obtained in Aspergillus oryzae JeRS316, JeRS317, and HowB712, respectively. For pDSY68, 34 and 56 transformants, which are positive on ABTS plates, are obtained in JeRS317 and HowB712, respectively. On average >90% of the primary transformants are positive on ABTS plates. All of the transformants are spore purified and tested in shake flask for production of the laccase as described above. Laccase activity assays confirm that the transformants, which are positive on ABTS plates, are indeed producing laccase.
Example 15 Purification and Characterization of Recombinant Coprinus cinereus Lcc1
Aspergillus oryzae JeRS317 (pDSY68, lcc1) is inoculated into a 10 liter lab fermentor containing medium comprised of Nutriose, yeast extract, (NH4)2HPO4, MgSO4-7H2O, critic acid, K2SO4, CaCl2-H2O, and trace metals solution and supplemented with CuSO4 and fermented at 31° C., pH 7, 600-700 rpm for 7 days. The broth is then recovered and filtered through cheesecloth.
Cheesecloth filtered broth (pH 7.2, 15 mS) is filtered through Whatman #2 filter paper, then concentrated and washed on a Spiral Concentrator (Amicon) with a S1Y30 membrane (16-fold, 0.8 mS). The broth is frozen overnight at −20° C., thawed the next day, filtered again on Whatman #2 paper, and loaded onto a 120 ml Q-Sepharose XK26 column (Pharmacia, Uppsala, Sweden), pre-equilibrated with 10 mM Tris pH 7.7, 0.9 mS (Buffer A). After loading and washing with Buffer A, a linear gradient with Buffer B (Buffer A plus 2 M NaCl) is applied and the active fractions are eluted around 7% Buffer B. The active fractions are dialyzed in Buffer A and then loaded onto a 40 ml Mono-Q 16/10 (Pharmacia, Uppsala, Sweden) column, pre-equilibrated with Buffer A. The active fractions pass through the column.
The sequential ion-exchange chromatography on Q-Sepharose and Mono-Q yields a recombinant Coprinus cinereus laccase preparation with apparent homogeneity by SDS-PAGE analysis. An overall 64-fold purification and a recovery of 23% are achieved.
A molecular weight of 66 kDa for the recombinant laccase is observed by SDS-PAGE analysis, similar to that of wild type laccase. The difference between the observed molecular weight and that derived from the DNA sequence (56 kDa) suggests the laccase is 18% glycosylated. The chromatographic elution pattern of recombinant laccase is very close to that of the recombinant Myceliophthora thermophila laccase under the same conditions, where the recombinant Coprinus cinereus laccase has a similar pI to the pI of 4.2 for recombinant Myceliophthora thermophila laccase, which is also close to the pI of wild type Coprinus cinereus laccase (3.7-4.0).
Copper (Cu) titration of the purified recombinant laccase with 2,2′-biquinoline is carried out as described by Felsenfeld, 1960, Archives of Biochemistry and Biophysics 87: 247-251. Photometric titration with 2,2′-biquinoline gives a Cu to protein (subunit) stoichiometry of 3.4±0.2, indicating the four-Cu oxidase nature of recombinant Coprinus cinereus laccase.
The purified recombinant Coprinus cinereus laccase shows a UV-visible spectrum with two maxima at 278 and 614 nm. The ratio of absorbance at 280 mm to that at 600 nm is found as 22.
The extinction coefficient for the enzyme is determined by amino acid analysis and the molecular weight derived from the DNA sequence. Amino acid analysis suggests an extinction coefficient of 1.6 l/(g*cm), similar to the predicted value of 1.2.
The redox potential is measured by monitoring the recombinant Coprinus cinereus laccase's absorbance change at 600 nm with K3Fe(CN)6-K4Fe(CH)6 couple (0.433 V) and with I2-NaI couple (0.536 V) in 9 mM MES-NaOH pH 5.3 buffer. At pH 5.3, a redox potential of 0.55±0.06 V is observed for the recombinant Coprinus cinereus laccase.
The activity of recombinant Coprinus cinereus laccase is tested with syringaldazine and ABTS. With syringaldazine as the substrate, recombinant Coprinus cinereus laccase shows a LACU/A250 of 2.7 or a LACU/mg near 4. The recombinant laccase exhibits a pH activity profile in the pH range from about 4 to about 9 with optimal activity at pH 6 to 7 similar to that of wild type Coprinus cinereus laccase (FIG. 6A), at which its SOU/A280=5.6. At pH 5.3, syringaldazine shows a Km of 26±6 μM and a kcat of 180±20 min−1. With ABTS as the substrate, the recombinant laccase shows a pH activity profile in the pH range from about 2.7 to about 7 with optimal activity at pH 4 similar to wild type Coprinus cinereus laccase (FIG. 6B). At pH 5.3, a Km of 23±3 μM and a kcat of 1090±30 min−1 are observed for ABTS oxidation. The values for Km and kcat are determined by fitting initial rates (v=ΔA/Δt/ Δe; Δe: extinction coefficient change), laccase concentration (E), and substrate concentration (S) into v=kcat*E*S/(Km+S) with the Prizm nonlinear regression software (GraphPad, San Diego, Calif.). Total amino acid analysis, from which the extinction coefficient is determined, is performed on a HP AminoQuant instrument.
Example 16 N-Terminal Sequencing
Wild type Coprinus cinereus laccase is treated with a number of deblocking agents in order to remove the blocked N-terminus. Buffer exchange of samples is carried out in BioRad's BioSpin (P-6) device. Samples are treated with pyroglutamate aminopeptidase (Boehringer Mannheim, Indianapolis, Ind. and Sigma, St. Louis Mo.) with deblocking protocols adapted from manufacturer's recommendations as follows. For pyroglutamate aminopeptidase treatment, a laccase sample is exchanged into 5% glycerol-10 mM EDTA-0.1 M sodium phosphate pH 8, then mixed with dithiothreitol (DTT) to 0.7 mM and horse liver peptidase (Sigma, St Louis, Mo.) to 1/216 w/w laccase. The mixture (˜6.2 mg/ml in laccase) is divided into three aliquots, of which one is adjusted 1 M urea and another is adjusted 0.5 M guanidine-HCl. Each sample is incubated at 4° C. for 16 hours. For acylamino acid peptidase, a laccase sample is exchanged into 0.2 M NH4HCO3 pH 7.8, then mixed with EDTA to 1 mM, 2-mercaptoethanol to 1 mM, and peptidase to 1/5 w/w laccase. The mixture (˜14 mg/ml in laccase) is divided into three aliquots, of which one is adjusted 0.01% in SDS, one is adjusted 0.08 M in guanidine-HCl, and another is adjusted 0.7 M is urea. Each sample is incubated at 37° C. for 20 hours. For treatment with acylase L, a laccase sample is exchanged into 0.1 M sodium phosphate pH 7 then mixed with the acylase to ⅓ w/w of laccase. The mixture (˜15 mg/ml in laccase) is incubated at 37° C. for 22 hours.
The enzyme-treated laccase samples are concentrated using Amicon Microcon 10 devices. The concentrated samples are run on SDS-PAGE and electroblotted onto a PVDF membrane of sequencing grade (Novex, San Diego, Calif.). The PVDF membrane is stained with Coommassie blue R-250 to visualize the treated laccase bands. The PVDF membrane is cut to isolate the pieces containing the individual bands. Several lanes are combined and subjected directly to N-terminal sequencing on an ABI 476 Sequencer using a blot cartridge and liquid TFA delivery.
The purified wild-type Coprinus cinereus laccase has a blocked N-terminus. However, treatment with both acylamino acid peptidase and acylase I leads to an identical sequenceable N-terminus. The resulting N-terminal sequence is shown below where it is uncertain whether S represents the actual N-terminus in the mature laccase, as, if this is the case, it would require an unexpected deacylase function by acylamino peptidase.
SVDTMTLTNANVSPDGFTRAGI (SEQ ID NO:36)
Under the conditions described, no deblocking is observed with pyroglutamate aminopeptidase.
Direct N-terminal sequencing of the recombinant Coprinus cinereus laccase yields a blocked N-terminus, likely due to the same acylation at a Ser as observed in the wild-type laccase.
Deposit of Biological Materials
The following biological materials have been deposited under the terms of the Budapest Treaty with the Agricultural Research Service Patent Culture Collection, Northern Regional Research Center, 1815 University Street, Peoria, Ill., 61604, and given the following accession numbers:
Deposit Accession Number Date of Deposit
E. coli DH5α with pDSY71 NRRL-B 21495 August 18, 1995
(lcc2 partial cDNA in pCRII)
E. coli DH5α with pDSY72 NRRL-B 21496 August 19, 1995
(lcc3 partial cDNA in pCRII)
E. coli DH10B(ZL) with NRRL-B 21497 August 18, 1995
pDSY73 (lcc1 genomic clone in
pZL)
E. coli DH5α with pDSY100 NRRL B-21589 June 21, 1996
E. coli DH5α with pDSY105 NRRL B-21602 July 11, 1996
36 40 amino acids amino acid linear peptide unknown 1 Glu Val Asp Gly Gln Leu Thr Glu Pro His Thr Val Asp Arg Leu Gln 1 5 10 15 Ile Phe Thr Gly Gln Arg Tyr Ser Phe Val Leu Asp Ala Asn Gln Pro 20 25 30 Val Asp Asn Tyr Trp Ile Arg Ala 35 40 7 amino acids amino acid linear peptide unknown 2 Xaa Xaa Asp Asn Pro Gly Pro 1 5 8 amino acids amino acid single linear peptide unknown 3 Phe Val Thr Asp Asn Pro Gly Pro 1 5 9 amino acids amino acid single linear peptide unknown 4 Phe Val Thr Asp Asn Pro Gly Pro Trp 1 5 17 amino acids amino acid single linear peptide unknown 5 Ile Leu Asp Pro Ala Xaa Pro Gly Ile Pro Thr Pro Gly Ala Ala Asp 1 5 10 15 Val 8 amino acids amino acid single linear peptide unknown 6 Gly Val Leu Gly Asn Pro Gly Ile 1 5 7 amino acids amino acid single linear peptide unknown 7 Xaa Phe Asp Asn Leu Thr Asn 1 5 16 amino acids amino acid single linear peptide unknown 8 Tyr Arg Xaa Arg Leu Ile Ser Leu Ser Cys Asn Pro Asp Trp Gln Phe 1 5 10 15 4 amino acids amino acid single linear peptide unknown 9 Ala Asp Trp Tyr 1 8 amino acids amino acid single linear peptide unknown 10 Ile Pro Ala Asp Pro Ser Ile Gln 1 5 11 amino acids amino acid single linear peptide unknown 11 Glu Ser Pro Ser Val Pro Thr Leu Ile Arg Phe 1 5 10 4 amino acids amino acid single linear peptide unknown 12 Ala Gly Thr Phe 1 13 amino acids amino acid single linear peptide unknown 13 Ser Gly Ala Gln Ser Ala Asn Asp Leu Leu Pro Ala Gly 1 5 10 15 amino acids amino acid single linear peptide unknown 14 Ile Pro Ala Pro Ser Ile Gln Gly Ala Ala Gln Pro Asx Ala Thr 1 5 10 15 17 base pairs nucleic acid single linear cDNA unknown 15 ATCANTGGCA NGGNTNT 17 19 base pairs nucleic acid single linear cDNA unknown 16 ATCANTGGCA NGGTTNTTN 19 23 base pairs nucleic acid single linear cDNA unknown 17 TCATNTGNCA NTGANNAACC AGG 23 1176 base pairs nucleic acid single linear cDNA unknown CDS 1..1176 18 CAT TGG CAC GGT CTC TTC CAA CGA GGG ACC AAC TGG GCT GAT GGT GCA 48 His Trp His Gly Leu Phe Gln Arg Gly Thr Asn Trp Ala Asp Gly Ala 1 5 10 15 GAT GGT GTC AAC CAG TGC CCG ATC TCT CCA GGC CAT GCT TTC CTC TAC 96 Asp Gly Val Asn Gln Cys Pro Ile Ser Pro Gly His Ala Phe Leu Tyr 20 25 30 AAG TTC ACT CCA GCT GGC CAC GCT GGT ACT TTC TGG TAC CAT TCC CAC 144 Lys Phe Thr Pro Ala Gly His Ala Gly Thr Phe Trp Tyr His Ser His 35 40 45 TTT GGC ACC CAA TAC TGC GAT GGT CTC CGT GGT CCA ATG GTC ATT TAC 192 Phe Gly Thr Gln Tyr Cys Asp Gly Leu Arg Gly Pro Met Val Ile Tyr 50 55 60 GAC GAC AAT GAC CCA CAC GCT GCC CTC TAC GAC GAG GAT GAC GAG AAC 240 Asp Asp Asn Asp Pro His Ala Ala Leu Tyr Asp Glu Asp Asp Glu Asn 65 70 75 80 ACC ATC ATT ACC CTC GCC GAT TGG TAC CAT ATC CCC GCT CCC TCC ATT 288 Thr Ile Ile Thr Leu Ala Asp Trp Tyr His Ile Pro Ala Pro Ser Ile 85 90 95 CAG GGT GCT GCC CAG CCT GAC GCT ACG CTC ATC AAC GGT AAG GGT CGC 336 Gln Gly Ala Ala Gln Pro Asp Ala Thr Leu Ile Asn Gly Lys Gly Arg 100 105 110 TAC GTG GGC GGC CCA GCT GCC GAG CTT TCG ATC GTC AAT GTC GAG CAA 384 Tyr Val Gly Gly Pro Ala Ala Glu Leu Ser Ile Val Asn Val Glu Gln 115 120 125 GGG AAG AAG TAC CGA ATG CGT TTG ATC TCG CTG TCC TGC GAC CCC AAC 432 Gly Lys Lys Tyr Arg Met Arg Leu Ile Ser Leu Ser Cys Asp Pro Asn 130 135 140 TGG CAG TTC TCC ATT GAC GGA CAT GAG TTG ACG ATC ATT GAA GTC GAT 480 Trp Gln Phe Ser Ile Asp Gly His Glu Leu Thr Ile Ile Glu Val Asp 145 150 155 160 GGT CAG CTT ACT GAG CCG CAT ACG GTT GAT CGT CTC CAG ATC TTC ACT 528 Gly Gln Leu Thr Glu Pro His Thr Val Asp Arg Leu Gln Ile Phe Thr 165 170 175 GGT CAA AGG TAC TCC TTC GTT CTC GAC GCC AAC CAG CCG GTG GAC AAC 576 Gly Gln Arg Tyr Ser Phe Val Leu Asp Ala Asn Gln Pro Val Asp Asn 180 185 190 TAC TGG ATC CGT GCT CAA CCC AAC AAG GGT CGA AAC GGA CTT GCT GGT 624 Tyr Trp Ile Arg Ala Gln Pro Asn Lys Gly Arg Asn Gly Leu Ala Gly 195 200 205 ACC TTC GCC AAC GGT GTC AAC TCG GCC ATC CTT CGC TAT GCC GGC GCT 672 Thr Phe Ala Asn Gly Val Asn Ser Ala Ile Leu Arg Tyr Ala Gly Ala 210 215 220 GCC AAC GCT GAT CCA ACC ACC TCC GCC AAC CCC AAC CCC GCC CAA CTC 720 Ala Asn Ala Asp Pro Thr Thr Ser Ala Asn Pro Asn Pro Ala Gln Leu 225 230 235 240 AAC GAA GCC GAC CTC CAT GCT CTC ATC GAC CCC GCT GCT CCC GGT ATC 768 Asn Glu Ala Asp Leu His Ala Leu Ile Asp Pro Ala Ala Pro Gly Ile 245 250 255 CCC ACT CCG GGC GCT GCA GAC GTC AAC CTC CGA TTC CAA TTG GGC TTC 816 Pro Thr Pro Gly Ala Ala Asp Val Asn Leu Arg Phe Gln Leu Gly Phe 260 265 270 AGC GGC GGT CGA TTC ACG ATT AAC GGA ACC GCA TAC GAG AGT CCA AGC 864 Ser Gly Gly Arg Phe Thr Ile Asn Gly Thr Ala Tyr Glu Ser Pro Ser 275 280 285 GTT CCT ACG CTC TTG CAG ATT ATG AGT GGT GCG CAG AGT GCG AAC GAC 912 Val Pro Thr Leu Leu Gln Ile Met Ser Gly Ala Gln Ser Ala Asn Asp 290 295 300 TTG CTC CCT GCT GGA TCG GTG TAT GAG TTG CCC AGG AAC CAA GTT GTT 960 Leu Leu Pro Ala Gly Ser Val Tyr Glu Leu Pro Arg Asn Gln Val Val 305 310 315 320 GAG CTT GTT GTT CCT GCT GGT GTC CTC GGT GGT CCT CAT CCT TTC CAT 1008 Glu Leu Val Val Pro Ala Gly Val Leu Gly Gly Pro His Pro Phe His 325 330 335 CTC CAC GGT CAT GCG TTC AGT GTC GTC AGG AGT GCA GGC AGC AGC ACC 1056 Leu His Gly His Ala Phe Ser Val Val Arg Ser Ala Gly Ser Ser Thr 340 345 350 TAC AAC TTT GTC AAC CCC GTC AAG CGC GAT GTT GTT AGT CTT GGT GTT 1104 Tyr Asn Phe Val Asn Pro Val Lys Arg Asp Val Val Ser Leu Gly Val 355 360 365 ACT GGA GAC GAA GTT ACC ATT CGA TTC GTC ACC GAT AAC CCA GGC CCG 1152 Thr Gly Asp Glu Val Thr Ile Arg Phe Val Thr Asp Asn Pro Gly Pro 370 375 380 TGG TTC TTC CAC TGC CAC ATT GAA 1176 Trp Phe Phe His Cys His Ile Glu 385 390 392 amino acids amino acid linear protein unknown 19 His Trp His Gly Leu Phe Gln Arg Gly Thr Asn Trp Ala Asp Gly Ala 1 5 10 15 Asp Gly Val Asn Gln Cys Pro Ile Ser Pro Gly His Ala Phe Leu Tyr 20 25 30 Lys Phe Thr Pro Ala Gly His Ala Gly Thr Phe Trp Tyr His Ser His 35 40 45 Phe Gly Thr Gln Tyr Cys Asp Gly Leu Arg Gly Pro Met Val Ile Tyr 50 55 60 Asp Asp Asn Asp Pro His Ala Ala Leu Tyr Asp Glu Asp Asp Glu Asn 65 70 75 80 Thr Ile Ile Thr Leu Ala Asp Trp Tyr His Ile Pro Ala Pro Ser Ile 85 90 95 Gln Gly Ala Ala Gln Pro Asp Ala Thr Leu Ile Asn Gly Lys Gly Arg 100 105 110 Tyr Val Gly Gly Pro Ala Ala Glu Leu Ser Ile Val Asn Val Glu Gln 115 120 125 Gly Lys Lys Tyr Arg Met Arg Leu Ile Ser Leu Ser Cys Asp Pro Asn 130 135 140 Trp Gln Phe Ser Ile Asp Gly His Glu Leu Thr Ile Ile Glu Val Asp 145 150 155 160 Gly Gln Leu Thr Glu Pro His Thr Val Asp Arg Leu Gln Ile Phe Thr 165 170 175 Gly Gln Arg Tyr Ser Phe Val Leu Asp Ala Asn Gln Pro Val Asp Asn 180 185 190 Tyr Trp Ile Arg Ala Gln Pro Asn Lys Gly Arg Asn Gly Leu Ala Gly 195 200 205 Thr Phe Ala Asn Gly Val Asn Ser Ala Ile Leu Arg Tyr Ala Gly Ala 210 215 220 Ala Asn Ala Asp Pro Thr Thr Ser Ala Asn Pro Asn Pro Ala Gln Leu 225 230 235 240 Asn Glu Ala Asp Leu His Ala Leu Ile Asp Pro Ala Ala Pro Gly Ile 245 250 255 Pro Thr Pro Gly Ala Ala Asp Val Asn Leu Arg Phe Gln Leu Gly Phe 260 265 270 Ser Gly Gly Arg Phe Thr Ile Asn Gly Thr Ala Tyr Glu Ser Pro Ser 275 280 285 Val Pro Thr Leu Leu Gln Ile Met Ser Gly Ala Gln Ser Ala Asn Asp 290 295 300 Leu Leu Pro Ala Gly Ser Val Tyr Glu Leu Pro Arg Asn Gln Val Val 305 310 315 320 Glu Leu Val Val Pro Ala Gly Val Leu Gly Gly Pro His Pro Phe His 325 330 335 Leu His Gly His Ala Phe Ser Val Val Arg Ser Ala Gly Ser Ser Thr 340 345 350 Tyr Asn Phe Val Asn Pro Val Lys Arg Asp Val Val Ser Leu Gly Val 355 360 365 Thr Gly Asp Glu Val Thr Ile Arg Phe Val Thr Asp Asn Pro Gly Pro 370 375 380 Trp Phe Phe His Cys His Ile Glu 385 390 1170 base pairs nucleic acid single linear cDNA unknown CDS 1..1170 20 CAC TGG CAC GGC ATG TTC CAA AGG GGG ACT GCC TGG GCT GAT GGT CCT 48 His Trp His Gly Met Phe Gln Arg Gly Thr Ala Trp Ala Asp Gly Pro 395 400 405 GCT GGC GTC ACC CAA TGC CCT ATT TCC CCA GGG CAT TCG TTC TTG TAC 96 Ala Gly Val Thr Gln Cys Pro Ile Ser Pro Gly His Ser Phe Leu Tyr 410 415 420 AAG TTC CAG GCT CTT AAC CAA GCC GGT ACT TTC TGG TAC CAC TCC CAT 144 Lys Phe Gln Ala Leu Asn Gln Ala Gly Thr Phe Trp Tyr His Ser His 425 430 435 440 CAC GAA TCG CAA TAT TGT GAC GGT TTG CGT GGG GCT ATG GTC GTA TAT 192 His Glu Ser Gln Tyr Cys Asp Gly Leu Arg Gly Ala Met Val Val Tyr 445 450 455 GAC CCA GTC GAC CCA CAT CGC AAC TTG TAT GAC ATT GAC AAC GAG GCC 240 Asp Pro Val Asp Pro His Arg Asn Leu Tyr Asp Ile Asp Asn Glu Ala 460 465 470 ACG ATC ATT ACG CTC GCA GAC TGG TAT CAC GTC CCT GCT CCC TCT GCA 288 Thr Ile Ile Thr Leu Ala Asp Trp Tyr His Val Pro Ala Pro Ser Ala 475 480 485 GGT CTC GTT CCC ACC CCA GAT TCC ACG CTT ATC AAC GGT AAG GGC CGG 336 Gly Leu Val Pro Thr Pro Asp Ser Thr Leu Ile Asn Gly Lys Gly Arg 490 495 500 TAT GCT GGT GGC CCT ACC GTA CCT CTC GCG GTC ATT TCT GTA ACC CGA 384 Tyr Ala Gly Gly Pro Thr Val Pro Leu Ala Val Ile Ser Val Thr Arg 505 510 515 520 AAC CGA CGA TAC CGG TTC CGC CTT GTT TCC CTT TCA TGC GAT CCT AAT 432 Asn Arg Arg Tyr Arg Phe Arg Leu Val Ser Leu Ser Cys Asp Pro Asn 525 530 535 TAT GTA TTC TCT ATC GAT GGG CAT ACC ATG ACT GTT ATT GAG GTC GAC 480 Tyr Val Phe Ser Ile Asp Gly His Thr Met Thr Val Ile Glu Val Asp 540 545 550 GGA GTT AAC GTC CAA CCT CTC GTT GTC GAC TCG ATC CAG ATC TTC GCA 528 Gly Val Asn Val Gln Pro Leu Val Val Asp Ser Ile Gln Ile Phe Ala 555 560 565 GGT CAG CGC TAC TCG TTC GTT CTC AAC GCC AAC CGC CCC GTC GGC AAC 576 Gly Gln Arg Tyr Ser Phe Val Leu Asn Ala Asn Arg Pro Val Gly Asn 570 575 580 TAC TGG GTG CGA GCC AAC CCC AAC ATC GGT ACT ACG GGC TTC GTC GGT 624 Tyr Trp Val Arg Ala Asn Pro Asn Ile Gly Thr Thr Gly Phe Val Gly 585 590 595 600 GGA GTC AAT TCT GCG ATT CTG CGC TAT GTG GGC GCC TCC AAT ACA GAC 672 Gly Val Asn Ser Ala Ile Leu Arg Tyr Val Gly Ala Ser Asn Thr Asp 605 610 615 CCC ACT ACC ACC CAA ACT CCT TTC AGC AAC CCT CTC CTT GAG ACC AAT 720 Pro Thr Thr Thr Gln Thr Pro Phe Ser Asn Pro Leu Leu Glu Thr Asn 620 625 630 CTC CAC CCC TTG ACC AAC CCT GCT GCT CCT GGC TTG CCT ACC CCA GGT 768 Leu His Pro Leu Thr Asn Pro Ala Ala Pro Gly Leu Pro Thr Pro Gly 635 640 645 GGC GTC GAC GTC GCG ATC AAC CTT AAC ACG GTA TTC GAT TTC AGT AGT 816 Gly Val Asp Val Ala Ile Asn Leu Asn Thr Val Phe Asp Phe Ser Ser 650 655 660 CTC ACC TTC TCC GTT AAC GGA GCC ACT TTC CAT CAA CCG CCC GTC CCT 864 Leu Thr Phe Ser Val Asn Gly Ala Thr Phe His Gln Pro Pro Val Pro 665 670 675 680 GTC TTG CTT CAG ATC ATG AGC GGT GCA CAG ACT GCC CAG CAG CTT CTT 912 Val Leu Leu Gln Ile Met Ser Gly Ala Gln Thr Ala Gln Gln Leu Leu 685 690 695 CCC TCC GGT TCG GTC TAC GTC CTT CCC CGT AAC AAA GTC ATC GAG CTT 960 Pro Ser Gly Ser Val Tyr Val Leu Pro Arg Asn Lys Val Ile Glu Leu 700 705 710 TCT ATG CCT GGA GGC TCC ACT GGC AGT CCC CAT CCC TTC CAT CTC CAC 1008 Ser Met Pro Gly Gly Ser Thr Gly Ser Pro His Pro Phe His Leu His 715 720 725 GGT CAC GAA TTT GCT GTG GTG AGA AGC GCG GGG AGT TCG ACC TAC AAC 1056 Gly His Glu Phe Ala Val Val Arg Ser Ala Gly Ser Ser Thr Tyr Asn 730 735 740 TTC GCG AAC CCG GTA CGC AGG GAT GTC GTG AGT GCC GGT GTT GCT GGT 1104 Phe Ala Asn Pro Val Arg Arg Asp Val Val Ser Ala Gly Val Ala Gly 745 750 755 760 GAC AAC GTC ACC ATT CGA TTC CGT ACC GAT AAC CCT GGA CCA TGG ATT 1152 Asp Asn Val Thr Ile Arg Phe Arg Thr Asp Asn Pro Gly Pro Trp Ile 765 770 775 CTC CAT TGC CAT ATC GAC 1170 Leu His Cys His Ile Asp 780 390 amino acids amino acid linear protein unknown 21 His Trp His Gly Met Phe Gln Arg Gly Thr Ala Trp Ala Asp Gly Pro 1 5 10 15 Ala Gly Val Thr Gln Cys Pro Ile Ser Pro Gly His Ser Phe Leu Tyr 20 25 30 Lys Phe Gln Ala Leu Asn Gln Ala Gly Thr Phe Trp Tyr His Ser His 35 40 45 His Glu Ser Gln Tyr Cys Asp Gly Leu Arg Gly Ala Met Val Val Tyr 50 55 60 Asp Pro Val Asp Pro His Arg Asn Leu Tyr Asp Ile Asp Asn Glu Ala 65 70 75 80 Thr Ile Ile Thr Leu Ala Asp Trp Tyr His Val Pro Ala Pro Ser Ala 85 90 95 Gly Leu Val Pro Thr Pro Asp Ser Thr Leu Ile Asn Gly Lys Gly Arg 100 105 110 Tyr Ala Gly Gly Pro Thr Val Pro Leu Ala Val Ile Ser Val Thr Arg 115 120 125 Asn Arg Arg Tyr Arg Phe Arg Leu Val Ser Leu Ser Cys Asp Pro Asn 130 135 140 Tyr Val Phe Ser Ile Asp Gly His Thr Met Thr Val Ile Glu Val Asp 145 150 155 160 Gly Val Asn Val Gln Pro Leu Val Val Asp Ser Ile Gln Ile Phe Ala 165 170 175 Gly Gln Arg Tyr Ser Phe Val Leu Asn Ala Asn Arg Pro Val Gly Asn 180 185 190 Tyr Trp Val Arg Ala Asn Pro Asn Ile Gly Thr Thr Gly Phe Val Gly 195 200 205 Gly Val Asn Ser Ala Ile Leu Arg Tyr Val Gly Ala Ser Asn Thr Asp 210 215 220 Pro Thr Thr Thr Gln Thr Pro Phe Ser Asn Pro Leu Leu Glu Thr Asn 225 230 235 240 Leu His Pro Leu Thr Asn Pro Ala Ala Pro Gly Leu Pro Thr Pro Gly 245 250 255 Gly Val Asp Val Ala Ile Asn Leu Asn Thr Val Phe Asp Phe Ser Ser 260 265 270 Leu Thr Phe Ser Val Asn Gly Ala Thr Phe His Gln Pro Pro Val Pro 275 280 285 Val Leu Leu Gln Ile Met Ser Gly Ala Gln Thr Ala Gln Gln Leu Leu 290 295 300 Pro Ser Gly Ser Val Tyr Val Leu Pro Arg Asn Lys Val Ile Glu Leu 305 310 315 320 Ser Met Pro Gly Gly Ser Thr Gly Ser Pro His Pro Phe His Leu His 325 330 335 Gly His Glu Phe Ala Val Val Arg Ser Ala Gly Ser Ser Thr Tyr Asn 340 345 350 Phe Ala Asn Pro Val Arg Arg Asp Val Val Ser Ala Gly Val Ala Gly 355 360 365 Asp Asn Val Thr Ile Arg Phe Arg Thr Asp Asn Pro Gly Pro Trp Ile 370 375 380 Leu His Cys His Ile Asp 385 390 1161 base pairs nucleic acid single linear cDNA unknown CDS 1..1161 22 CAC TGG CAC GGT TTC TTG CAG GAG GGT ACA GCT TGG GCC GAC GGT CCT 48 His Trp His Gly Phe Leu Gln Glu Gly Thr Ala Trp Ala Asp Gly Pro 395 400 405 GCG GGT GTT ACT CAA TGC CCC ATT GCC CCT GGT CAC TCT TTC CTC TAT 96 Ala Gly Val Thr Gln Cys Pro Ile Ala Pro Gly His Ser Phe Leu Tyr 410 415 420 AAG TTC CAG GCC AAA AAC CAA GCT GGT ACC TTC TGG TAC CAT TCC CAC 144 Lys Phe Gln Ala Lys Asn Gln Ala Gly Thr Phe Trp Tyr His Ser His 425 430 435 CAC ATG TCT CAG TAT TGT GAC GGC CTG AGA GGC GTC ATG GTC GTT TAC 192 His Met Ser Gln Tyr Cys Asp Gly Leu Arg Gly Val Met Val Val Tyr 440 445 450 GAT CCC CTA GAT CCC CAT CGT CAC CTG TAT GAC GTT GAT AAC GAG AAT 240 Asp Pro Leu Asp Pro His Arg His Leu Tyr Asp Val Asp Asn Glu Asn 455 460 465 470 ACT ATC ATC ACG CTC GCG GAC TGG TAT CAC GAT CCC GCC CCT TCT GCT 288 Thr Ile Ile Thr Leu Ala Asp Trp Tyr His Asp Pro Ala Pro Ser Ala 475 480 485 GGA CTC GTC CCA ACC CCC TGG TCG ACT TTG ATC AAT GGC AAG GGC CGT 336 Gly Leu Val Pro Thr Pro Trp Ser Thr Leu Ile Asn Gly Lys Gly Arg 490 495 500 TAC CCA GGC GGA CCC GTC GTG CCC TTG GCC GTC ATT CAC GTC AGC CGC 384 Tyr Pro Gly Gly Pro Val Val Pro Leu Ala Val Ile His Val Ser Arg 505 510 515 GGA AAG CGC TAC CGC TTC CGC CTC GTC TCC CTT TCG TGC GAC CCT AAC 432 Gly Lys Arg Tyr Arg Phe Arg Leu Val Ser Leu Ser Cys Asp Pro Asn 520 525 530 TAT GTA TTC TCT ATT GAC GGT CAC ACC ATG ACG GTC ATT GAA GTC GAT 480 Tyr Val Phe Ser Ile Asp Gly His Thr Met Thr Val Ile Glu Val Asp 535 540 545 550 GGT GTC AAC CAT GAA CCG TTG GTT GTC GAC CAC ATT CAA ATC TTT GCT 528 Gly Val Asn His Glu Pro Leu Val Val Asp His Ile Gln Ile Phe Ala 555 560 565 GGT CAA CGG TAC TCG TTT GTC TTG AAC GCC AAC CGG CCC GTC AAC AAC 576 Gly Gln Arg Tyr Ser Phe Val Leu Asn Ala Asn Arg Pro Val Asn Asn 570 575 580 TAC TGG GTC AGG GCT AAC CCC AAC CTC GGC TCT GTC GGC TTC GGT GGC 624 Tyr Trp Val Arg Ala Asn Pro Asn Leu Gly Ser Val Gly Phe Gly Gly 585 590 595 GGT ATT AAT TCC GCA ATT CTG CGA TAT GTT GGA GCT CCT GCC GTC GAC 672 Gly Ile Asn Ser Ala Ile Leu Arg Tyr Val Gly Ala Pro Ala Val Asp 600 605 610 CCA ACC ACC TCC CAA TTG CCT TTC AGC AAC CCA CTC CTC GAG ACC AAC 720 Pro Thr Thr Ser Gln Leu Pro Phe Ser Asn Pro Leu Leu Glu Thr Asn 615 620 625 630 TTG CAC CCT CTC GTA AAT CCT GCT GCA CCT GGC GGC CCT TCC CCC GGT 768 Leu His Pro Leu Val Asn Pro Ala Ala Pro Gly Gly Pro Ser Pro Gly 635 640 645 GAC GTC GAT GTC GCC ATC AAC CTG GAT ATC TTG TTC GAC GTC TCA ATC 816 Asp Val Asp Val Ala Ile Asn Leu Asp Ile Leu Phe Asp Val Ser Ile 650 655 660 CTC AAG TTC ACT GTC AAC GGT GCT ACC TTC GAT GAA CCA CCC GTT CCG 864 Leu Lys Phe Thr Val Asn Gly Ala Thr Phe Asp Glu Pro Pro Val Pro 665 670 675 GTC CTT CTC CAG ATT TTG AGC GGT GCA CAT ACC GCC TCA TCT CTT CTC 912 Val Leu Leu Gln Ile Leu Ser Gly Ala His Thr Ala Ser Ser Leu Leu 680 685 690 CCC TCT GGC AGC GTC TAC ACT CTT CCC CCT AAC AAG GTC ATT GAG CTC 960 Pro Ser Gly Ser Val Tyr Thr Leu Pro Pro Asn Lys Val Ile Glu Leu 695 700 705 710 ACT ATT CCC GGT GGT GGT ATC GGT GCT CCT CAC CCC ATC CAT CTT CAC 1008 Thr Ile Pro Gly Gly Gly Ile Gly Ala Pro His Pro Ile His Leu His 715 720 725 GGC CAT ACC TTC AAG GTT GTC CGT AGC GCA GGC AGC TCG ACT TAC AAC 1056 Gly His Thr Phe Lys Val Val Arg Ser Ala Gly Ser Ser Thr Tyr Asn 730 735 740 TTC GTC AAT CCC GTT GAG CGA GAT GTT GTC AAC GTT GGT CAA GCT GGC 1104 Phe Val Asn Pro Val Glu Arg Asp Val Val Asn Val Gly Gln Ala Gly 745 750 755 GAC AAT GTC ACC ATT CGA TTC GTC ACT GAT AAT GCT GGT CCC TGG ATT 1152 Asp Asn Val Thr Ile Arg Phe Val Thr Asp Asn Ala Gly Pro Trp Ile 760 765 770 CTT CAC TGC 1161 Leu His Cys 775 387 amino acids amino acid linear protein unknown 23 His Trp His Gly Phe Leu Gln Glu Gly Thr Ala Trp Ala Asp Gly Pro 1 5 10 15 Ala Gly Val Thr Gln Cys Pro Ile Ala Pro Gly His Ser Phe Leu Tyr 20 25 30 Lys Phe Gln Ala Lys Asn Gln Ala Gly Thr Phe Trp Tyr His Ser His 35 40 45 His Met Ser Gln Tyr Cys Asp Gly Leu Arg Gly Val Met Val Val Tyr 50 55 60 Asp Pro Leu Asp Pro His Arg His Leu Tyr Asp Val Asp Asn Glu Asn 65 70 75 80 Thr Ile Ile Thr Leu Ala Asp Trp Tyr His Asp Pro Ala Pro Ser Ala 85 90 95 Gly Leu Val Pro Thr Pro Trp Ser Thr Leu Ile Asn Gly Lys Gly Arg 100 105 110 Tyr Pro Gly Gly Pro Val Val Pro Leu Ala Val Ile His Val Ser Arg 115 120 125 Gly Lys Arg Tyr Arg Phe Arg Leu Val Ser Leu Ser Cys Asp Pro Asn 130 135 140 Tyr Val Phe Ser Ile Asp Gly His Thr Met Thr Val Ile Glu Val Asp 145 150 155 160 Gly Val Asn His Glu Pro Leu Val Val Asp His Ile Gln Ile Phe Ala 165 170 175 Gly Gln Arg Tyr Ser Phe Val Leu Asn Ala Asn Arg Pro Val Asn Asn 180 185 190 Tyr Trp Val Arg Ala Asn Pro Asn Leu Gly Ser Val Gly Phe Gly Gly 195 200 205 Gly Ile Asn Ser Ala Ile Leu Arg Tyr Val Gly Ala Pro Ala Val Asp 210 215 220 Pro Thr Thr Ser Gln Leu Pro Phe Ser Asn Pro Leu Leu Glu Thr Asn 225 230 235 240 Leu His Pro Leu Val Asn Pro Ala Ala Pro Gly Gly Pro Ser Pro Gly 245 250 255 Asp Val Asp Val Ala Ile Asn Leu Asp Ile Leu Phe Asp Val Ser Ile 260 265 270 Leu Lys Phe Thr Val Asn Gly Ala Thr Phe Asp Glu Pro Pro Val Pro 275 280 285 Val Leu Leu Gln Ile Leu Ser Gly Ala His Thr Ala Ser Ser Leu Leu 290 295 300 Pro Ser Gly Ser Val Tyr Thr Leu Pro Pro Asn Lys Val Ile Glu Leu 305 310 315 320 Thr Ile Pro Gly Gly Gly Ile Gly Ala Pro His Pro Ile His Leu His 325 330 335 Gly His Thr Phe Lys Val Val Arg Ser Ala Gly Ser Ser Thr Tyr Asn 340 345 350 Phe Val Asn Pro Val Glu Arg Asp Val Val Asn Val Gly Gln Ala Gly 355 360 365 Asp Asn Val Thr Ile Arg Phe Val Thr Asp Asn Ala Gly Pro Trp Ile 370 375 380 Leu His Cys 385 21 base pairs nucleic acid single linear cDNA unknown 24 ACTGCGATGG TCTCCGTGGT C 21 21 base pairs nucleic acid single linear cDNA unknown 25 GGGGCCTGGG TTATCGGTGA C 21 3327 base pairs nucleic acid single linear DNA (genomic) unknown CDS join(726..851, 907..1023, 1101..1247, 1316..1696, 1752..2240, 2321..2494, 2548..2607, 2670..2793) 26 CAACGTCAAA GGGCGAAAAA CCGTCTATCA GGGCGATGGC CCACTACGTG AACCATCACC 60 CTAATCAAGT TTTTTGGGGT CGAGGTGCCG TAAAGCACTA AATCGGAACC CTAAAGGGAG 120 CCCCCGATTT AGAGCTTGAC GGGGAAAGCC GGCGAACGTG GCGAGAAAGG AAGGGAAGAA 180 AGCGAAAGGA GCGGGCGCTA GGGCGCTGGC AAGTGTAGCG GTCACGCTGC GCGTAACCAC 240 CACACCCGCC GCGCTTAATG CGCCGCTACA GGGCGCGTCC CATTCGCCAT TCAGGCTGCG 300 CAACTGTTGG GAAGGGCGAT CGGTGCGGGC CTCTTCGCTA TTACGCCAGC TGGCGAAAGG 360 GGGATGTGCT GCAAGGCGAT TAAGTTGGGT AACGCCAGGG TTTTCCCAGT CACGACGTTG 420 TAAAACGACG GCCAGTGAAT TGAATTTAGG TGACACTATA GAAGAGCTAT GACGTCGCAT 480 GCACGCGTAC GTAAGCTTGG ATCCTCTAGA GCGACCGCCG ACTAGTGAGC TCGTCGACCC 540 GGGAATTGCA GCGTCCCTGG TCGTACGTTA GCCTACGCTT TACAGCACCG AAAGAAGTAT 600 AAAATCTGTA TGAAAGTTGG CGAAGAAACC TCAGACTACT CTCGTCGTCT ATCTTCACTC 660 CTCTGCTCCT CTCTCCTCCA CAGACTCTCC TTGACAGCCT CGTCGTATCA GAGAACAGAA 720 CAACA ATG TTC AAG AAC CTC CTC TCG TTC GCC CTT CTG GCG ATT AGC 767 Met Phe Lys Asn Leu Leu Ser Phe Ala Leu Leu Ala Ile Ser 1 5 10 GTT GCC AAC GCT CAG ATC GTC AAT TCG GTC GAT ACC ATG ACC CTC ACC 815 Val Ala Asn Ala Gln Ile Val Asn Ser Val Asp Thr Met Thr Leu Thr 15 20 25 30 AAC GCG AAC GTC AGT CCC GAC GGT TTC ACT CGA GCT GTAAGTATAG 861 Asn Ala Asn Val Ser Pro Asp Gly Phe Thr Arg Ala 35 40 GTCTTCAGCA CACTGTTGAT TATCCATTAC TTACCAACTT AACAG GGT ATC CTC 915 Gly Ile Leu 45 GTC AAT GGA GTT CAT GGA CCT CTT ATT CGA GGT GGA AAG AAC GAC AAC 963 Val Asn Gly Val His Gly Pro Leu Ile Arg Gly Gly Lys Asn Asp Asn 50 55 60 TTT GAG CTC AAC GTC GTT AAC GAC TTG GAC AAC CCC ACT ATG CTT CGG 1011 Phe Glu Leu Asn Val Val Asn Asp Leu Asp Asn Pro Thr Met Leu Arg 65 70 75 CCT ACC AGT ATC GTGAGTTCTA CAGAAATAAA CACTGATCCA TCATGATCCA 1063 Pro Thr Ser Ile 80 GAACACTGAC AACGTTCTGA TTTTGGTTTG CTTGTAG CAT TGG CAC GGT CTC TTC 1118 His Trp His Gly Leu Phe 85 CAA CGA GGG ACC AAC TGG GCT GAT GGT GCA GAT GGT GTC AAC CAG TGC 1166 Gln Arg Gly Thr Asn Trp Ala Asp Gly Ala Asp Gly Val Asn Gln Cys 90 95 100 CCG ATC TCT CCA GGC CAT GCT TTC CTC TAC AAG TTC ACT CCA GCT GGC 1214 Pro Ile Ser Pro Gly His Ala Phe Leu Tyr Lys Phe Thr Pro Ala Gly 105 110 115 CAC GCT GGT ACT TTC TGG TAC CAT TCC CAC TTT GTAAGCCCGA CCCCCCGACT 1267 His Ala Gly Thr Phe Trp Tyr His Ser His Phe 120 125 130 ATGATCATCT TGACTGGAGT CCTGATTGAT GTCCAACTAA TTTACTAG GGC ACC CAA 1324 Gly Thr Gln TAC TGC GAT GGT CTC CGT GGT CCA ATG GTC ATT TAC GAC GAC AAT GAC 1372 Tyr Cys Asp Gly Leu Arg Gly Pro Met Val Ile Tyr Asp Asp Asn Asp 135 140 145 CCA CAC GCT GCC CTC TAC GAC GAG GAT GAC GAG AAC ACC ATC ATT ACC 1420 Pro His Ala Ala Leu Tyr Asp Glu Asp Asp Glu Asn Thr Ile Ile Thr 150 155 160 165 CTC GCC GAT TGG TAC CAT ATC CCC GCT CCC TCC ATT CAG GGT GCT GCC 1468 Leu Ala Asp Trp Tyr His Ile Pro Ala Pro Ser Ile Gln Gly Ala Ala 170 175 180 CAG CCT GAC GCT ACG CTC ATC AAC GGT AAG GGT CGC TAC GTG GGC GGC 1516 Gln Pro Asp Ala Thr Leu Ile Asn Gly Lys Gly Arg Tyr Val Gly Gly 185 190 195 CCA GCT GCC GAG CTT TCG ATC GTC AAT GTC GAG CAA GGG AAG AAG TAC 1564 Pro Ala Ala Glu Leu Ser Ile Val Asn Val Glu Gln Gly Lys Lys Tyr 200 205 210 CGA ATG CGT TTG ATC TCG CTG TCC TGC GAC CCC AAC TGG CAG TTC TCC 1612 Arg Met Arg Leu Ile Ser Leu Ser Cys Asp Pro Asn Trp Gln Phe Ser 215 220 225 ATT GAC GGA CAT GAG TTG ACG ATC ATT GAA GTC GAT GGT CAG CTT ACT 1660 Ile Asp Gly His Glu Leu Thr Ile Ile Glu Val Asp Gly Gln Leu Thr 230 235 240 245 GAG CCG CAT ACG GTT GAT CGT CTC CAG ATC TTC ACT GTAAGCATTG 1706 Glu Pro His Thr Val Asp Arg Leu Gln Ile Phe Thr 250 255 AAATCGGTGT GTTTCCGTTG AGAAAGCACA CTCACCTTTA ATCAG GGT CAA AGG 1760 Gly Gln Arg 260 TAC TCC TTC GTT CTC GAC GCC AAC CAG CCG GTG GAC AAC TAC TGG ATC 1808 Tyr Ser Phe Val Leu Asp Ala Asn Gln Pro Val Asp Asn Tyr Trp Ile 265 270 275 CGT GCT CAA CCC AAC AAG GGT CGA AAC GGA CTT GCT GGT ACC TTC GCC 1856 Arg Ala Gln Pro Asn Lys Gly Arg Asn Gly Leu Ala Gly Thr Phe Ala 280 285 290 AAC GGT GTC AAC TCG GCC ATC CTT CGC TAT GCC GGC GCT GCC AAC GCT 1904 Asn Gly Val Asn Ser Ala Ile Leu Arg Tyr Ala Gly Ala Ala Asn Ala 295 300 305 GAT CCA ACC ACC TCC GCC AAC CCC AAC CCC GCC CAA CTC AAC GAA GCC 1952 Asp Pro Thr Thr Ser Ala Asn Pro Asn Pro Ala Gln Leu Asn Glu Ala 310 315 320 GAC CTC CAT GCT CTC ATC GAC CCC GCT GCT CCC GGT ATC CCC ACT CCG 2000 Asp Leu His Ala Leu Ile Asp Pro Ala Ala Pro Gly Ile Pro Thr Pro 325 330 335 340 GGC GCT GCA GAC GTC AAC CTC CGA TTC CAA TTG GGC TTC AGC GGC GGT 2048 Gly Ala Ala Asp Val Asn Leu Arg Phe Gln Leu Gly Phe Ser Gly Gly 345 350 355 CGA TTC ACG ATT AAC GGA ACC GCA TAC GAG AGT CCA AGC GTT CCT ACG 2096 Arg Phe Thr Ile Asn Gly Thr Ala Tyr Glu Ser Pro Ser Val Pro Thr 360 365 370 CTC TTG CAG ATT ATG AGT GGT GCG CAG AGT GCG AAC GAC TTG CTC CCT 2144 Leu Leu Gln Ile Met Ser Gly Ala Gln Ser Ala Asn Asp Leu Leu Pro 375 380 385 GCT GGA TCG GTG TAT GAG TTG CCC AGG AAC CAA GTT GTT GAG CTT GTT 2192 Ala Gly Ser Val Tyr Glu Leu Pro Arg Asn Gln Val Val Glu Leu Val 390 395 400 GTT CCT GCT GGT GTC CTC GGT GGT CCT CAT CCT TTC CAT CTC CAC GGT 2240 Val Pro Ala Gly Val Leu Gly Gly Pro His Pro Phe His Leu His Gly 405 410 415 420 GTACGTCAAG TTTTCTTTTC TCTTCTTTTT TTCATGGGTG GTCAAGTGTA CATGAGCTTA 2300 CCAAGGATTG AATTGTGTAG CAT GCG TTC AGT GTC GTC AGG AGT GCA GGC 2350 His Ala Phe Ser Val Val Arg Ser Ala Gly 425 430 AGC AGC ACC TAC AAC TTT GTC AAC CCC GTC AAG CGC GAT GTT GTT AGT 2398 Ser Ser Thr Tyr Asn Phe Val Asn Pro Val Lys Arg Asp Val Val Ser 435 440 445 CTT GGT GTT ACT GGA GAC GAA GTT ACC ATT CGA TTC GTC ACC GAT AAC 2446 Leu Gly Val Thr Gly Asp Glu Val Thr Ile Arg Phe Val Thr Asp Asn 450 455 460 CCA GGC CCG TGG TTC TTC CAC TGC CAC ATT GAA TTC CAT CTC ATG AAC 2494 Pro Gly Pro Trp Phe Phe His Cys His Ile Glu Phe His Leu Met Asn 465 470 475 GTAAGTCTTC ATATCCATCG TTGTATACTC CAGAGTCTAA CCCACCTCCA CAG GGC 2550 Gly TTG GCG ATC GTC TTT GCT GAA GAC ATG GCG AAC ACG GTT GAT GCT AAC 2598 Leu Ala Ile Val Phe Ala Glu Asp Met Ala Asn Thr Val Asp Ala Asn 480 485 490 495 AAC CCA CCT GTACGTCCCC TCCTATTGAC TCAAATACTA ATTTCCGAAG 2647 Asn Pro Pro CTAACTTCGG CATCAATTAC AG GTC GAG TGG GCC CAG CTT TGC GAG ATT TAC 2699 Val Glu Trp Ala Gln Leu Cys Glu Ile Tyr 500 505 GAT GAC CTG CCG CCT GAG GCG ACC TCG ATT CAA ACC GTT GTG CGT CGC 2747 Asp Asp Leu Pro Pro Glu Ala Thr Ser Ile Gln Thr Val Val Arg Arg 510 515 520 GCT GAG CCC ACC GGC TTT TCG GCC AAG TTC CGC AGG GAG GGC TTG 2792 Ala Glu Pro Thr Gly Phe Ser Ala Lys Phe Arg Arg Glu Gly Leu 525 530 535 TAGATAATAT TATAGTTGAC CAGAGGGCCA GTGGTAGGAG GCTGCTATAG TCAAAGTTGG 2852 TCACAGAGGG AAGAGTTAGT CGCAGAGAAG TCGTTTGAGT ACTACTAGTT ATTCATCGTG 2912 TTGTTATTTA TCGTGGTTGT TACATACTTA TTAACTATCG TTATGTGTGC TTGAGTTTGG 2972 AATGACAATG TATTTGATTG TCGAGTTGGA ATCCTTGTTG AAGTGCTAGT AACCTTTTGA 3032 TGGACCTCCG ACCTGCCTTT TCCCCGCACT TCCTCGATTG AATATTTGAG CGCGAGGCAC 3092 GAATCGAACC CACGACCCGC GAATGTCCAA ATTCCGGACC GGTACCTGCA GGCGTACCAG 3152 CTTTCCCTAT AGTGAGTCGT ATTAGAGCTT GGCGTAATCA TGGTCATAGC TGTTTCCTGT 3212 GTGAAATTGT TATCCGCTCA CAATTCCACA CAACATACGA GCCGGAAGCA TAAAGTGTAA 3272 AGCCTGGGGT GCCTAATGAG TGAGCTAACT CACATTAATT GCGTTGCGCT CACTG 3327 539 amino acids amino acid linear protein unknown 27 Met Phe Lys Asn Leu Leu Ser Phe Ala Leu Leu Ala Ile Ser Val Ala 1 5 10 15 Asn Ala Gln Ile Val Asn Ser Val Asp Thr Met Thr Leu Thr Asn Ala 20 25 30 Asn Val Ser Pro Asp Gly Phe Thr Arg Ala Gly Ile Leu Val Asn Gly 35 40 45 Val His Gly Pro Leu Ile Arg Gly Gly Lys Asn Asp Asn Phe Glu Leu 50 55 60 Asn Val Val Asn Asp Leu Asp Asn Pro Thr Met Leu Arg Pro Thr Ser 65 70 75 80 Ile His Trp His Gly Leu Phe Gln Arg Gly Thr Asn Trp Ala Asp Gly 85 90 95 Ala Asp Gly Val Asn Gln Cys Pro Ile Ser Pro Gly His Ala Phe Leu 100 105 110 Tyr Lys Phe Thr Pro Ala Gly His Ala Gly Thr Phe Trp Tyr His Ser 115 120 125 His Phe Gly Thr Gln Tyr Cys Asp Gly Leu Arg Gly Pro Met Val Ile 130 135 140 Tyr Asp Asp Asn Asp Pro His Ala Ala Leu Tyr Asp Glu Asp Asp Glu 145 150 155 160 Asn Thr Ile Ile Thr Leu Ala Asp Trp Tyr His Ile Pro Ala Pro Ser 165 170 175 Ile Gln Gly Ala Ala Gln Pro Asp Ala Thr Leu Ile Asn Gly Lys Gly 180 185 190 Arg Tyr Val Gly Gly Pro Ala Ala Glu Leu Ser Ile Val Asn Val Glu 195 200 205 Gln Gly Lys Lys Tyr Arg Met Arg Leu Ile Ser Leu Ser Cys Asp Pro 210 215 220 Asn Trp Gln Phe Ser Ile Asp Gly His Glu Leu Thr Ile Ile Glu Val 225 230 235 240 Asp Gly Gln Leu Thr Glu Pro His Thr Val Asp Arg Leu Gln Ile Phe 245 250 255 Thr Gly Gln Arg Tyr Ser Phe Val Leu Asp Ala Asn Gln Pro Val Asp 260 265 270 Asn Tyr Trp Ile Arg Ala Gln Pro Asn Lys Gly Arg Asn Gly Leu Ala 275 280 285 Gly Thr Phe Ala Asn Gly Val Asn Ser Ala Ile Leu Arg Tyr Ala Gly 290 295 300 Ala Ala Asn Ala Asp Pro Thr Thr Ser Ala Asn Pro Asn Pro Ala Gln 305 310 315 320 Leu Asn Glu Ala Asp Leu His Ala Leu Ile Asp Pro Ala Ala Pro Gly 325 330 335 Ile Pro Thr Pro Gly Ala Ala Asp Val Asn Leu Arg Phe Gln Leu Gly 340 345 350 Phe Ser Gly Gly Arg Phe Thr Ile Asn Gly Thr Ala Tyr Glu Ser Pro 355 360 365 Ser Val Pro Thr Leu Leu Gln Ile Met Ser Gly Ala Gln Ser Ala Asn 370 375 380 Asp Leu Leu Pro Ala Gly Ser Val Tyr Glu Leu Pro Arg Asn Gln Val 385 390 395 400 Val Glu Leu Val Val Pro Ala Gly Val Leu Gly Gly Pro His Pro Phe 405 410 415 His Leu His Gly His Ala Phe Ser Val Val Arg Ser Ala Gly Ser Ser 420 425 430 Thr Tyr Asn Phe Val Asn Pro Val Lys Arg Asp Val Val Ser Leu Gly 435 440 445 Val Thr Gly Asp Glu Val Thr Ile Arg Phe Val Thr Asp Asn Pro Gly 450 455 460 Pro Trp Phe Phe His Cys His Ile Glu Phe His Leu Met Asn Gly Leu 465 470 475 480 Ala Ile Val Phe Ala Glu Asp Met Ala Asn Thr Val Asp Ala Asn Asn 485 490 495 Pro Pro Val Glu Trp Ala Gln Leu Cys Glu Ile Tyr Asp Asp Leu Pro 500 505 510 Pro Glu Ala Thr Ser Ile Gln Thr Val Val Arg Arg Ala Glu Pro Thr 515 520 525 Gly Phe Ser Ala Lys Phe Arg Arg Glu Gly Leu 530 535 2940 base pairs nucleic acid single linear DNA (genomic) unknown CDS join(588..704, 758..823, 877..945, 999..1145, 1200..1271, 1324..1338, 1409..1438, 1488..1685, 1749..2276, 2340..2360, 2413..2562, 2619..2642, 2694..2750, 2804..2859) 28 ACTCACTATA GGGAAAGCTG GTACGCCTGC AGGTACCGGT CCGGAATTCC TTTCACCCCA 60 GATCCTGGTA TAGGATAGAC CCAGATACTC TTACTAAGGT GGCACGAATG ACCGACCGAA 120 TCTCGCGAGA AATCTTTCAA CTTTTCCAGA CACTTGATGA GTCGAAAACA ATGCGTTTAC 180 CCCTGGAGTT ACGGATTGGG TCTCAAGTGA CTGTTACAAC AAGCGCTCAG GATCCCCTAG 240 TATGTCTAAT CGTGACGTCT CTACCGACGC TTGGCGCTCA TTGACAGCTA TCGCGACAGA 300 TTCTTACATT TTTGTCAACG CCATCCTTTC TCGTTTACGT AGCTTTCTGC TACGGTGCTG 360 TCCTTTGTCA GAGATCCCTC CAGCACGACG ATTGATAACG AGATCTCAGT CGACGGAACG 420 GCTCCCTGGA CCTGATGCAC TTATCCTCTT ACTCATTGCA GTCATTACAA TCGAGTCTCG 480 TTCGCACGTT GTCACGGAAC GGGACCTGAA AAATGAAGGA TATAAACCCC CAAGTGCCGC 540 CCTGAAACTT TCAGACTTTT TGAGTCGACA AGCTCGAGGT CTCCAAC ATG CAA TTG 596 Met Gln Leu 1 CTT GCC TTC GTC CTC GCT GCT TTA CCC CTC GCA CGG GCT GCC ATT GGC 644 Leu Ala Phe Val Leu Ala Ala Leu Pro Leu Ala Arg Ala Ala Ile Gly 5 10 15 CCT GTT GGC AAC CTA GTC ATC GCC AAC GCG AAC GTC TCA CCA GAC GGC 692 Pro Val Gly Asn Leu Val Ile Ala Asn Ala Asn Val Ser Pro Asp Gly 20 25 30 35 TTC GTT CGC TCG GTGAGTGGGC CCGCGGCCTT TCACCATTTC TTTTCATTAA 744 Phe Val Arg Ser CTCTCCTCTG CAG GCT GTC CTT GCC GGC GCT ACA GGT ACC AGC CTT GAG 793 Ala Val Leu Ala Gly Ala Thr Gly Thr Ser Leu Glu 40 45 50 CAC CCA GGG CCT GTT ATC GTG GGC CAG AAG GTAACACTAT TGACGTCCCT 843 His Pro Gly Pro Val Ile Val Gly Gln Lys 55 60 TGGTCAGAAT CCTTCCTTAC ACCCTTTATC TAG GGC GAC ACT TTC CAC ATC AAT 897 Gly Asp Thr Phe His Ile Asn 65 GTC ATC GAT GAC CTT ACT GAC CCC ACT ATG CTT CGA ACA ACC AGT ATT 945 Val Ile Asp Asp Leu Thr Asp Pro Thr Met Leu Arg Thr Thr Ser Ile 70 75 80 GTAAAGCAAA TTTGCTTGGC ATCCTTCAAA CTTCACACTG ACGTTCATGT CAG CAC 1001 His 85 TGG CAC GGT TTC TTG CAG GAG GGT ACA GCT TGG GCC GAC GGT CCT GCG 1049 Trp His Gly Phe Leu Gln Glu Gly Thr Ala Trp Ala Asp Gly Pro Ala 90 95 100 GGT GTT ACT CAA TGC CCC ATT GCC CCT GGT CAC TCT TTC CTC TAT AAG 1097 Gly Val Thr Gln Cys Pro Ile Ala Pro Gly His Ser Phe Leu Tyr Lys 105 110 115 TTC CAG GCC AAA AAC CAA GCT GGT ACC TTC TGG TAC CAT TCC CAC CAC 1145 Phe Gln Ala Lys Asn Gln Ala Gly Thr Phe Trp Tyr His Ser His His 120 125 130 GTGAGAGCGA TGCTGGTAAC GGACCTTGGG TCAATACTGA CTCTTGACTT ACAG ATG 1202 Met TCT CAG TAT TGT GAC GGC CTG AGA GGC GTC ATG GTC GTT TAC GAT CCC 1250 Ser Gln Tyr Cys Asp Gly Leu Arg Gly Val Met Val Val Tyr Asp Pro 135 140 145 150 CTA GAT CCC CAT CGT CAC CTG GTGCGTACGC CTATCTATGA CTCTCACCTT 1301 Leu Asp Pro His Arg His Leu 155 CGTACTCATT CCACCTACAC AG TAT GAC GTT GAT AAC GTAATCCTTC 1348 Tyr Asp Val Asp Asn 160 CAACCCTTAC GTCTCCGCTA AAGCTTACAT TCAATCTTCA TTGTTTCCTC ATTTTCTCAG 1408 GAG AAT ACT ATC ATC ACG CTC GCG GAC TGG GTAAGCGCGC AAATAACCTA 1458 Glu Asn Thr Ile Ile Thr Leu Ala Asp Trp 165 170 CGAAAGTTCC AGTATCTGAC TGTTTTCAG TAT CAC GAT CCC GCC CCT TCT GCT 1511 Tyr His Asp Pro Ala Pro Ser Ala 175 180 GGA CTC GTC CCA ACC CCC TGG TCG ACT TTG ATC AAT GGC AAG GGC CGT 1559 Gly Leu Val Pro Thr Pro Trp Ser Thr Leu Ile Asn Gly Lys Gly Arg 185 190 195 TAC CCA GGC GGA CCC GTC GTG CCC TTG GCC GTC ATT CAC GTC AGC CGC 1607 Tyr Pro Gly Gly Pro Val Val Pro Leu Ala Val Ile His Val Ser Arg 200 205 210 GGA AAG CGC TAC CGC TTC CGC CTC GTC TCC CTT TCG TGC GAC CCT AAC 1655 Gly Lys Arg Tyr Arg Phe Arg Leu Val Ser Leu Ser Cys Asp Pro Asn 215 220 225 TAT GTA TTC TCT ATT GAC GGT CAC ACC ATG GTTCGTAACC CTCCCATAAT 1705 Tyr Val Phe Ser Ile Asp Gly His Thr Met 230 235 CCACTCCTCC CCTGCCTCAT ATTTTACGTT TTGCGACTGT TAG ACG GTC ATT GAA 1760 Thr Val Ile Glu 240 GTC GAT GGT GTC AAC CAT GAA CCG TTG GTT GTC GAC CAC ATT CAA ATC 1808 Val Asp Gly Val Asn His Glu Pro Leu Val Val Asp His Ile Gln Ile 245 250 255 TTT GCT GGT CAA CGG TAC TCG TTT GTC TTG AAC GCC AAC CGG CCC GTC 1856 Phe Ala Gly Gln Arg Tyr Ser Phe Val Leu Asn Ala Asn Arg Pro Val 260 265 270 AAC AAC TAC TGG GTC AGG GCT AAC CCC AAC CTC GGC TCT GTC GGC TTC 1904 Asn Asn Tyr Trp Val Arg Ala Asn Pro Asn Leu Gly Ser Val Gly Phe 275 280 285 290 GGT GGC GGT ATT AAT TCC GCA ATT CTG CGA TAT GTT GGA GCT CCT GCC 1952 Gly Gly Gly Ile Asn Ser Ala Ile Leu Arg Tyr Val Gly Ala Pro Ala 295 300 305 GTC GAC CCA ACC ACC TCC CAA TTG CCT TTC AGC AAC CCA CTC CTC GAG 2000 Val Asp Pro Thr Thr Ser Gln Leu Pro Phe Ser Asn Pro Leu Leu Glu 310 315 320 ACC AAC TTG CAC CCT CTC GTA AAT CCT GCT GCA CCT GGC GGC CCT TCC 2048 Thr Asn Leu His Pro Leu Val Asn Pro Ala Ala Pro Gly Gly Pro Ser 325 330 335 CCC GGT GAC GTC GAT GTC GCC ATC AAC CTG GAT ATC TTG TTC GAC GTC 2096 Pro Gly Asp Val Asp Val Ala Ile Asn Leu Asp Ile Leu Phe Asp Val 340 345 350 TCA ATC CTC AAG TTC ACT GTC AAC GGT GCT ACC TTC GAT GAA CCA CCC 2144 Ser Ile Leu Lys Phe Thr Val Asn Gly Ala Thr Phe Asp Glu Pro Pro 355 360 365 370 GTT CCG GTC CTT CTC CAG ATT TTG AGC GGT GCA CAT ACC GCC TCA TCT 2192 Val Pro Val Leu Leu Gln Ile Leu Ser Gly Ala His Thr Ala Ser Ser 375 380 385 CTT CTC CCC TCT GGC AGC GTC TAC ACT CTT CCC CCT AAC AAG GTC ATT 2240 Leu Leu Pro Ser Gly Ser Val Tyr Thr Leu Pro Pro Asn Lys Val Ile 390 395 400 GAG CTC ACT ATT CCC GGT GGT GGT ATC GGT GCT CCT GTAGGTCTTT 2286 Glu Leu Thr Ile Pro Gly Gly Gly Ile Gly Ala Pro 405 410 CTTCTTCATC TTTCTCTCGA TCTCGATGGT GTTCACTCAC TATTTGAAAC CAG CAC 2342 His 415 CCC ATC CAT CTT CAC GGC GTGAGTATCC ATCCGTTAAG CTTCATTAAG 2390 Pro Ile His Leu His Gly 420 TCCCATGCTG ACCGTTTGAC AG CAT ACC TTC AAG GTT GTC CGT AGC GCA GGC 2442 His Thr Phe Lys Val Val Arg Ser Ala Gly 425 430 AGC TCG ACT TAC AAC TTC GTC AAT CCC GTT GAG CGA GAT GTT GTC AAC 2490 Ser Ser Thr Tyr Asn Phe Val Asn Pro Val Glu Arg Asp Val Val Asn 435 440 445 GTT GGT CAA GCT GGC GAC AAT GTC ACC ATT CGA TTC GTC ACT GAT AAT 2538 Val Gly Gln Ala Gly Asp Asn Val Thr Ile Arg Phe Val Thr Asp Asn 450 455 460 GCT GGT CCC TGG ATT CTT CAC TGC GTGCGCTATT TCTTTAGGCA TTCAACGTGT 2592 Ala Gly Pro Trp Ile Leu His Cys 465 470 CAGAGTCTTA CCCCCGTTCT TTTCAG CAC ATT GAC TGG CAT TTG GTT TTG 2642 His Ile Asp Trp His Leu Val Leu 475 GTAAGTTCAC GTTTTGACGC ATCAGGCGAA TGGTACTCTA ACTTCCTCCA G GGC CTG 2699 Gly Leu 480 TCT GTC GTC TTC GCG GAA GAT GTC CCC ACC ATC GAT AGC TCC GTT CAA 2747 Ser Val Val Phe Ala Glu Asp Val Pro Thr Ile Asp Ser Ser Val Gln 485 490 495 CCT GTAAGTTCTG CGTGCCTCTG CTCGATATCA TTTGGCTGAC TTCTTGGCTT TAG 2803 Pro CCC GCC TGG CAT GAT CTG TGC CCC ATC TAT GAC GCT CTT CCC CCC GGC 2851 Pro Ala Trp His Asp Leu Cys Pro Ile Tyr Asp Ala Leu Pro Pro Gly 500 505 510 ACG AGG TAATCTCGCC CATGACATAC TGGCACGGTA TGACTTGGAC AGGTTACGGA 2907 Thr Arg 515 AATCAAAGTA AATGTTGGAT AAGAAGAATA ACA 2940 516 amino acids amino acid linear protein unknown 29 Met Gln Leu Leu Ala Phe Val Leu Ala Ala Leu Pro Leu Ala Arg Ala 1 5 10 15 Ala Ile Gly Pro Val Gly Asn Leu Val Ile Ala Asn Ala Asn Val Ser 20 25 30 Pro Asp Gly Phe Val Arg Ser Ala Val Leu Ala Gly Ala Thr Gly Thr 35 40 45 Ser Leu Glu His Pro Gly Pro Val Ile Val Gly Gln Lys Gly Asp Thr 50 55 60 Phe His Ile Asn Val Ile Asp Asp Leu Thr Asp Pro Thr Met Leu Arg 65 70 75 80 Thr Thr Ser Ile His Trp His Gly Phe Leu Gln Glu Gly Thr Ala Trp 85 90 95 Ala Asp Gly Pro Ala Gly Val Thr Gln Cys Pro Ile Ala Pro Gly His 100 105 110 Ser Phe Leu Tyr Lys Phe Gln Ala Lys Asn Gln Ala Gly Thr Phe Trp 115 120 125 Tyr His Ser His His Met Ser Gln Tyr Cys Asp Gly Leu Arg Gly Val 130 135 140 Met Val Val Tyr Asp Pro Leu Asp Pro His Arg His Leu Tyr Asp Val 145 150 155 160 Asp Asn Glu Asn Thr Ile Ile Thr Leu Ala Asp Trp Tyr His Asp Pro 165 170 175 Ala Pro Ser Ala Gly Leu Val Pro Thr Pro Trp Ser Thr Leu Ile Asn 180 185 190 Gly Lys Gly Arg Tyr Pro Gly Gly Pro Val Val Pro Leu Ala Val Ile 195 200 205 His Val Ser Arg Gly Lys Arg Tyr Arg Phe Arg Leu Val Ser Leu Ser 210 215 220 Cys Asp Pro Asn Tyr Val Phe Ser Ile Asp Gly His Thr Met Thr Val 225 230 235 240 Ile Glu Val Asp Gly Val Asn His Glu Pro Leu Val Val Asp His Ile 245 250 255 Gln Ile Phe Ala Gly Gln Arg Tyr Ser Phe Val Leu Asn Ala Asn Arg 260 265 270 Pro Val Asn Asn Tyr Trp Val Arg Ala Asn Pro Asn Leu Gly Ser Val 275 280 285 Gly Phe Gly Gly Gly Ile Asn Ser Ala Ile Leu Arg Tyr Val Gly Ala 290 295 300 Pro Ala Val Asp Pro Thr Thr Ser Gln Leu Pro Phe Ser Asn Pro Leu 305 310 315 320 Leu Glu Thr Asn Leu His Pro Leu Val Asn Pro Ala Ala Pro Gly Gly 325 330 335 Pro Ser Pro Gly Asp Val Asp Val Ala Ile Asn Leu Asp Ile Leu Phe 340 345 350 Asp Val Ser Ile Leu Lys Phe Thr Val Asn Gly Ala Thr Phe Asp Glu 355 360 365 Pro Pro Val Pro Val Leu Leu Gln Ile Leu Ser Gly Ala His Thr Ala 370 375 380 Ser Ser Leu Leu Pro Ser Gly Ser Val Tyr Thr Leu Pro Pro Asn Lys 385 390 395 400 Val Ile Glu Leu Thr Ile Pro Gly Gly Gly Ile Gly Ala Pro His Pro 405 410 415 Ile His Leu His Gly His Thr Phe Lys Val Val Arg Ser Ala Gly Ser 420 425 430 Ser Thr Tyr Asn Phe Val Asn Pro Val Glu Arg Asp Val Val Asn Val 435 440 445 Gly Gln Ala Gly Asp Asn Val Thr Ile Arg Phe Val Thr Asp Asn Ala 450 455 460 Gly Pro Trp Ile Leu His Cys His Ile Asp Trp His Leu Val Leu Gly 465 470 475 480 Leu Ser Val Val Phe Ala Glu Asp Val Pro Thr Ile Asp Ser Ser Val 485 490 495 Gln Pro Pro Ala Trp His Asp Leu Cys Pro Ile Tyr Asp Ala Leu Pro 500 505 510 Pro Gly Thr Arg 515 21 base pairs nucleic acid single linear cDNA unknown 30 AGCTCGATGA CTTTGTTACG G 21 21 base pairs nucleic acid single linear cDNA unknown 31 CAGCGCTACT CGTTCGTTCT C 21 3566 base pairs nucleic acid single linear DNA (genomic) unknown CDS join(456..578, 631..696, 746..814, 869..1015, 1069..1140, 1199..1213, 1271..1300, 1366..1563, 1622..2149, 2213..2233, 2303..2452, 2514..2537, 2598..2654, 2725..2776) 32 TGAAGGAGAA TCCCTCGAAG TGGAATTTTC TTTCCAGAAG ATGCAATCTG GTTTTGTCTC 60 ATCCATTTTT GTGACGTTTA CTCACCATTT CGAATCTAGG ATCGTTCGCC GATTTGCTCA 120 TATCTTTGCG ACCACTCAAT ATTGCTTTAC GTACCCCCTC GTGAGAGGCA CAAATGCATT 180 CCTTGCGATG CCCGATTCCA ATCTCAATGC AGGTACGTCC CTGGTTTCAT ACCAATGCGT 240 GTTTTGGACT GGCATTCCTG ACCTTTGTTC CGGTTGACGT TTCTAGTTAT TTCGTGTGAC 300 CTGTATGATT AATCGTACAG CCTGAATCTT GTCCTCAAAG TGCACAAATT AGGGCTCAAG 360 CTACCAGGCG AGGCAGGTAT AAAGCGCTCT ACTCTCCATC CGACGTTCCC CACTCACCAC 420 CAGCCGGCTG AGTTCACCCG TTCTTGAAAC TCGTT ATG TTG CTT TTA GCG ACT 473 Met Leu Leu Leu Ala Thr 1 5 GCT CTC GCT ACA TCC CTC TTA CCT TTC GTG CTG GGA GCC ATT GGC CCC 521 Ala Leu Ala Thr Ser Leu Leu Pro Phe Val Leu Gly Ala Ile Gly Pro 10 15 20 AGT ACC AAC CTT GTC GTC GCG AAC AAG GTC ATC GCT CCC GAC GGC TTC 569 Ser Thr Asn Leu Val Val Ala Asn Lys Val Ile Ala Pro Asp Gly Phe 25 30 35 AGT CGA TCT GTGAGCCTTT TCTGTGGACT GGACGCTTCT TCAGTGACTG 618 Ser Arg Ser 40 ATCATGTCGC AG GCT GTC CTC GCT GGC GCT ACC CAG CCA ACG GTG CAG 666 Ala Val Leu Ala Gly Ala Thr Gln Pro Thr Val Gln 45 50 TTC CCT GGC CCC GTC ATT CAA GGG AAT AAG GTAGGCAGAT TTCAACCGTT 716 Phe Pro Gly Pro Val Ile Gln Gly Asn Lys 55 60 TCCTGTCACA TCATGTTGAG TCTTTGTAG AAC AGT TTC TTT GCG ATC AAC GTC 769 Asn Ser Phe Phe Ala Ile Asn Val 65 70 ATT GAC GCT CTG ACC GAC CCC ACT ATG CTG AGG ACT ACG AGT ATC 814 Ile Asp Ala Leu Thr Asp Pro Thr Met Leu Arg Thr Thr Ser Ile 75 80 85 GTAAGTCAGT TCTATTGATG CTGCGATCAG CGGAAGCTCA CCATCTTTTA ACAG CAC 871 His TGG CAC GGC ATG TTC CAA AGG GGG ACT GCC TGG GCT GAT GGT CCT GCT 919 Trp His Gly Met Phe Gln Arg Gly Thr Ala Trp Ala Asp Gly Pro Ala 90 95 100 GGC GTC ACC CAA TGC CCT ATT TCC CCA GGG CAT TCG TTC TTG TAC AAG 967 Gly Val Thr Gln Cys Pro Ile Ser Pro Gly His Ser Phe Leu Tyr Lys 105 110 115 TTC CAG GCT CTT AAC CAA GCC GGT ACT TTC TGG TAC CAC TCC CAT CAC 1015 Phe Gln Ala Leu Asn Gln Ala Gly Thr Phe Trp Tyr His Ser His His 120 125 130 135 GTAACTACAA TCTATCTGTA CTGACGTGAC GATGTTGACT CAGTCATTCT CAG GAA 1071 Glu TCG CAA TAT TGT GAC GGT TTG CGT GGG GCT ATG GTC GTA TAT GAC CCA 1119 Ser Gln Tyr Cys Asp Gly Leu Arg Gly Ala Met Val Val Tyr Asp Pro 140 145 150 GTC GAC CCA CAT CGC AAC TTG GTGAGCATCC TTTACTTTAT TCCCAAGGAA 1170 Val Asp Pro His Arg Asn Leu 155 GCCATCAGTC TAATGACTTG CCATTTAG TAT GAC ATT GAC AAC GTATGTAACC 1223 Tyr Asp Ile Asp Asn 160 TCCGGCGTTT GGTCGTCTTG TGATCCGCAG TTCACCTTGT TTTACAG GAG GCC ACG 1279 Glu Ala Thr 165 ATC ATT ACG CTC GCA GAC TGG GTAAGAATCT AATTACTTTC GATTACCTTC 1330 Ile Ile Thr Leu Ala Asp Trp 170 GAGCATACCT AACTCGGGGC CCTTCTGTTC GCCAG TAT CAC GTC CCT GCT CCC 1383 Tyr His Val Pro Ala Pro 175 180 TCT GCA GGT CTC GTT CCC ACC CCA GAT TCC ACG CTT ATC AAC GGT AAG 1431 Ser Ala Gly Leu Val Pro Thr Pro Asp Ser Thr Leu Ile Asn Gly Lys 185 190 195 GGC CGG TAT GCT GGT GGC CCT ACC GTA CCT CTC GCG GTC ATT TCT GTA 1479 Gly Arg Tyr Ala Gly Gly Pro Thr Val Pro Leu Ala Val Ile Ser Val 200 205 210 ACC CGA AAC CGA CGA TAC CGG TTC CGC CTT GTT TCC CTT TCA TGC GAT 1527 Thr Arg Asn Arg Arg Tyr Arg Phe Arg Leu Val Ser Leu Ser Cys Asp 215 220 225 CCT AAT TAT GTA TTC TCT ATC GAT GGG CAT ACC ATG GTACGCACTA 1573 Pro Asn Tyr Val Phe Ser Ile Asp Gly His Thr Met 230 235 240 GTTCCCATCC CTGTAAAACG GGTGCTAACG ACGTGTATCA TCCCTTAG ACT GTT ATT 1630 Thr Val Ile GAG GTC GAC GGA GTT AAC GTC CAA CCT CTC GTT GTC GAC TCG ATC CAG 1678 Glu Val Asp Gly Val Asn Val Gln Pro Leu Val Val Asp Ser Ile Gln 245 250 255 ATC TTC GCA GGT CAG CGC TAC TCG TTC GTT CTC AAC GCC AAC CGC CCC 1726 Ile Phe Ala Gly Gln Arg Tyr Ser Phe Val Leu Asn Ala Asn Arg Pro 260 265 270 275 GTC GGC AAC TAC TGG GTG CGA GCC AAC CCC AAC ATC GGT ACT ACG GGC 1774 Val Gly Asn Tyr Trp Val Arg Ala Asn Pro Asn Ile Gly Thr Thr Gly 280 285 290 TTC GTC GGT GGA GTC AAT TCT GCG ATT CTG CGC TAT GTG GGC GCC TCC 1822 Phe Val Gly Gly Val Asn Ser Ala Ile Leu Arg Tyr Val Gly Ala Ser 295 300 305 AAT ACA GAC CCC ACT ACC ACC CAA ACT CCT TTC AGC AAC CCT CTC CTT 1870 Asn Thr Asp Pro Thr Thr Thr Gln Thr Pro Phe Ser Asn Pro Leu Leu 310 315 320 GAG ACC AAT CTC CAC CCC TTG ACC AAC CCT GCT GCT CCT GGC TTG CCT 1918 Glu Thr Asn Leu His Pro Leu Thr Asn Pro Ala Ala Pro Gly Leu Pro 325 330 335 ACC CCA GGT GGC GTC GAC GTC GCG ATC AAC CTT AAC ACG GTA TTC GAT 1966 Thr Pro Gly Gly Val Asp Val Ala Ile Asn Leu Asn Thr Val Phe Asp 340 345 350 355 TTC AGT AGT CTC ACC TTC TCC GTT AAC GGA GCC ACT TTC CAT CAA CCG 2014 Phe Ser Ser Leu Thr Phe Ser Val Asn Gly Ala Thr Phe His Gln Pro 360 365 370 CCC GTC CCT GTC TTG CTT CAG ATC ATG AGC GGT GCA CAG ACT GCC CAG 2062 Pro Val Pro Val Leu Leu Gln Ile Met Ser Gly Ala Gln Thr Ala Gln 375 380 385 CAG CTT CTT CCC TCC GGT TCG GTC TAC GTC CTT CCC CGT AAC AAA GTC 2110 Gln Leu Leu Pro Ser Gly Ser Val Tyr Val Leu Pro Arg Asn Lys Val 390 395 400 ATC GAG CTT TCT ATG CCT GGA GGC TCC ACT GGC AGT CCC GTAAGTCTTA 2159 Ile Glu Leu Ser Met Pro Gly Gly Ser Thr Gly Ser Pro 405 410 415 ATTGTCTTCA TTTCCAACAA GTCGGTGATT AACGCTGGAT CATTCGCTGA CAG CAT 2215 His CCC TTC CAT CTC CAC GGT GTATGTAGGC CTCTGTCTGA TCTCATTCGG 2263 Pro Phe His Leu His Gly 420 AAGCGTTACT GACGGTGCTT CTTTGTTTCG ATCTGATAG CAC GAA TTT GCT GTG 2317 His Glu Phe Ala Val 425 GTG AGA AGC GCG GGG AGT TCG ACC TAC AAC TTC GCG AAC CCG GTA CGC 2365 Val Arg Ser Ala Gly Ser Ser Thr Tyr Asn Phe Ala Asn Pro Val Arg 430 435 440 AGG GAT GTC GTG AGT GCC GGT GTT GCT GGT GAC AAC GTC ACC ATT CGA 2413 Arg Asp Val Val Ser Ala Gly Val Ala Gly Asp Asn Val Thr Ile Arg 445 450 455 460 TTC CGT ACC GAT AAC CCT GGA CCA TGG ATT CTC CAT TGC GTGCGTCAAG 2462 Phe Arg Thr Asp Asn Pro Gly Pro Trp Ile Leu His Cys 465 470 TCATCGTCCT CGTGCTGAAT TGATTGTCTA ACCAAGATAT CACATACTTA G CAT ATC 2519 His Ile 475 GAC TGG CAC CTT GTT TTG GTAAGTCTTC GCTTCTTCCA GACGTGATTA 2567 Asp Trp His Leu Val Leu 480 ACTTTACTGA TCGCGATGAT GGGAATACAG GGG TTG GCT GTA GTG TTC GCT GAG 2621 Gly Leu Ala Val Val Phe Ala Glu 485 GAC GCT CCT ACT GTT GCA ACC ATG GAT CCC CCT GTGAGTAGCG CCCGTGCTTT 2674 Asp Ala Pro Thr Val Ala Thr Met Asp Pro Pro 490 495 500 TGAGGAGTTG TGAAACCCGA GCTCAACGTG AAACGTTTTC CACTTTACAG CCT GCT 2730 Pro Ala TGG GAC CAA CTT TGC CCG ATC TAC GAT GCT CTC CCT CCC AAC ACA 2775 Trp Asp Gln Leu Cys Pro Ile Tyr Asp Ala Leu Pro Pro Asn Thr 505 510 515 TAAGTCGTTC AATTCAAGGC TGTTGACGTG AAGGGAGCAA GAAGGAAAGT AAGAGAAAGG 2835 CAGTCACATC CCGTCGGTTT GCCTCTGAAA TATCGATTAA TCACGCTTTT TATCACTTGT 2895 AATTATCTTT CTTTGTTACA GTGGCTCTTT GACGCTGGCT CTCCAGTGCG TTAGAGTCGA 2955 TAATAATAGC AATTCTCTAC TTTTAGGCAG ATTTTTAGGC AGGGCTGTGG TACGCTTTAT 3015 ATTAAGTTAA AAGAGCACCA ATAATGTCGC CCTCAGCTGG GCTCTTGTCG GCCGACTAGC 3075 TCAGTTGGTT AGAGCGTCGT GCTAATAACG CGAAGGTCTT GGGTTCGATC CCCACGTTGG 3135 CCAGTAGCCC CCTTTTTGTT AATCCTGGCA CTTTCCTGTT CCTACTAACC CTTTTGAGAG 3195 TCCAGAAAAA TCACCATGAC TTAATTTTTT CTTTTCATAG AAGTCCTGGA AGGGTAAGGA 3255 AGTGATATAA CTAGATGACC CAACATTCAG TGCTGGTCGT CAGATGCAGG TGTCTTTTCG 3315 ACCAATCGAA GCATTCGGCG AAGATTCGAT CCAATTGCGC CTGCCTGTCC GCAGCATCTT 3375 CGAACGGCGA AGGACTGTCG AAGAACGTTA CGTACGCGCG GATTGTCAGT TTACGAAGGC 3435 GAGGAAACCC CATTGAGAGT AGATCGTCAA GCGTCTTCCA TTGGCCCAGG TCCACATTCA 3495 GATCGCAGCC GATTTGAACG ATAGGGATGA TATTGAGTCC TCCAGAACGT TCTGTCCCTG 3555 CATCAAAGCG A 3566 517 amino acids amino acid linear protein unknown 33 Met Leu Leu Leu Ala Thr Ala Leu Ala Thr Ser Leu Leu Pro Phe Val 1 5 10 15 Leu Gly Ala Ile Gly Pro Ser Thr Asn Leu Val Val Ala Asn Lys Val 20 25 30 Ile Ala Pro Asp Gly Phe Ser Arg Ser Ala Val Leu Ala Gly Ala Thr 35 40 45 Gln Pro Thr Val Gln Phe Pro Gly Pro Val Ile Gln Gly Asn Lys Asn 50 55 60 Ser Phe Phe Ala Ile Asn Val Ile Asp Ala Leu Thr Asp Pro Thr Met 65 70 75 80 Leu Arg Thr Thr Ser Ile His Trp His Gly Met Phe Gln Arg Gly Thr 85 90 95 Ala Trp Ala Asp Gly Pro Ala Gly Val Thr Gln Cys Pro Ile Ser Pro 100 105 110 Gly His Ser Phe Leu Tyr Lys Phe Gln Ala Leu Asn Gln Ala Gly Thr 115 120 125 Phe Trp Tyr His Ser His His Glu Ser Gln Tyr Cys Asp Gly Leu Arg 130 135 140 Gly Ala Met Val Val Tyr Asp Pro Val Asp Pro His Arg Asn Leu Tyr 145 150 155 160 Asp Ile Asp Asn Glu Ala Thr Ile Ile Thr Leu Ala Asp Trp Tyr His 165 170 175 Val Pro Ala Pro Ser Ala Gly Leu Val Pro Thr Pro Asp Ser Thr Leu 180 185 190 Ile Asn Gly Lys Gly Arg Tyr Ala Gly Gly Pro Thr Val Pro Leu Ala 195 200 205 Val Ile Ser Val Thr Arg Asn Arg Arg Tyr Arg Phe Arg Leu Val Ser 210 215 220 Leu Ser Cys Asp Pro Asn Tyr Val Phe Ser Ile Asp Gly His Thr Met 225 230 235 240 Thr Val Ile Glu Val Asp Gly Val Asn Val Gln Pro Leu Val Val Asp 245 250 255 Ser Ile Gln Ile Phe Ala Gly Gln Arg Tyr Ser Phe Val Leu Asn Ala 260 265 270 Asn Arg Pro Val Gly Asn Tyr Trp Val Arg Ala Asn Pro Asn Ile Gly 275 280 285 Thr Thr Gly Phe Val Gly Gly Val Asn Ser Ala Ile Leu Arg Tyr Val 290 295 300 Gly Ala Ser Asn Thr Asp Pro Thr Thr Thr Gln Thr Pro Phe Ser Asn 305 310 315 320 Pro Leu Leu Glu Thr Asn Leu His Pro Leu Thr Asn Pro Ala Ala Pro 325 330 335 Gly Leu Pro Thr Pro Gly Gly Val Asp Val Ala Ile Asn Leu Asn Thr 340 345 350 Val Phe Asp Phe Ser Ser Leu Thr Phe Ser Val Asn Gly Ala Thr Phe 355 360 365 His Gln Pro Pro Val Pro Val Leu Leu Gln Ile Met Ser Gly Ala Gln 370 375 380 Thr Ala Gln Gln Leu Leu Pro Ser Gly Ser Val Tyr Val Leu Pro Arg 385 390 395 400 Asn Lys Val Ile Glu Leu Ser Met Pro Gly Gly Ser Thr Gly Ser Pro 405 410 415 His Pro Phe His Leu His Gly His Glu Phe Ala Val Val Arg Ser Ala 420 425 430 Gly Ser Ser Thr Tyr Asn Phe Ala Asn Pro Val Arg Arg Asp Val Val 435 440 445 Ser Ala Gly Val Ala Gly Asp Asn Val Thr Ile Arg Phe Arg Thr Asp 450 455 460 Asn Pro Gly Pro Trp Ile Leu His Cys His Ile Asp Trp His Leu Val 465 470 475 480 Leu Gly Leu Ala Val Val Phe Ala Glu Asp Ala Pro Thr Val Ala Thr 485 490 495 Met Asp Pro Pro Pro Ala Trp Asp Gln Leu Cys Pro Ile Tyr Asp Ala 500 505 510 Leu Pro Pro Asn Thr 515 21 base pairs nucleic acid single linear cDNA unknown 34 AGAATTGACT CCACCGACGA A 21 27 base pairs nucleic acid single linear cDNA unknown 35 GAATTCTGGC ATTCCTGACC TTTGTTC 27 22 amino acids amino acid single linear peptide unknown 36 Ser Val Asp Thr Met Thr Leu Thr Asn Ala Asn Val Ser Pro Asp Gly 1 5 10 15 Phe Thr Arg Ala Gly Ile 20

Claims (5)

What is claimed is:
1. An isolated nucleic acid sequence encoding a polypeptide having laccase activity obtained by (a) hybridizing a DNA from a Coprinus strain under medium stringency conditions with (i) the mature coding region of SEQ ID NO:26, SEQ ID NO:28, or SEQ ID NO:32 or (ii) its complementary strand, wherein the medium stringency conditions are defined by prehybridization and hybridization at 42° C. in 5X SSPE, 0.3% SDS, 200 μg/ml sheared and denatured salmon sperm DNA, and 35% formamide, and wash conditions are defined at 60° C. for 30 minutes in 0.2X SSC, 0.1% SDS, and (b) isolating the nucleic and sequence from the DNA.
2. A nucleic acid construct comprising the nucleic acid sequence of claim 1 operably linked to one or more control sequences capable of directing the expression of the polypeptide in a suitable expression host.
3. A recombinant expression vector comprising the nucleic acid construct of claim 2, a promoter, and transcriptional and translational stop signals.
4. A recombinant host cell comprising the nucleic acid construct of claim 2.
5. A method for producing a polypeptide having laccase activity, comprising: (A) cultivating the recombinant host cell of claim 4 under conditions conducive for production of the polypeptide, and (B) isolating the polypeptide.
US09/389,528 1995-08-25 1999-09-02 Nucleic acids encoding polypeptides having laccase activity Expired - Lifetime US6207430B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/389,528 US6207430B1 (en) 1995-08-25 1999-09-02 Nucleic acids encoding polypeptides having laccase activity

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US280095P 1995-08-25 1995-08-25
US08/689,421 US6008029A (en) 1995-08-25 1996-08-09 Purified coprinus laccases and nucleic acids encoding the same
US09/389,528 US6207430B1 (en) 1995-08-25 1999-09-02 Nucleic acids encoding polypeptides having laccase activity

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/689,421 Continuation US6008029A (en) 1995-08-25 1996-08-09 Purified coprinus laccases and nucleic acids encoding the same

Publications (1)

Publication Number Publication Date
US6207430B1 true US6207430B1 (en) 2001-03-27

Family

ID=21702569

Family Applications (3)

Application Number Title Priority Date Filing Date
US08/689,421 Expired - Lifetime US6008029A (en) 1995-08-25 1996-08-09 Purified coprinus laccases and nucleic acids encoding the same
US09/181,827 Expired - Lifetime US6242232B1 (en) 1995-08-25 1998-10-28 Purified Coprinus laccases and nucleic acids encoding same
US09/389,528 Expired - Lifetime US6207430B1 (en) 1995-08-25 1999-09-02 Nucleic acids encoding polypeptides having laccase activity

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US08/689,421 Expired - Lifetime US6008029A (en) 1995-08-25 1996-08-09 Purified coprinus laccases and nucleic acids encoding the same
US09/181,827 Expired - Lifetime US6242232B1 (en) 1995-08-25 1998-10-28 Purified Coprinus laccases and nucleic acids encoding same

Country Status (7)

Country Link
US (3) US6008029A (en)
EP (1) EP0788547B1 (en)
AT (1) ATE310090T1 (en)
AU (1) AU6860396A (en)
DE (1) DE69635444T2 (en)
WO (1) WO1997008325A2 (en)
ZA (1) ZA967173B (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003008556A3 (en) * 2001-07-18 2003-10-02 Expressive Constructs Inc A vector containing an enhanced p15a origin of replication
US20050142622A1 (en) * 2002-01-31 2005-06-30 Sanders Mitchell C. Method for detecting microorganisms
US20060257955A1 (en) * 2003-01-31 2006-11-16 Colpas Gerard J Method for detecting escherichia coli
US20070275423A1 (en) * 2003-11-03 2007-11-29 Shite Sebastian Methods, Peptides and Biosensors Useful for Detecting a Broad Spectrum of Bacteria
WO2009058956A1 (en) * 2007-11-01 2009-05-07 Danisco Us, Inc. Signal sequences and co-expressed chaperones for improving protein production in a host cell
WO2010129940A3 (en) * 2009-05-08 2011-04-07 University Of Florida Research Foundation, Inc. Archael laccases and multicopper oxidases (mcos) and their uses thereof

Families Citing this family (191)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008029A (en) * 1995-08-25 1999-12-28 Novo Nordisk Biotech Inc. Purified coprinus laccases and nucleic acids encoding the same
JP3320307B2 (en) * 1996-06-06 2002-09-03 株式会社エス・ディー・エス バイオテック Method for polymerizing phenolic compounds and its use
AU5983398A (en) * 1997-02-28 1998-09-18 Novo Nordisk A/S Laccase mutants
DE19814853A1 (en) * 1998-04-02 1999-10-21 Consortium Elektrochem Ind Expression system for the production of proteins
US6329332B1 (en) * 1998-12-23 2001-12-11 Genencor International, Inc. Pleurotus phenol oxidizing enzymes
FI113879B (en) 2000-05-23 2004-06-30 Valtion Teknillinen A new coating enzyme
US7319112B2 (en) 2000-07-14 2008-01-15 The Procter & Gamble Co. Non-halogenated antibacterial agents and processes for making same
US20040253696A1 (en) 2003-06-10 2004-12-16 Novozymes North America, Inc. Fermentation processes and compositions
WO2005100582A2 (en) 2004-03-25 2005-10-27 Novozymes Inc. Methods for degrading or converting plant cell wall polysaccharides
EP1637595A1 (en) * 2004-09-16 2006-03-22 Puratos N.V. Overexpressed and purified Aspergillus ficuum oxidase and nucleic acid encoding same
FI118339B (en) 2004-09-21 2007-10-15 Ab Enzymes Oy New laccase enzyme and its use
US7741093B2 (en) 2005-04-29 2010-06-22 Ab Enzymes Oy Cellulases and their uses
DK1969123T3 (en) 2005-12-22 2017-08-28 Ab Enzymes Oy Hitherto UNKNOWN ENZYMS
US7256032B2 (en) 2005-12-22 2007-08-14 Ab Enzymes Oy Enzymes
AU2007220977A1 (en) 2006-02-27 2007-09-07 Edenspace Systems Corporation Energy crops for improved biofuel feedstocks
US7361487B2 (en) 2006-04-13 2008-04-22 Ab Enzymes Oy Enzyme fusion proteins and their use
WO2008076322A2 (en) 2006-12-18 2008-06-26 Danisco Us, Inc., Genencor Division Novel laccases, compositions and methods of use
EP2468876A1 (en) 2007-04-24 2012-06-27 Novozymes North America, Inc. Detoxifying pre-treated lignocellulose-containing materials
WO2009031992A1 (en) 2007-09-04 2009-03-12 Elizabeth Varriano-Marston Method for controlling banana quality by packaging
AR073279A1 (en) 2008-09-05 2010-10-28 TransAlgae Ltd HERBICIDE RESISTANCE TO KEEP AXENIC CROPS OF ALGAE BY GENETIC HANDLING
FI20086236A0 (en) 2008-12-23 2008-12-23 Valtion Teknillinen Conversion of hexuronic acid to hexaric acid
FI122028B (en) 2008-12-30 2011-07-29 Ab Enzymes Oy Endoglucanases derived from fungi, their preparation and use
FI122029B (en) 2008-12-30 2011-07-29 Ab Enzymes Oy Endoglucanases derived from fungi, their preparation and use
WO2010096510A2 (en) 2009-02-17 2010-08-26 Edenspace Systems Corporation Tempering of cellulosic biomass
FI121712B (en) 2009-04-30 2011-03-15 Ab Enzymes Oy A new fungal-derived protease and its use
FI121711B (en) 2009-04-30 2011-03-15 Ab Enzymes Oy A fungal-derived serine protease and its use
WO2010138971A1 (en) 2009-05-29 2010-12-02 Edenspace Systems Corporation Plant gene regulatory elements
FI121851B (en) 2009-07-08 2011-05-13 Ab Enzymes Oy A fungal-derived protease and its use
FI122937B (en) 2009-12-30 2012-09-14 Roal Oy Method for treating cellulosic material and CBH II / Cel6A enzymes useful herein
TR201910932T4 (en) 2010-07-01 2019-08-21 Novozymes As The bleaching of paper pulp.
FI123942B (en) 2010-10-29 2013-12-31 Ab Enzymes Oy Variants of fungal-derived serine protease
FI123425B (en) 2011-03-31 2013-04-30 Ab Enzymes Oy PROTEAS ENTYMES AND USES OF THIS
EP2702153B1 (en) 2011-04-28 2018-12-12 Novozymes, Inc. Polypeptides having endoglucanase activity and polynucleotides encoding same
PL2753749T3 (en) 2011-09-09 2019-10-31 Novozymes As Improving properties of paper materials
EP2740840A1 (en) 2012-12-07 2014-06-11 Novozymes A/S Improving drainage of paper pulp
WO2014106593A1 (en) 2013-01-03 2014-07-10 Novozymes A/S Alpha-amylase variants and polynucleotides encoding same
EP2970830B1 (en) 2013-03-14 2017-12-13 Novozymes A/S Enzyme and inhibitor contained in water-soluble films
EP3569611A1 (en) 2013-04-23 2019-11-20 Novozymes A/S Liquid automatic dish washing detergent compositions with stabilised subtilisin
MX365786B (en) 2013-05-03 2019-06-14 Novozymes As Microencapsulation of detergent enzymes.
CN105209613A (en) 2013-05-17 2015-12-30 诺维信公司 Polypeptides having alpha amylase activity
EP3613853A1 (en) 2013-07-29 2020-02-26 Novozymes A/S Protease variants and polynucleotides encoding same
US20170015950A1 (en) 2014-04-01 2017-01-19 Novozymes A/S Polypeptides having alpha amylase activity
ES2813337T3 (en) 2014-04-11 2021-03-23 Novozymes As Detergent composition
WO2015181119A2 (en) 2014-05-27 2015-12-03 Novozymes A/S Lipase variants and polynucleotides encoding same
WO2015181118A1 (en) 2014-05-27 2015-12-03 Novozymes A/S Methods for producing lipases
EP3164476A1 (en) 2014-07-03 2017-05-10 Novozymes A/S Improved stabilization of non-protease enzyme
WO2016007309A1 (en) 2014-07-07 2016-01-14 Novozymes A/S Use of prehydrolysate liquor in engineered wood
WO2016079110A2 (en) 2014-11-19 2016-05-26 Novozymes A/S Use of enzyme for cleaning
EP3280791A1 (en) 2015-04-10 2018-02-14 Novozymes A/S Laundry method, use of dnase and detergent composition
US20180105772A1 (en) 2015-04-10 2018-04-19 Novozymes A/S Detergent composition
US10336971B2 (en) 2015-05-19 2019-07-02 Novozymes A/S Odor reduction
US10717576B2 (en) 2015-06-17 2020-07-21 Novozymes A/S Container for polypeptide
WO2016135351A1 (en) 2015-06-30 2016-09-01 Novozymes A/S Laundry detergent composition, method for washing and use of composition
EP3950939A3 (en) 2015-07-06 2022-06-08 Novozymes A/S Lipase variants and polynucleotides encoding same
US20180202011A1 (en) 2015-09-04 2018-07-19 Novozymes A/S Methods of inhibiting aa9 lytic polysaccharide monooxygenase catalyzed inactivation of enzyme compositions
EP3350303B1 (en) 2015-09-17 2020-04-08 Henkel AG & Co. KGaA Detergent compositions comprising polypeptides having xanthan degrading activity
CA2991114A1 (en) 2015-09-17 2017-03-23 Novozymes A/S Polypeptides having xanthan degrading activity and polynucleotides encoding same
EP3359659A1 (en) 2015-10-07 2018-08-15 Novozymes A/S Polypeptides
CN108291212A (en) 2015-10-14 2018-07-17 诺维信公司 Polypeptide variants
EP3362168A1 (en) 2015-10-14 2018-08-22 Novozymes A/S Cleaning of water filtration membranes
CN108431217B (en) 2015-12-01 2022-06-21 诺维信公司 Method for producing lipase
US20190002819A1 (en) 2015-12-28 2019-01-03 Novozymes Bioag A/S Heat priming of bacterial spores
CN109072133B (en) 2016-03-23 2021-06-15 诺维信公司 Use of a polypeptide with DNase activity for treating fabrics
CN109563450A (en) 2016-05-31 2019-04-02 诺维信公司 Stable liquid peroxide composition
EP3475404A1 (en) 2016-06-23 2019-05-01 Novozymes A/S Use of enzymes, composition and method for removing soil
WO2018002261A1 (en) 2016-07-01 2018-01-04 Novozymes A/S Detergent compositions
JP2019522988A (en) 2016-07-05 2019-08-22 ノボザイムス アクティーゼルスカブ Pectate lyase mutant and polynucleotide encoding the same
WO2018007573A1 (en) 2016-07-08 2018-01-11 Novozymes A/S Detergent compositions with galactanase
EP3485011B1 (en) 2016-07-13 2021-06-09 Novozymes A/S Bacillus cibi dnase variants
US20190284647A1 (en) 2016-09-29 2019-09-19 Novozymes A/S Spore Containing Granule
EP3519548A1 (en) 2016-09-29 2019-08-07 Novozymes A/S Use of enzyme for washing, method for washing and warewashing composition
WO2018077938A1 (en) 2016-10-25 2018-05-03 Novozymes A/S Detergent compositions
EP3535377B1 (en) 2016-11-01 2022-02-09 Novozymes A/S Multi-core granules
EP3571279A1 (en) 2016-12-01 2019-11-27 Basf Se Stabilization of enzymes in compositions
EP3551740B1 (en) 2016-12-12 2021-08-11 Novozymes A/S Use of polypeptides
WO2018178061A1 (en) 2017-03-31 2018-10-04 Novozymes A/S Polypeptides having rnase activity
US11053483B2 (en) 2017-03-31 2021-07-06 Novozymes A/S Polypeptides having DNase activity
WO2018177938A1 (en) 2017-03-31 2018-10-04 Novozymes A/S Polypeptides having dnase activity
US20200109354A1 (en) 2017-04-04 2020-04-09 Novozymes A/S Polypeptides
WO2018185181A1 (en) 2017-04-04 2018-10-11 Novozymes A/S Glycosyl hydrolases
US11352591B2 (en) 2017-04-06 2022-06-07 Novozymes A/S Cleaning compositions and uses thereof
US11499121B2 (en) 2017-04-06 2022-11-15 Novozymes A/S Detergent compositions and uses thereof
EP3607037A1 (en) 2017-04-06 2020-02-12 Novozymes A/S Cleaning compositions and uses thereof
EP3607044B1 (en) 2017-04-06 2024-11-13 Novozymes A/S Cleaning compositions and uses thereof
US20200190438A1 (en) 2017-04-06 2020-06-18 Novozymes A/S Cleaning compositions and uses thereof
DK3478811T3 (en) 2017-04-06 2020-01-27 Novozymes As Cleaning compositions and uses thereof
US20200032170A1 (en) 2017-04-06 2020-01-30 Novozymes A/S Cleaning compositions and uses thereof
US20200181542A1 (en) 2017-06-30 2020-06-11 Novozymes A/S Enzyme Slurry Composition
CN111247235A (en) 2017-09-20 2020-06-05 诺维信公司 Use of enzymes to improve water absorption and/or whiteness
US11414814B2 (en) 2017-09-22 2022-08-16 Novozymes A/S Polypeptides
CN111356762B (en) 2017-09-27 2024-09-17 诺维信公司 Lipase variants and microcapsule compositions comprising such lipase variants
EP3697881B1 (en) 2017-10-16 2024-12-18 Novozymes A/S Low dusting granules
WO2019076800A1 (en) 2017-10-16 2019-04-25 Novozymes A/S Cleaning compositions and uses thereof
US20200318037A1 (en) 2017-10-16 2020-10-08 Novozymes A/S Low dusting granules
EP3701017A1 (en) 2017-10-27 2020-09-02 Novozymes A/S Dnase variants
HUE057471T2 (en) 2017-10-27 2022-05-28 Procter & Gamble Detergent compositions comprising polypeptide variants
DE102017125560A1 (en) 2017-11-01 2019-05-02 Henkel Ag & Co. Kgaa CLEANSING COMPOSITIONS CONTAINING DISPERSINE III
US20200291330A1 (en) 2017-11-01 2020-09-17 Novozymes A/S Polypeptides and Compositions Comprising Such Polypeptides
US11767492B2 (en) 2017-11-01 2023-09-26 Novozymes A/S Methods of treating fabric using a Lactobacillus hexosaminidase
WO2019086532A1 (en) 2017-11-01 2019-05-09 Novozymes A/S Methods for cleaning medical devices
WO2019154951A1 (en) 2018-02-08 2019-08-15 Novozymes A/S Lipases, lipase variants and compositions thereof
WO2019154954A1 (en) 2018-02-08 2019-08-15 Novozymes A/S Lipase variants and compositions thereof
US20210002588A1 (en) 2018-03-13 2021-01-07 Novozymes A/S Microencapsulation Using Amino Sugar Oligomers
CN112262207B (en) 2018-04-17 2024-01-23 诺维信公司 Polypeptides comprising carbohydrate binding activity in detergent compositions and their use for reducing wrinkles in textiles or fabrics
US11566239B2 (en) 2018-04-19 2023-01-31 Novozymes A/S Stabilized cellulase variants
EP3781679A1 (en) 2018-04-19 2021-02-24 Novozymes A/S Stabilized cellulase variants
EP3802953A1 (en) 2018-05-31 2021-04-14 Novozymes A/S Method for treating dissolving pulp using lytic polysaccharide monooxygenase
WO2019238761A1 (en) 2018-06-15 2019-12-19 Basf Se Water soluble multilayer films containing wash active chemicals and enzymes
WO2020002604A1 (en) 2018-06-28 2020-01-02 Novozymes A/S Detergent compositions and uses thereof
WO2020002608A1 (en) 2018-06-29 2020-01-02 Novozymes A/S Detergent compositions and uses thereof
CN112352039B (en) 2018-07-02 2022-11-15 诺维信公司 Cleaning composition and use thereof
ES3027666T3 (en) 2018-07-03 2025-06-16 Henkel Ag & Co Kgaa Cleaning compositions and uses thereof
WO2020008024A1 (en) 2018-07-06 2020-01-09 Novozymes A/S Cleaning compositions and uses thereof
WO2020058253A1 (en) 2018-09-18 2020-03-26 Dsm Ip Assets B.V. Process for enzymatic hydrolysis of carbohydrate material and fermentation of sugars
WO2020058248A1 (en) 2018-09-18 2020-03-26 Dsm Ip Assets B.V. Process for enzymatic hydrolysis of carbohydrate material and fermentation of sugars
WO2020058249A1 (en) 2018-09-18 2020-03-26 Dsm Ip Assets B.V. Process for enzymatic hydrolysis of carbohydrate material and fermentation of sugars
WO2020070063A2 (en) 2018-10-01 2020-04-09 Novozymes A/S Detergent compositions and uses thereof
WO2020070014A1 (en) 2018-10-02 2020-04-09 Novozymes A/S Cleaning composition comprising anionic surfactant and a polypeptide having rnase activity
EP3861094A1 (en) 2018-10-02 2021-08-11 Novozymes A/S Cleaning composition
WO2020070209A1 (en) 2018-10-02 2020-04-09 Novozymes A/S Cleaning composition
EP3861008A1 (en) 2018-10-03 2021-08-11 Novozymes A/S Polypeptides having alpha-mannan degrading activity and polynucleotides encoding same
WO2020070249A1 (en) 2018-10-03 2020-04-09 Novozymes A/S Cleaning compositions
WO2020074499A1 (en) 2018-10-09 2020-04-16 Novozymes A/S Cleaning compositions and uses thereof
EP3864122A1 (en) 2018-10-09 2021-08-18 Novozymes A/S Cleaning compositions and uses thereof
US20220033739A1 (en) 2018-10-11 2022-02-03 Novozymes A/S Cleaning compositions and uses thereof
EP3636735B1 (en) 2018-10-12 2024-03-27 AB Enzymes Oy Protease enzyme variants and uses thereof
EP3647397A1 (en) 2018-10-31 2020-05-06 Henkel AG & Co. KGaA Cleaning compositions containing dispersins iv
ES2981999T3 (en) 2018-10-31 2024-10-14 Henkel Ag & Co Kgaa Cleaning compositions containing dispersins V
EP3891264A1 (en) 2018-12-03 2021-10-13 Novozymes A/S LOW pH POWDER DETERGENT COMPOSITION
US11959111B2 (en) 2018-12-21 2024-04-16 Novozymes A/S Polypeptides having peptidoglycan degrading activity and polynucleotides encoding same
EP3898919A1 (en) 2018-12-21 2021-10-27 Novozymes A/S Detergent pouch comprising metalloproteases
CN113454214A (en) 2019-03-21 2021-09-28 诺维信公司 Alpha-amylase variants and polynucleotides encoding same
WO2020207944A1 (en) 2019-04-10 2020-10-15 Novozymes A/S Polypeptide variants
US20220186151A1 (en) 2019-04-12 2022-06-16 Novozymes A/S Stabilized glycoside hydrolase variants
CN114207123A (en) 2019-07-02 2022-03-18 诺维信公司 Lipase variants and compositions thereof
BR112022001394A2 (en) 2019-07-26 2022-03-22 Novozymes As Enzymatic treatment of paper pulp
US20220325204A1 (en) 2019-08-27 2022-10-13 Novozymes A/S Detergent composition
CN114616312A (en) 2019-09-19 2022-06-10 诺维信公司 detergent composition
EP4038170A1 (en) 2019-10-03 2022-08-10 Novozymes A/S Polypeptides comprising at least two carbohydrate binding domains
CN113891931A (en) 2019-11-29 2022-01-04 巴斯夫欧洲公司 Compositions and polymers useful in such compositions
EP4077656A2 (en) 2019-12-20 2022-10-26 Novozymes A/S Polypeptides having proteolytic activity and use thereof
CN114829563A (en) 2019-12-20 2022-07-29 汉高股份有限及两合公司 Cleaning compositions comprising dispersed protein IX
WO2021122120A2 (en) 2019-12-20 2021-06-24 Henkel Ag & Co. Kgaa Cleaning compositions comprising dispersins viii
WO2021122118A1 (en) 2019-12-20 2021-06-24 Henkel Ag & Co. Kgaa Cleaning compositions comprising dispersins vi
WO2021122117A1 (en) 2019-12-20 2021-06-24 Henkel Ag & Co. Kgaa Cleaning composition coprising a dispersin and a carbohydrase
US20240228913A1 (en) 2019-12-23 2024-07-11 Novozymes A/S Enzyme compositions and uses thereof
US20230159861A1 (en) 2020-01-23 2023-05-25 Novozymes A/S Enzyme compositions and uses thereof
US12378542B2 (en) 2020-02-04 2025-08-05 Novozymes A/S Solid stabilized laccase compositions
EP3892708A1 (en) 2020-04-06 2021-10-13 Henkel AG & Co. KGaA Cleaning compositions comprising dispersin variants
EP4133066A1 (en) 2020-04-08 2023-02-15 Novozymes A/S Carbohydrate binding module variants
US20230167384A1 (en) 2020-04-21 2023-06-01 Novozymes A/S Cleaning compositions comprising polypeptides having fructan degrading activity
EP3907271A1 (en) 2020-05-07 2021-11-10 Novozymes A/S Cleaning composition, use and method of cleaning
CN115917081A (en) 2020-05-29 2023-04-04 诺维信公司 Method for controlling slime in pulp or paper making process
EP3936593A1 (en) 2020-07-08 2022-01-12 Henkel AG & Co. KGaA Cleaning compositions and uses thereof
WO2022043321A2 (en) 2020-08-25 2022-03-03 Novozymes A/S Variants of a family 44 xyloglucanase
MX2023003275A (en) 2020-09-22 2023-04-12 Basf Se Improved combination of protease and protease inhibitor with secondary enzyme.
CN116507725A (en) 2020-10-07 2023-07-28 诺维信公司 Alpha-amylase variants
EP4232539A2 (en) 2020-10-20 2023-08-30 Novozymes A/S Use of polypeptides having dnase activity
EP4237525A1 (en) 2020-10-28 2023-09-06 Novozymes A/S Use of lipoxygenase
WO2022106400A1 (en) 2020-11-18 2022-05-27 Novozymes A/S Combination of immunochemically different proteases
WO2022106404A1 (en) 2020-11-18 2022-05-27 Novozymes A/S Combination of proteases
WO2022162043A1 (en) 2021-01-28 2022-08-04 Novozymes A/S Lipase with low malodor generation
EP4291646A2 (en) 2021-02-12 2023-12-20 Novozymes A/S Alpha-amylase variants
EP4305146A1 (en) 2021-03-12 2024-01-17 Novozymes A/S Polypeptide variants
EP4060036A1 (en) 2021-03-15 2022-09-21 Novozymes A/S Polypeptide variants
WO2022194673A1 (en) 2021-03-15 2022-09-22 Novozymes A/S Dnase variants
WO2022199418A1 (en) 2021-03-26 2022-09-29 Novozymes A/S Detergent composition with reduced polymer content
US20240279875A1 (en) 2021-06-16 2024-08-22 Novozymes A/S Method for controlling slime in a pulp or paper making process
WO2022268885A1 (en) 2021-06-23 2022-12-29 Novozymes A/S Alpha-amylase polypeptides
EP4486859A1 (en) 2022-03-02 2025-01-08 Novozymes A/S Use of xyloglucanase for improvement of sustainability of detergents
AU2023228020A1 (en) 2022-03-04 2024-07-11 Novozymes A/S Dnase variants and compositions
KR20240170826A (en) 2022-04-08 2024-12-04 노보자임스 에이/에스 Hexosaminidase variants and compositions
CN120265743A (en) 2022-12-14 2025-07-04 诺维信公司 Improved lipase (GCL1) variants
KR20250130619A (en) 2022-12-23 2025-09-02 노보자임스 에이/에스 Detergent composition comprising catalase and amylase
WO2024156628A1 (en) 2023-01-23 2024-08-02 Novozymes A/S Cleaning compositions and uses thereof
WO2024163584A1 (en) 2023-02-01 2024-08-08 Danisco Us Inc. Subtilisin variants and methods of use
WO2024194245A1 (en) 2023-03-21 2024-09-26 Novozymes A/S Detergent compositions based on biosurfactants
WO2024213513A1 (en) 2023-04-12 2024-10-17 Novozymes A/S Compositions comprising polypeptides having alkaline phosphatase activity
WO2025002934A1 (en) 2023-06-28 2025-01-02 Novozymes A/S Detergent composition comprising lipases
WO2025011933A1 (en) 2023-07-07 2025-01-16 Novozymes A/S Washing method for removing proteinaceous stains
WO2025071996A1 (en) 2023-09-28 2025-04-03 Danisco Us Inc. Variant cutinase enzymes with improved solubility and uses thereof
WO2025088003A1 (en) 2023-10-24 2025-05-01 Novozymes A/S Use of xyloglucanase for replacement of optical brightener
WO2025103765A1 (en) 2023-11-17 2025-05-22 Novozymes A/S Lytic polysaccharide monooxygenases and their use in detergent
WO2025114053A1 (en) 2023-11-30 2025-06-05 Novozymes A/S Biopolymers for use in detergent
WO2025132258A1 (en) 2023-12-20 2025-06-26 Basf Se Stabilized enzyme composition comprising a protease
WO2025202372A1 (en) 2024-03-27 2025-10-02 Basf Se Polypeptides having protease activity for use in detergent compositions
WO2025202379A1 (en) 2024-03-27 2025-10-02 Basf Se Polypeptides having protease activity for use in detergent compositions
WO2025202370A1 (en) 2024-03-27 2025-10-02 Basf Se Polypeptides having protease activity for use in detergent compositions
WO2025202369A1 (en) 2024-03-27 2025-10-02 Basf Se Polypeptides having protease activity for use in detergent compositions
EP4624572A1 (en) 2024-03-27 2025-10-01 Basf Se Polypeptides having protease activity for use in detergent compositions
WO2025202374A1 (en) 2024-03-27 2025-10-02 Basf Se Polypeptides having protease activity for use in detergent compositions

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991005839A1 (en) 1989-10-13 1991-05-02 Novo Nordisk A/S Dye transfer inhibition
WO1992018687A1 (en) 1991-04-12 1992-10-29 Novo Nordisk A/S Removal of excess dye from new textiles
WO1992018683A1 (en) 1991-04-12 1992-10-29 Novo Nordisk A/S Process for bleaching of dyed textiles
WO1996000290A1 (en) 1994-06-24 1996-01-04 Novo Nordisk Biotech, Inc. Purified polyporus laccases and nucleic acids encoding same
WO1996006930A1 (en) 1994-08-26 1996-03-07 Novo Nordisk A/S Coprinaceae laccases
US6008029A (en) * 1995-08-25 1999-12-28 Novo Nordisk Biotech Inc. Purified coprinus laccases and nucleic acids encoding the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200313A (en) * 1983-08-05 1993-04-06 Miles Inc. Nucleic acid hybridization assay employing detectable anti-hybrid antibodies
JPH0685717B2 (en) * 1988-06-16 1994-11-02 新王子製紙株式会社 Phenol oxidase gene (▲ II ▼)
JPH0227986A (en) * 1988-07-15 1990-01-30 Oji Paper Co Ltd Phenol oxidase gene (ii)
FI903443A7 (en) * 1990-07-06 1992-01-07 Valtion Teknillinen FRAMSTAELLNING AV LACKAS GENOM RECOMBINANTORGANISMER.
US5480801A (en) * 1993-09-17 1996-01-02 Novo Nordisk A/S Purified PH neutral Rhizoctonia laccases and nucleic acids encoding same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991005839A1 (en) 1989-10-13 1991-05-02 Novo Nordisk A/S Dye transfer inhibition
WO1992018687A1 (en) 1991-04-12 1992-10-29 Novo Nordisk A/S Removal of excess dye from new textiles
WO1992018683A1 (en) 1991-04-12 1992-10-29 Novo Nordisk A/S Process for bleaching of dyed textiles
WO1996000290A1 (en) 1994-06-24 1996-01-04 Novo Nordisk Biotech, Inc. Purified polyporus laccases and nucleic acids encoding same
WO1996006930A1 (en) 1994-08-26 1996-03-07 Novo Nordisk A/S Coprinaceae laccases
US6008029A (en) * 1995-08-25 1999-12-28 Novo Nordisk Biotech Inc. Purified coprinus laccases and nucleic acids encoding the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Abstract, Kyowa Hakki Kogyo K.K., Takemitsu Arai, "Preparation of Laccase", 60-156385, vol. 9, No. 324 (C-320), 1985.
Giardina et al., "The Gene, Protein And Glycam Structures Of Laccase From Pleurotus Ostreatus", Eur. J. Biochem 235., pp. 508-515, 1996.
Kojima et al., The Journal of Biological Chemistry, Inc., vol. 265 No. 25 Kim et al., "Selection Of Laccase Over-Secreting Mutant In Coprinus Congregarus", Jour. Microbiol., Jun. 1995, pp. 146-148.

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040259252A1 (en) * 2001-07-18 2004-12-23 Sanders Mitchell C. Vector containing an enhanced p15a origin of replication
WO2003008556A3 (en) * 2001-07-18 2003-10-02 Expressive Constructs Inc A vector containing an enhanced p15a origin of replication
US20050142622A1 (en) * 2002-01-31 2005-06-30 Sanders Mitchell C. Method for detecting microorganisms
US9017963B2 (en) 2002-01-31 2015-04-28 Woundchek Laboratories (Us), Inc. Method for detecting microorganisms
US20060257955A1 (en) * 2003-01-31 2006-11-16 Colpas Gerard J Method for detecting escherichia coli
US8609358B2 (en) 2003-11-03 2013-12-17 Systagenix Wound Management (Us), Inc. Methods, peptides and biosensors useful for detecting a broad spectrum of bacteria
US20070275423A1 (en) * 2003-11-03 2007-11-29 Shite Sebastian Methods, Peptides and Biosensors Useful for Detecting a Broad Spectrum of Bacteria
US9315851B2 (en) 2003-11-03 2016-04-19 Woundchek Laboratories (Us), Inc. Methods, peptides, and biosensors useful for detecting a broad spectrum of bacteria
US20090221030A1 (en) * 2007-11-01 2009-09-03 Kai Bao Signal sequences and co-expressed chaperones for improving protein production in a host cell
AU2008318644B2 (en) * 2007-11-01 2013-05-02 Danisco Us Inc. Signal sequences and co-expressed chaperones for improving protein production in a host cell
JP2013121354A (en) * 2007-11-01 2013-06-20 Danisco Us Inc Signal sequence and co-expressed chaperone for improving protein production in host cell
JP2011502483A (en) * 2007-11-01 2011-01-27 ダニスコ・ユーエス・インク Signal sequences and co-expressed chaperones for improving protein production in host cells
WO2009058956A1 (en) * 2007-11-01 2009-05-07 Danisco Us, Inc. Signal sequences and co-expressed chaperones for improving protein production in a host cell
US8414660B2 (en) 2009-05-08 2013-04-09 University Of Florida Research Foundation, Inc. Haloferax volcanii laccase and variants and fragments thereof
WO2010129940A3 (en) * 2009-05-08 2011-04-07 University Of Florida Research Foundation, Inc. Archael laccases and multicopper oxidases (mcos) and their uses thereof

Also Published As

Publication number Publication date
US6008029A (en) 1999-12-28
WO1997008325A3 (en) 1997-04-17
WO1997008325A2 (en) 1997-03-06
US6242232B1 (en) 2001-06-05
ZA967173B (en) 1997-03-12
EP0788547A2 (en) 1997-08-13
EP0788547B1 (en) 2005-11-16
DE69635444D1 (en) 2005-12-22
DE69635444T2 (en) 2006-08-10
AU6860396A (en) 1997-03-19
ATE310090T1 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
US6207430B1 (en) Nucleic acids encoding polypeptides having laccase activity
US5795760A (en) Purified Myceliophthora laccases and nucleic acids encoding same
US5843745A (en) Purified scytalidium laccases and nucleic acids encoding same
AU698423B2 (en) Purified pH neutral rhizoctonia laccases and nucleic acids encoding same
JP3510263B2 (en) Purified polyporus laccase and nucleic acid encoding the same
US5770418A (en) Purified polyporus laccases and nucleic acids encoding same
WO1995033836A9 (en) Phosphonyldipeptides useful in the treatment of cardiovascular diseases
US5667531A (en) Dye compositions containing purified polyporus laccases and nucleic acids encoding same
US8609386B2 (en) Polypeptides having tyrosinase activity and polynucleotides encoding same
CA2441212A1 (en) Methods for isolating genes from microorganisms
AU720045B2 (en) Polypeptides having mutanase activity and nucleic acids encoding same
US5770419A (en) Mutants of Myceliophthora laccase with enhanced activity
WO1997029197A9 (en) Polypeptides having mutanase activity and nucleic acids encoding same
US6146865A (en) Nucleic acids encoding polypeptides having pyranose oxidase activity
ZA200104311B (en) Detergent compositions comprising phenol oxidizing enzymes from fungi.

Legal Events

Date Code Title Description
STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: NOVOZYMES BIOTECH, INC., CALIFORNIA

Free format text: CHANGE OF NAME;ASSIGNOR:NOVO NORDISK BIOTECH, INC.;REEL/FRAME:012232/0819

Effective date: 20010511

AS Assignment

Owner name: NOVOZYMES A/S, DENMARK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVO NORDISK A/S;REEL/FRAME:012366/0350

Effective date: 20011029

FPAY Fee payment

Year of fee payment: 4

AS Assignment

Owner name: NOVOZYMES, INC., CALIFORNIA

Free format text: CHANGE OF NAME;ASSIGNOR:NOVOZYMES, INC.;REEL/FRAME:016937/0522

Effective date: 20050829

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12